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Innate immunity is the first-line defense against pathogens. Recent 
studies demonstrate that innate immunity also plays a regulatory role. 
Natural Killer (NK) cells have been appreciated as effective killing 
machinery against infected and malignant cells for decades, but the 
regulatory roles of NK cells are still lacking. NK cells are one of the early 
defense mechanisms against influenza infection. An effective immune 
response against influenza A infection depends on the generation of 
virus-specific T cells. Hence, we set out to delineate the role of NK cells 
in T cell immunity using a murine model of influenza infection with 
A/PR/8/34. We showed that NK cells were activated during the early 
phase of infection. Depletion of NK cells significantly impaired pulmonary 
dendritic cell (DC) activation, migration into the posterior mediastinal 
lymph node (pMLN) and IL-12p70 production. Similarly, NK cells 
mediated naïve and activated T cell recruitment to the pMLN mediated 
through IFN- dependent chemokine expression as transfer of IFN-+/+ 
naïve NK cells into IFN--/- mice restored T cell recruitment while IFN- 
deficient NK cells failed to do so. Additionally, NK cell depletion reduced 
uptake and transport of influenza virus by DCs via perforin and IFN- 
dependent pathways, and hence, significantly impaired the virus-specific 
T cell response.  
To further understand the immune regulatory roles of NK cells on DC 
migration, we extend our study using a sterile inflammation model—
ozone exposure. As pulmonary surfactant protein D has been shown to 
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mediate DC migration and NKp46 is an activating receptor that mediates 
IFN- production in NK cells, we set out to understand role of SP-D and 
NKp46 in NK cell regulation during ozone-induced lung inflammation. 
Post ozone exposure, migration of pulmonary DCs, expression of IFN- 
especially derived from NK cells and CCL-21 were dampened. However, 
NKp46gfp/gfp (NKp46 deficient) mice showed no blockade of DC migration 
and reduction in NK cell derived IFN- production suggesting that ozone 
actively suppresses DC migration by blocking NKp46 signaling. In SP-
D-/- mice, pulmonary NK cells had reduced intracellular IFN-γ expression 
and similar DC migration blockade compared to wild type mice. In 
contrast, treatment with recombinant SP-D increased IFN- release from 
cultured splenocytes in vitro. SP-D-/- NKp46+/+ pulmonary NK cells dose 
dependently bound recombinant SP-D in while NKp46gfp/gfp pulmonary 
NK cell failed to do so. 
In summary, NK cells mediate both DC and T cell migration via IFN- 
dependent pathways. SP-D is a likely regulator of lung resident NK cells 
promoting anti-inflammatory actions as well as host defenses through 
IFN- release possibly through engaging NKp46. NK cells also promoted 
antigen uptake by DCs via perforin mediated cytotoxicity. Through these 
mechanisms, NK cells effectively regulate the ensuing innate and 
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Chapter 1: Introduction 
1.1 Overview of the Immune system 
Immunity is the ability to resist pathological changes to the body caused 
by microorganisms such as bacteria, virus, and parasites, and other 
danger signals such as transformed cells and foreign substances. The 
immune system is a necessary product of evolution to maintain 
homeostasis and prevent diseases.  
The concept of the innate immune system was first introduced by 
Charles Janeway in 1989 (1). Innate immunity provides non-specific 
protection against infection through generating an inflammatory 
response (2). There are two major components of innate immune system 
– cellular and humoral responses. The cellular responses include 
macrophages, dendritic cells (DCs), mast cells, neutrophils, eosinophils, 
natural killer (NK) cells, NK T cells, T cells and recently discovered 
innate lymphoid cells (ILCs). The humoral responses include 
complement, LPS binding protein, C reactive protein, antimicrobial 
peptides and mannose-binding lectin. Besides these defense 
mechanisms, the innate immune system also utilizes an array of the 
germ-line coded sensors to detect pathogens and initiate immediate 
responses towards them. These sensors recognize conserved microbial 
structures and changes—1) pathogen associated molecular pattern 
(PAMPs); 2) common metabolic changes of cellular infection and 
damage (DAMPs); 3) missing self-structures. These innate sensors are 
Toll-like receptors (TLRs), nucleotide oligomerization domain (NOD)-like 
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receptors, collectin (collagen-containing C-type lectins) family, Receptor 
for Advanced Glycation Endproducts (RAGE) family and MHC class  
specific inhibitory receptors. Upon recognition, an inflammatory 
response will be quickly activated through pro-inflammatory signal 
cascades.  
In contrast to innate immunity, adaptive immunity is a more advanced 
defense system, as it only starts to appear in evolution in jawed 
vertebrates. Adaptive immunity provides specific protection – it mounts 
a specific response against a particular pathogen; a memory response 
is also formed after first encounter to ensure a more rapid activation of 
adaptive immunity against the same pathogen upon further encounters. 
However, to achieve these, adaptive immunity requires a long induction 
time during a primary infection. There are also cellular and humoral 
components of the adaptive immune system - T and B lymphocytes; and 
antibodies produced by B lymphocytes respectively. Compared to innate 
sensors, T and B cell receptors are generated by somatic rearrangement 
of gene segments to provide a wide repertoire that are specific for 
recognizing a particular epitope from the pathogens.  
1.2 Innate regulation on adaptive immunity - focus on dendritic 
cells (DCs) 
Innate and adaptive immunity have been described as two separate 
arms of host defense, but in fact, they act together to defend against 
pathogen invasions. Innate immunity serves as the first line of defense 
while adaptive immunity activates much later to clear the pathogens. 
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Innate immunity is shown to play important role in the induction, 
differentiation and maintenance of adaptive immunity via various 
mechanisms.  
Initiation of adaptive immune responses critically depends on the antigen 
presenting cells (APCs). APCs are specialized in antigen acquisition, 
processing and presenting cytoplasmic and extracellular antigens on 
MHC  and MHC  molecules respectively for TCR recognition on naïve 
T cells. Although many different cell types could present antigen on their 
surface, the most potent APCs are dendritic cells (DCs).  
Dendritic cells (DCs) were discovered in the 1970s (3, 4) and named 
after their distinctive dendritic morphology. They phagocytose 
pathogens and present antigens to initiate adaptive T cell responses (5). 
DCs can be further divided into three subsets—conventional DCs (cDCs), 
plasmacytoid DCs (pDCs) and inflammatory DCs. Both cDCs and pDCs 
are present at steady state and during inflammation while inflammatory 
DCs are only found during inflammation (6). Both cDCs and 
inflammatory DCs are derived from the myeloid lineage while pDCs are 
derived from the lymphoid lineage (7). Conventional DCs serve as 
sentinels and scavenge antigens constantly. cDCs are commonly found 
at the places most vulnerable to pathogen attack such as the skin and 
mucosal areas. Upon acquiring antigens, cDCs mature and migrate to 
the lymph node to initiate T cell responses. pDCs, also found in tissues, 
are specialized in producing a huge amount of Type I interferon upon 
pathogen insults (8). Inflammatory DCs are quickly recruited and 
differentiated from circulating monocytes during inflammation. These 
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DCs maintain inflammation through secretion of pro-inflammatory 
mediators such as TNF- and they can also migrate to lymph nodes for 
antigen presentation (6). 
Conventional cDCs comprise two major subsets divided according to the 
surface expression of CD103 and CD11b. CD103+CD11b- cDCs reside 
mostly in non-lymphoid tissues and survey the host microenvironment 
for pathogens (9). Upon sensing of pathogens, CD103+CD11b- cDCs 
actively migrate to the regional lymph nodes to present antigens to T 
cells. CD103+CD11b- cDCs have a high expression of the scavenger 
receptor CD36 and C-type lectin Clec9A to enable their superior binding 
to dead cells and sensing of necrotic bodies respectively (10, 11). These 
machineries ensure efficient antigen acquisition and presentation to 
activate CD8+ T cells (12, 13). CD103+CD11b- cDCs are also found 
important in initiating CD4+ T cell responses against infection with 
Candida albicans and experimental autoimmune encephalomyelitis (14, 
15). However, T cell activation does not only require antigen recognition, 
but also co-stimulation. Innate receptors—pattern-recognition receptors 
(PPRs) such as TLRs, are important in up-regulating co-stimulatory 
molecules expression such as CD80, CD86 on DCs. DCs express a wide 
range of TLRs, however CD103+CD11b- cDCs are one of two subsets of 
DCs that express TLR3 and TLR11 to sense dsRNA and proteins from 
Toxoplasma Gondii respectively (16, 17). This renders CD103+CD11b- 
cDCs more efficient in T cell response induction. CD103+CD11b- cDCs 
are also excellent in presenting extracellular antigen on MHC molecules 
to activate CD8 T cells (18). Another subset of DCs—CD8+ DCs share 
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similar properties with CD103+CD11b- cDCs except that they reside 
mainly in lymphoid tissues. CD103-CD11b+ cDCs also present antigens 
on MHC molecules to activate CD4 T cell responses (19). By mediating 
CD4 T cell activation, cDCs indirectly regulate B cell activation as well. 
In addition to up-regulating the co-stimulatory molecules on APCs, PPRs 
can also control the activation, differentiation, and memory formation of 
T cell responses and B cell antibody production by mediating cytokine 
production. Activation of almost any TLR leads to Th1 differentiation. 
Many TLRs also support Th17 responses (20). Besides TLRs, C-type 
lectins – dectin-1, dectin-1 and Mincle are also found to impact adaptive 
immunity (21). Dectin-1 is specialized in recognizing fungi and 
mycobacterial antigens (22, 23). Dectin-1 synergizes with other TLRs in 
pro-inflammatory cytokine production such as TNF-, IL-6, IL-10 and IL-
23; they also switch Th cells into Th17 responses for host defenses 
against fungal infections (24, 25). Besides these sensors, other PPRs 
such as NLRs also lead to production of cytokines such as IL-1 and IL-
18, which are important in mediating T cell responses.  
Furthermore, upon activation via PPR dependent and independent 
pathways, innate immune cells including DCs and other innate cells, 
regulate the magnitude and extent of adaptive immune responses 
through cytokines production. Activated DCs secrete IL-12 and IL-15 to 
support differentiation of cytotoxic CD8 T cells (26-28). Macrophages 
can secrete IL-12, IL-10 and TGF- to promote Th1, Th2 and IgA 
responses respectively (29). NK cells are an important source of IFN-, 
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which support Th1 and IgG2a responses; Mast cells, basophils and NK T 
cells can produce IL-4 to promote Th2, IgG1 and IgE responses (29). 
Recent studies have identified that IL-1 and IL-6 also mediate T cell 
responses directly. IL-1 is found to act as a co-stimulatory signal for 
antigen dependent T cell activation during primary and secondary 
responses through promoting IL-2 receptor –CD25 expression and T cell 
survival (30, 31). IL-1 also supports Th17 differentiation in vitro and in 
vivo (32, 33). IL-6, secreted by neutrophils, is necessary for 
differentiation and maintenance of effector Th17 cells at the local 
inflammation sites, in part, by prolonging the survival of Th17 cells (32, 
34-36).  
Furthermore, the effect of PPRs on cytokine production by innate 
immune cells, PPRs can directly regulate T and B cell functions. CD4 T 
cells express TLR2 and TLR9 on the surface. Stimulation of these TLRs 
leads to enhanced survival, proliferation and IL-2 secretion by CD4 T 
cells (37). T cells also express NLRs, which are important in promoting 
IFN- and Th1 differentiation (38). Similarly, B cells also express TLRs. 
Activation of TLRs on B cell stimulate IgG2c production (39).  
Innate immunity does not only serve as host defense, but also has an 
important immune regulatory role. Hence, it is very important to further 
our understanding of the diverse functions of innate immune cells 
especially in the context of adaptive immune response regulation. With 
this understanding, we can manipulate the immune system to fight 
against novel infections and malignancy, and improve vaccine design 
and drug development.  
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NK cells are well studied for their effector function but the regulatory 
roles of NK cells are still not clear. NK cells produce various cytokines 
and actively interact with DCs to modulate their maturation status and 
functions. Since DCs act as an important bridge between innate and 
adaptive immunity, it is of great importance to understand the regulation 
of DC functions by NK cells at steady state and inflammation. Moreover, 
NK cells can also possibly influence T cell responses directly. Thus, we 
selected NK cells to explore their possible regulatory roles on DCs and 
T cells responses during various pulmonary inflammation.  
1.3 Natural Killer (NK) cells 
The discovery of natural killer (NK) cells was in the 1970s when they 
were described morphologically as large granular lymphocytes, which 
can mediate significant level of cytotoxicity without priming or antigen 
recognition through MHC molecules (40-42). NK cells have since been 
classified as an important component of innate immunity and recently, 
with the discovery of various innate lymphoid cells, NK cells have been 
officially described as group 1 innate lymphoid cells (43, 44). NK cells 
have long been viewed as a primitive form of immune response (45), but 
recent data showed that some of newly discovered NK cell surface 
receptors were only preserved within mammals (46, 47), revert this view 
and suggest a later evolutionary development of NK cells than T and B 
cells. NK cells are found in both lymphoid and non-lymphoid tissues with 
a turnover of 14 days, representing 2-18% of the total lymphocyte 
population (48). NK cells are classically defined by cell surface receptor 
expression. Human NK cells are characterized as CD3-CD56+ (49), while 
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murine NK cells are characterized as CD3-NKp46+ (50). In different strains 
of mice, NK cells showed differential expression of surface receptors—
expression of NK1.1 is only found in C57BL/6 mice while Dx5 is 
expressed both in C57BL/6 and BALB/c mice. Asialo ganglio-N-
tetraosylceramide (AGM1) is also expressed at a high level on NK cells 
in almost all species of rodent (51).  
1.3.1 Development of NK cells 
During embryonic genesis, NK cell development occurs in the yolk sac, 
aortogonad mesonephric region and fetal liver (52). After birth, the 
majority of NK cells are believed to be developed from the bone marrow 
hematopoietic stem cells in five different stages both in human and 
mouse (53). Mature NK cells exit from the bone marrow and reside in 
the blood, spleen, liver, mucosal tissues and other organs (54). Recent 
studies have identified NK cell development intermediates (NKDIs) in the 
thymus (55), liver (56, 57), lymph nodes (58), uterus (59), and intestine 
(60), suggesting an extramedullary development for tissue-specific NK 
cells. IL-3, IL-7, c-kit ligand and flt3 ligand are implied in increasing 
responsiveness of NKDIs to IL-15 mediated maturation (61-63) while 
transforming growth factor (TGF)- (64), and IL-1 (65) are found to 
suppress NK cell maturation. NK cells surface receptors are also found 






1.3.2 NK cell subsets 
Functionally competent NK cells can be further divided into subsets 
based on their surface marker expressions. Human NK cells are 
comprised of two subsets – CD56lowCD16+ and CD56hiCD16- 
populations. The former is mainly found in blood and are capable of 
killing and cytokine secretion (66, 67). The latter resides mainly in 
peripheral lymphoid organs and is programmed to produce large 
amounts of cytokines rather than killing target cells. The former is also 
considered a more mature form of the latter. In mice, the subsets of NK 
cells are not as clearly defined as in humans. Surface expression of 
CD11b, CD27, CD127 and B220 has been used to subdivide murine NK 
cells (68-71). Most commonly, murine NK cells were divided to three 
subsets by surface expression of CD11b and CD27—CD11blowCD27+, 
CD11b+CD27+ and CD11bhiCD27low (72). These three subsets also 
represent the NK maturation stages with CD11blowCD27+ NK cells as the 
most immature subset, and CD11bhiCD27low considered as the most 
mature NK subset showing the highest level of cytokine production and 
cytotoxicity (71). CD11blowCD27+ NK cells reside mainly in bone marrow 
and lymph nodes, while CD11bhiCD27low NK cells are mainly found in 
the blood, spleen, lung and liver and CD11b+CD27+ NK cells are evenly 
distributed in different organs (48). CD127+ and B220+CD11c+ NK cells 
are functionally similar to CD56lowCD16+ and CD56hiCD16- subsets in 





1.3.3 NK cells activation – regulation by surface receptors 
NK cell activation is delicately controlled by the balance of activating and 
inhibitory surface receptors (73). Activation receptors include natural 
cytotoxicity receptors (NCRs) such as NKp30, NKp44 and NKp46, lectin-
like receptors such as NKG2C, NKG2D and NKG2E, activating killer cell 
immunoglobulin-like receptors (KIRs) such as KIR2DS and KIR3DS and 
others (74). Activation receptors recognize viral proteins (75) along with 
various proteins up-regulated on stressed cells (76) and tumor cells (77). 
Ligation of activation receptors will recruit adaptors containing 
immunoreceptor tyrosine-based activation motifs (ITAMs) domain, which 
will eventually promote cytotoxicity and cytokine secretion by NK cells 
(78). The majority of inhibitory receptors are members of the inhibitory 
KIR and Ly49 family in human and mouse respectively. Major 
histocompatibility complex (MHC) class  molecules represent one group 
of important NK cell inhibitory receptor ligands expressed on target cell 
(79). Ligation of inhibitory receptors will recruit adaptors containing 
immunoreceptor tyrosine-based inhibitory motifs (ITAMs) domain, which 
will inhibit NK cell cytotoxicity and cytokine production (78).  
1.3.4 Functions of NK cells 
Functions of NK cells include killing infected and transformed cells, and 
producing various cytokines and chemokines, especially IFN-. NK cells 
are also important in regulating other arms of the immune response and 
maintaining homeostasis. NK cell deficiencies could lead to many 
human diseases. Patients lacking NK cells or with dysfunctional NK cells 
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showed high susceptibility to life-threatening viral infection caused by 
varicella zoster virus, herpes simplex virus cytomegalovirus, various 
respiratory virus, Epstein–Barr virus, and human papilloma virus, 
disseminating fungi infection and increased tumor incidences (80). The 
mortality rate was around 50% in reported cases (80). These clinical 
observations highlight the importance of NK cells in host defense, 
especially during infections.  
1.3.5 Interactions with other cells 
NK cells are not alone in health or disease; they actively interact with 
other compartments of immune system and structural cells to achieve 
optimal function and regulation. NK cells can be functionally regulated 
by dendritic cells and macrophages (81), CD4 T cells (82), CD8 T cells 
(83) and regulatory T cells (84) by released mediators and/or contact-
dependent pathways. On the other hand, NK cells also promote DC 
maturation and differentiation (85), support Th1 polarization (86, 87) and 
CTL generation (88). NK cells also interact with non-immune cells in 
various organs. Kupffer cells in the liver are shown to suppress NK cell 
activation through IL-10 production (89). Keratinocytes are thought to 
promote NK cell recruitment and in return NK cells promote keratinocyte 
activation through IFN- release (90). NK cells are also implicated in 
killing -cells in the pancreas leading to diabetes development (91). NK 
cells can kill microglia in the brain and control the inflammation in 




1.3.6 NK cell memory 
Recent studies have shown a new property of NK cells—generation of a 
memory phenotype. Memory cells are defined as long-lived effector cells 
with enhanced response to previously encountered pathogens. The first 
evidence for NK cell memory comes from transplantation studies, which 
shows more rapid rejection of parental graft in F1 offspring upon priming 
with parental bone marrow cells (94). Recent studies demonstrate NK 
cell memory induced by cytokines, irritants and different pathogens. In a 
murine model of contact hypersensitivity against the chemical hapten – 
DNFB, NK cells are found to be sufficient to induce skin inflammation 
and mediate the recall response to DNFB, but not to other chemical 
irritants (95). More importantly, adoptive transfer of CXCR6 expressing 
liver NK cells is sufficient to mediate recall response to DNFB as late as 
4 months post primary response (95). During infection with mouse 
cytomegalovirus (MCMV), Ly49H+ NK cells recognizing m157 viral 
protein, show clonal expansion (96, 97). Transfer of this subset of NK 
cells to naive mice also confers protection against MCMV infection (97). 
Other studies also show that NK cells are important in mediating recall 
responses towards vesicular stomatitis virus and virus-like particles 
containing influenza or HIV proteins, vaccinia virus and herpes simplex 
virus 2 (95, 98-100). Besides this evidence, IL-12/IL-18 stimulated NK 
cells and their progenitors show enhanced IFN- production after 





1.4 Adaptive immune cell –T lymphocytes 
T lymphocytes develop in thymus from progenitor cells derived from 
bone marrow and fetal liver (102). T cell precursor cells undergo 
proliferation, lineage commitment and recombination activating gene 
(RAG) dependent VDJ recombination to generate a large pool of T cell 
receptors (TCRs) in the thymus. These cells then undergo positive 
selection to ensure proper TCR-MHC interaction and negative selection 
to delete autoreactive T cells recognizing self-antigens. These naïve T 
cells then exit the thymus and circulate constantly in lymphoid tissues 
via blood and lymph. Activation of naïve T cells normally occurs at the 
lymph nodes where APCs and naïve T cell encounter one another. If the 
naïve T cells recognize the antigen presented and co-stimulatory signals 
are present, T cells will be activated and differentiated into effector and 
memory populations. If co-stimulatory signals are absent, T cells will 
undergo anergy and become unresponsive. T cells can be divided into 
CD4+ and CD8+ subsets. CD4+ and CD8+ T cells recognize antigen 
presented by MHC  and MHC  respectively. Upon ligation of TCRs, T 
cells undergo multiple cycles of divisions to generate up to 1000 progeny 
cells from one single precursor. Most of progeny cells acquire the 
effector phenotype and migrate to the site of infection while some of 
them will acquire a memory phenotype and remain in the lymph node. 
There are mainly two subtypes of effector cells – T helper (Th) and T 





1.4.1 Cytotoxic CD8 T cells 
Cytotoxic CD8 T cells kill any cells presenting antigens recognized by 
the TCRs. Cytotoxic CD8 T cells bind to the target cells and break up the 
cell membrane through perforin insertion and they subsequently release 
granzymes from their granules into the cytoplasm of the target cells to 
induce apoptosis. Cytotoxic CD8 T cells can also induce apoptosis 
through engaging the FAS-FAS ligand pathway. Cytotoxic CD8 T cells 
make up a third of circulating T cells. They are important in host defense 
against intracellular pathogens and malignant cells. Cytotoxic CD8 T 
cells can be differentiated into Tc1 and Tc2 subsets, which produce IFN-
 and IL-4 respectively.  
1.4.2 CD4 helper T cells 
CD4 Th cells represent the largest population of T cells. Upon activation, 
they can produce the full spectrum of cytokines found in the T cell 
population (103). Th cells are differentiated to various subsets from Th0 
precursors under the regulation of different transcription factors and 
cytokines. There are four major subsets – Th1, Th2, Th17 and T 
regulatory cells (Tregs) and many minor subsets such as Th9, follicular 
T helper cells (Tfh), etc. 
The first subset of Th cells is Th1, which differentiate from the Th0 cells 
with activation of transcription factor T-bet in the presence of IL-12 and 
IFN-. Activated Th1 cells produce IFN- and IL-2 to activate 
macrophages, monocytes, DCs, NK cells and cytotoxic T cells to combat 
against infection and tumor cells. The second major subset is Th2 cells. 
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Th2 cell differentiation requires IL-4 and transcription factor GATA-3. 
Activated Th2 cells produce IL-4, IL-5, IL-10 and IL-13 to repel parasites, 
promote antibody production as well as support pathogenesis of allergy 
and asthma. Over the decades, Th1 and Th2 cells are viewed as the Yin 
and Yang of the immune system as they suppress each other’s 
differentiation. But recent study has observed plasticity between Th1 and 
Th2 cells. Under certain conditions, Th1 and Th2 cells are shown to 
produce IL-4 (104) and IFN- (105) respectively.  
The third major subset is Th17 cells, which differentiate in the presence 
of TGF- and IL-6 with activation of transcription factor ROR. Activated 
Th17 cells produce IL-17, IL-22, IL-25 and TNF-. IL-17 and IL-25 are 
pro-inflammatory and further potentiate production of TNF- and IL-6. 
Th17 cells recruit granulocytes and induce tissue repair. Th 17 cells are 
implicated in autoimmune diseases such as arthritis, multiple sclerosis 
and systemic lupus erythematous (106). Th17 cells also play an 
important role in allergy and asthma (107). 
The last major subset of Th cells is regulatory T cells (Tregs). 
Differentiation of Tregs requires TGF- and IL-2 with activation of 
transcription factor Forkhead box protein 3 (FoxP3). Activated Tregs 
produce IL-10 and TGF-. Tregs act to suppress the activation of T cells 
and hence maintain peripheral tolerance and curb excessive 
inflammation. Tregs can be divided to two major subsets—natural and 
inducible Tregs (nTregs and iTregs). Natural Tregs are important to 
suppress autoreactive T cells and dampen T cell responses to 
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exogenous antigens (108, 109). Natural Tregs can directly induce 
apoptosis of autoreactive T cells through perforin and granzyme 
dependent mechanisms in vitro (110); while in vivo the suppressive 
effect is mediated largely through IL-10 and TGF- dependent pathways 
(111). The other subset of Tregs is inducible Tregs, which are shown to 
be differentiated from natural Tregs in vitro (112) or from peripheral CD4 
T cells de novo (113). iTregs share the same features of nTregs in that 
they suppress T cell proliferation and allergic pulmonary inflammation 
induced by ovalbumin (112). In summary, both subsets play an important 
role in suppressing autoimmune diseases and modulating host defenses 
against infections (114). 
Besides Th1/Th2/TH17/Tregs, there are many other Th cell subsets 
including Th9, follicular helper T cells (Tfh), etc. Although helper T cells 
can differentiate into various subsets, there is a certain amount of 
plasticity among the subsets. During the early stage of their 
differentiation, Th1, Th2, T17 and Tregs can still switch to other fates. 
Th17 and Treg during their late stages of differentiation can still switch 
to Th1 or Th2 cells (115). This plasticity provides a sensitive regulation 
in T helper cell responses toward the local inflammation and fine-tunes 
the immunity to fast changing microenvironments.  
1.5 Influenza A virus infection 
1.5.1 Influenza A virus 
Influenza A virus is a single stranded RNA virus in the family of 
Orthomyxoviridae. Influenza A virus has been isolated from various host 
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species, including seals, whales, birds and humans (116). The virus is 
usually spherical, with a diameter of 80-120nm. The viral genome is 
made of 8 segments of negative-sense RNAs encoding 11 proteins – 
hemagglutinin (HA), neuraminidase (NA), nucleoprotein (NP), matrix 
protein (M1), ion channel protein (M2), non-structural protein (NS1, NS2), 
and polymerase proteins (PA, PB1, PB1-F2 and PB2). 
HA and NA are surface glycoproteins representing major epitopes that 
are recognized by the adaptive immune system. Influenza A viruses are 
therefore subtyped by expressions of surface HA and NA. While 16 
isoforms of HA and 9 isoforms of NA have been identified from aquatic 
birds and bats, only three types of HA (H1, H2, H3) and two types of NA 
(N1, N2) are commonly found in humans (117). 
1.5.2 Influenza infection impact on global health 
Within last century, there were four outbreaks of pandemic influenza. 
The most severe pandemic, popularly known as “Spanish flu”, caused 
50-100 million deaths between 1918 and 1919, the highest mortality due 
to infectious disease outbreak (118). In 2009, a novel strain of swine-
origin pandemic influenza A/H1N1 broke out in over 212 countries (119). 
Therefore, influenza A infection still calls for intensive study.  
1.5.3 Overview of host defenses against Influenza Infection 
Influenza A virus infection results in a rapid and vigorous host response. 
Initial viral attachment is blocked through specific IgA antibodies, mucus 
trapping and other barrier mechanisms (120). Upon establishment of 
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infection, infected epithelial cells, DCs and macrophages actively 
produce cytokines and chemokines to induce an antiviral state within the 
epithelium and mediate the recruitment and activation of cellular innate 
immunity, including neutrophils, granulocytes and NK cells (121, 122). 
When the virus is not controlled by innate immune mechanisms, 
adaptive immune responses are triggered to clear the pathogen. 
Following engagement with antigen presenting cells (APCs), CD8+ 
cytotoxic T cells are activated and recruited to the lung for vial clearance 
(123). CD4+ T-helper (Th) cells are also activated and potentiate B cell 
dependent virus specific antibody production, and the virus-specific 
CD8+ cytotoxic T lymphocyte generation (124). Thus, an effective 
eradication of the virus is achieved by CD8+ cytotoxic T cells and 
antibody-dependent cell-mediated cytotoxicity. Immune memory is also 
established by antibodies and CTL to confer long-term resistance to 
antigenically similar strains. 
1.5.4 NK cells and influenza  
NK cells comprise around 10% of total lymphocytes in the healthy mouse 
lung (125). Generally, NK cells are viewed as the first line of defense 
against influenza A infection before T cell and B cell activation. The 
importance of NK cells in combating influenza A infection has been 
studied since the 1980s. Stein-Sterilein and colleagues demonstrated 
that NK cell depletion increased pulmonary virus load and hence 
increased morbidity and mortality in mice and hamsters upon lethal 
infection (126, 127). In infants, NK deficiency acts as an important 
predictor of severe influenza infection (128). Tsuru and colleagues 
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further showed that polymorphonuclear leukocytes (i.e. NK cells) 
reduced influenza virus load significantly post adoptive transfer in mice 
(129). However, Bot and co-workers, found that NK depletion in scid 
mice lacking B and T cells, did not change overall survival with a lethal 
infection suggesting that NK cells were not critical for viral control (130). 
All these data suggest that NK cells are important in defense against 
influenza virus and remain an active research field. 
1.5.5 NK cell recruitment during influenza infection 
Upon the establishment of infection, NK cells are rapidly recruited to the 
lungs and regional lymph nodes to mount an early anti-viral response. 
During the first few hours of infection, chemokines such as CCL-3, CCL-
4 and CCL-5, are produced by epithelial cells, macrophages, and 
plasmacytoid dendritic cells (pDCs) to recruit NK cells to the site of 
infection (131). NK cell number is also increased in peripheral blood as 
early as D1 p.i. in healthy volunteers receiving influenza A virus (132). 
In mice, pulmonary NK cell number significantly increases at D2 p.i. 
(133). NK cells are also recruited to regional draining lymph nodes during 
an inflammatory response (86). But the kinetics of NK cells recruitment 
in influenza infection is not fully studied yet. 
1.5.6 Recognition of the virus/viral protein by NK cells 
NK cells recognize HA directly through surface receptors. Both NKp44 
and NKp46 can directly recognize influenza HA in vitro, in both mouse 
and humans (121,134, 135). This recognition is also conserved among 
various strains of influenza virus including H1-, H3- and the highly 
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virulent H5- subtypes (135, 136). However, this recognition is relatively 
weak (137). Upon the recognition of HA by NKp46 or NKp44, NK cell-
mediated, killing of infected cells is initiated (121). NKp46 has also been 
suggested to recognize influenza-infected cells in vivo and a higher 
mortality was observed in NKp46-/- mice post sublethal influenza 
infection (138). Furthermore, NK cell responses are also mediated by 
surface inhibitory receptors NK receptors and HLA genotypes through 
possible novel mechanisms (Ahlenstiel et al, 2008).  
1.5.7 Activation stimuli for NK cells 
Type I interferons (IFNs) act as a potent stimuli for priming antiviral 
responses of NK cells. Type I IFNs induce NK cell cytotoxicity by 
upregulation of FAS ligand, perforin and activating receptor NKG2D 
dependent pathways. During the early course of infection, any nucleated 
cell such as epithelial cells, dendritic cells (DCs) especially plasmacytoid 
DCs (pDCs), and macrophages, can produce type I IFNs, (139). In 
humans, the level of type I IFNs is rapidly increased upon influenza 
infection (140). In IFN--/- mouse, a 10-fold increase in viral titer was 
observed at D2 p.i. compared to wild type (141). During the course of 
infection, IFN- and IFN- only showed a significant increase in mRNA 
level around D2 p.i. (142), which is in accordance with the timing of NK 
activation. IFN- could activate IFN- production by NK cells in a cell-cell 
dependent mechanism (143). Therefore, a correlation between NK cell 
activation status and pulmonary Type I IFNs is proposed in the infected 
mice (144, 145). IL-12 is another potent cytokine for NK cell activation, 
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especially in promoting IFN- production by NK cells. Blocking of IL-12 
in mice significantly impaired IFN- production by NK cells during 
influenza infection (146). IL-12 also works synergistically with IL-18 to 
promote optimal IFN- production. However, the ability of IL-18 alone to 
induce NK cell IFN- production remains controversial (147-151). IL-12 
could also synergize with TLR signaling to induce IFN- release by NK 
cells in vitro (152). Cell contact is also important in stimulating NK 
function. Borg and colleagues showed IL-12 mediated stimulation of NK 
cells required the presence of DCs (153). The loss of contact with 
infected macrophages greatly reduced cytokine production of human NK 
cells (143).  
1.5.8 Effector functions of NK cells 
One of the most important roles of NK cells is to kill infected cells. In 
mice, increased pulmonary NK cell mediated killing is observed D2 p.i. 
with influenza A virus (154-158), while in hamsters, the activity is 
observed at D3 p.i. (158). NK cell mediated cytotoxicity is largely 
dependent on perforin as perforin knockout mice displayed delayed viral 
clearance and loss of NK mediated cytotoxicity (159). Furthermore, NK 
cell mediated cytotoxicity is age dependent as older mice showed 
attenuated NK cell responses with increased pulmonary viral loads and 
increased mortality (133, 155). Influenza A virus infection also results in 
greatly elevated NK cell-derived pulmonary IFN- production in both 
humans and mice. The production of IFN- itself acts as a positive 
feedback mechanism, whereby elevated IFN- levels results in 
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enhanced NK cell mediated killing, and potentiated cytokine production 
(138, 160). However, during an influenza infection, mice deficient in IFN-
 did not exhibit any difference in initiating immunity and disease 
progression (161). Thus, the importance of IFN- in protective immunity 
against Influenza infection remains to be elucidated. During the 
resolution phase of influenza infection, NK cells are also implicated in 
inhibition of immunopathology (85,162,163). 
However, Influenza could also suppress NK cell function. Influenza 
A/PR/8/34 suppresses IL-2 and NK cell mediated cytotoxicity in mice 
(164) and recently, the ability of Influenza virus to infect murine NK cells 
has been demonstrated in vitro and in vivo (165), but there has not clear 
data to demonstrate that this is a productive infection. The virus-infected 
NK cells exhibit reduced killing and cytokine production including IFN- 
and GM-CSF, compared to mock-infected NK cells in vitro (165). 
Influenza is also found to directly infect human NK cells and induce their 
apoptosis and/or suppression of function (166). One mechanism 
employed by influenza virus to suppress NK cell functions is through 
redistribution of MHC class  molecules which bind to inhibitory receptors 
on NK cells (167). The impairment of NK cell functions by influenza virus 
also affects subsequent bacterial co-infection. NK cell recruitment and 
TNF- production was impaired in an IL-15 dependent manner in the 
lung during S. aureus infection following prior influenza A infection (168). 
Adoptive transfer of naïve NK cells into the lung could rescue the mouse 
from the effect of prior influenza A infection which further demonstrates 
dysfunction of NK cells post influenza infection (168). 
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1.5.9 Regulation of the adaptive immunity 
NK cells not only act as one of the innate mechanisms against influenza 
infection, they also influence the generation of virus-specific cytotoxic T 
cells (CTLs). In 1984, Burlington et al demonstrated that Large Granular 
Lymphocytes (i.e. NK cells) were necessary to induce CTL responses 
against Influenza in vitro (88). Moreover, depletion of NK cells abrogated 
virus-specific CD8 T cell generation in human PBMC as well as in vitro 
and in an in vivo mouse model (169). However, other cell types are also 
implicated in supporting CTL generation. Alveolar macrophages were 
also shown to affect the kinetics and activity of CTLs (170). Dendritic 
cells (DCs) were also implicated in enhancement of CTL activity both in 
vitro and in vivo in a CD4-independent manner (171). However, whether 
the mechanisms underlying NK cells mediated CTL induction are DCs 
and macrophages dependent or independent still remain unknown.  
1.6 Ozone induced pulmonary inflammation 
Ozone is a highly oxidative gas made of three oxygen atoms. When 
present in the lower atmosphere, ozone is identified as harmful air 
pollutant leading to hospitalization (172), asthma exacerbations (173, 
174) and increased risk of mortality (175, 176). Ozone exposure could 
lead to oxidative stress, barrier damage, enhanced apoptosis, airway 
hyperresponsiveness (AHR), and activation of innate and adaptive 




1.6.1 Ozone induced oxidative stress  
Oxidative stress contributes to many diseases including lung injuries. 
Oxidation products lead to pulmonary damage directly due to their 
toxicity or indirectly through activating pro-inflammatory and/or apoptotic 
pathways by receptor ligand binding (177). Ozone could also lead to 
formation of intracellular and extracellular reactive oxygen species (ROS) 
in the lung, which lead to tissue injuries and changes in innate signal 
transduction (178). Specifically, ozone could induce lipid peroxidation 
and formation of 4-hydrxy-2-nonenal and isoprostanes in humans (179, 
180) and animals (181, 182). These products are potent inducers of 
alveolar macrophage and epithelial cell death (183-185) and airway 
remodeling (186), ROS generation (187), smooth muscle contraction 
(188) and proinflammatory cytokine release (184, 187). The importance 
of oxidative stress in ozone induced pulmonary inflammation is further 
illustrated in antioxidant genes deficiency mice and human 
polymorphisms. A combination of gluthathione-0S-transferase isoform 
M1 (GSTM1) deficiency and NAD(P)H quinine oxidoreductase (NQO1) 
allele Pro187Pro in humans, leads to significantly reduced forced 
expiratory volume in 1 second (FEV1) caused by ozone exposure (189). 
Similarly, NQO1-/- mice showed reduced AHR and pulmonary 
inflammation post ozone exposure (190). Therefore, ozone induced 





1.6.2 Ozone induced structural damage to the lung 
Ozone exposure is known to induce epithelial and other structural 
changes in the lung (191, 192). Barrier functions of lung epithelial cells 
including cilliary function (193) and mucocilliary clearance (194) are 
shown to be defective post ozone inhalation. Epithelial permeability is 
also shown to increase substantially post ozone exposure in humans 
(195, 196). Besides epithelium, extracellular matrix (ECM) is also 
modified by ozone inhalation. Mindin and hyaluronan are two of the ECM 
proteins, which have been implicated in ozone induced pulmonary 
inflammation. Mindin-/- mice showed a significant reduction in lung 
inflammation and AHR compared to wild type mice (197). Hyaluronan 
was found to convert from high molecular weight form to the lower 
molecular weight form post ozone exposure (198, 199). This low 
molecular weight form of hyaluronan is found to mediate AHR using 
CD44 and toll like receptor 4 (TLR4) dependent pathways (200, 201). 
These studies have demonstrated a crucial role of ECM proteins in 
ozone mediated pulmonary inflammation and AHR. 
1.6.3 Surfactant protein and ozone 
Surfactant proteins (SPs) are found at the air-liquid interface in the 
airways and alveoli to reduce surface tension (202, 203) and modulate 
host defense in the lung (204). It is not surprising that surfactant proteins 
are also involved in ozone induced pulmonary inflammation. Both 
surfactant protein A (SP-A) (205) and surfactant protein D (SP-D) (206) 
deficient mice showed heightened pulmonary inflammation post ozone 
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exposure. Ozone is also shown to directly oxidize surfactant proteins 
(207, 208) and leads to surfactant protein dysfunction. Dysfunction of 
surfactant protein could lead to impaired pathogen binding and 
clearance, increased ROS generation by macrophages (209, 210) and 
activation of pro-inflammatory pathways (211). However, the underlying 
mechanisms mediated by surfactant proteins post ozone exposure are 
still unclear. 
1.6.4 Innate immune responses to ozone  
The innate immune response is the first line defense again pathogen and 
non-pathogen insults in the lung. During ozone inhalation, various 
compartments of innate immunity are activated. The first responder of 
innate immune compartments is neutrophils. Neutrophilia is observed in 
the BAL at 3-24 hour post ozone exposure using various schemes of 
ozone exposure (206, 212, 213). Neutrophil recruitment is also 
implicated in ozone induced AHR (214) and airway injury (215). 
Pulmonary macrophages are also recruited post ozone exposure (216) 
to release mediators such as TNF-, IL-1, IL-6 and IL-8, which 
contribute to ozone induced AHR and injuries (217-219). Exposure to 
ozone also enhances innate responses towards LPS (220), allergen 
sensitization to OVA (221) and reduces bacterial clearance by 
macrophages (222). Activation and modification of innate immunity 





1.8 Aim of this study 
As evidenced by many studies, NK cells have various functions including 
classical killing of infected and transformed cells and production of 
various soluble mediators. Additionally, the role of NK cells as regulatory 
cells is emerging. Moreover, with the discovery of the NK cell memory 
phenotype, NK cells can also be considered as part of the adaptive 
immune system. There is definitely a need to further our understanding 
of NK cells during homeostasis and inflammation. 
Therefore, we aim to unveil the various functions of NK cells during 
influenza A infection and sterile inflammation induced by ozone in the 
lung. Since NK cells represent a major component of pulmonary 
lymphocytes and lung inflammation involves various players including 
structural cells, immune cells and various released mediators such as 
surfactant proteins, both influenza and ozone models provide us with a 
great platform to study multiple possible interactions of NK cells with 
various other components of the lung. These interactions will lead to new 
insights into NK cell functions especially as regulatory cells during host 
defense. Specifically, we aim to understand the activation of NK cells, 
interaction/regulation of other immune cells such as dendritic cells and 
T cells and interaction with non-immune components of lung during 
influenza A infection and ozone induced sterile inflammation. With this 
understanding, we could influence other arms of lung host defense 







Chapter 2: Material and Methods 
2.1 Media and buffers 
PBS Buffer 
10 x PBS buffer (ultrapure grade, 1st base, Singapore) comprises of 
137mM NaCl, 2.7mM KCl and 10mM phosphate buffer. 10 x PBS was 
diluted with autoclaved water to 1 x PBS with pH adjusted to 7.4 prior to 
usage. 10 x and 1 x PBS buffer, which does not contain NaCl or KCl, 
was purchased from Gibco (NY, USA) and Mediatech (VA, USA) 
respectively.  
MACS buffer 
MACS buffer was made of 1 x PBS (sterile) with 2% FCS (v/v) and 5mM 
EDTA with pH adjusted to 7.4. 
FACS buffer 
FACS buffer was made of 1 x PBS (sterile) with 1% FCS (v/v), 5mM 
EDTA, and 0.05% sodium azide, which is a preservative to allow usage 
and storage under non-sterile conditions. pH of FACS buffer was 
adjusted to 7.4. 
Permeabilization buffer 
For intracellular staining, permeabilization buffer (pH adjusted to 7.4) 
containing 1x PBS (sterile) supplemented with 0.1% BSA, 0.1% Saponin 
and 0.1% sodium azide was used. Alternatively, intracellular staining 
was carried out using commercial cell fixation and permeabilization 





Red Blood Cell Lysis solution  
10 x RBC lysis solution was made of 8.3% ammonium chloride, 0.84% 
sodium bicarbonate and 0.03% EDTA in water. Stock solution was 
sterility filtered and adjusted to pH 7.4. Stock RBC lysis solution was 
diluted 10 times with autoclaved water prior usage. 
OptiprepTM density gradient medium 
OptiprepTM density gradient medium (Sigma, MO USA) contains 60% 
Iodixanol (w/v) in water with a density equal to 1.32g/ml. The endotoxin 
level in Optiprep is tested to be less than 0.13EU/ml. For enrichment of 
dendritic cells and macrophages, stock Optiprep solution was diluted 
using optiprep diluent (18.62:81.38; v/v) to achieve a final density of 
1.064g/ml, which is equivalent to 11.173% Iodixanol solution. Working 
solution of Optiprep was stored at 4oC. 
Optiprep diluent 
Optiprep diluent is prepared with 0.8% NaCl, 5mM EDTA and 10mM 
Tricine NaOH and then sterile filtered. pH was adjusted to 7.4 and the 
solution was stored at 4oC.  
Liberase Enzyme Solution 
Liberase TL Research Grade contains highly purified Collagenase I and 
Collagenase II with low concentration of Thermolysin (Roche Applied 
Science, Germany). For the 10 x stock, liberase was dissolved in plain 
RPMI-1640 to a final concentration of 2mg/ml, which represented a 0.52 
Wunsch units/ml of collagenase activity. Stock solution was stored in 
600l aliquots at -30oC. For tissue digestion, stock solution was diluted 




ELISA Wash buffer was made of 1 x PBS supplemented with 0.5% 
Tween-20 v/v with pH adjusted to 7.4. ELISA reagent diluent was made 
of 1 x PBS supplemented with 1% BSA with pH adjusted to 7.2-7.4. 
Reagent diluent was sterilely filtered and stored at -30oC. 
Complete RPMI medium 
Complete RPMI was made of plain RPMI-1640 with L-Glutamine (Gibco, 
Invitrogen, Singapore), 10% heat inactivated FBS (v/v, Gibco, Invitrogen, 
Singapore), 1% 100 x Non-essential amino acid (v/v, Sigma, Singapore), 
1mM Sodium Pyruvate (Sigma, Singapore), 50μM -Mercaptoethanol 
(Sigma, Singapore), and 100 IU/ml Penicillin& 0.1mg/ml Streptomycin 
(Sigma, Singapore) under sterile conditions. 
Complete DMEM medium 
Complete DMEM was made of plain Dulbecco’s Modified Eagle Medium 
supplemented with L-Glutamine and 4.5g/L D-glucose (Gibco, Invitrogen, 
Singapore) and the same ingredients as complete RPMI under sterile 
conditions. 
2x Plain DMEM medium 
Powder of plain DMEM supplemented with L-Glutamine and 4.5g/L D-
glucose (Gibco, Invitrogen, Singapore) was dissolved in sterile water 
with only half of the recommended volume with addition of 2% Non-
essential amino acid (v/v, Sigma, Singapore) and 200 IU/ml Penicillin 
and 0.2mg/ml Streptomycin (Sigma, Singapore). The solution was then 
sterile filtered using a 0.22m filter (Nalgene, USA) and pH was adjusted 
to 7.4.  
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Paraformaldehyde (PFA) solution (4%) 
Paraformaldehyde was weighted in a fume hood with mask worn to avoid 
inhalation of the powder and diluted in 1 x PBS to a 4% solution. This 
solution was incubated in the water bath at 60°C for at least 40 mins with 
constant shaking to facilitate dissolving of PFA. When the solution turned 
clear, aliquots were made and store at -30oC for long-term storage or 
4oC for short-term storage. 
Annexin V binding buffer 
Annexin V binding buffer was made of 10mM HEPES/NaOH 
supplemented with 140 mM NaCl, 2.5mM CaCl2. pH was adjusted to 7.4 
and stored at 4ºC prior usage. 
Scott’s Tap Water Substitute 
Scott’s tap water substitute is made of 0.35% (w/v) Sodium Bicarbonate, 
2% (w/v) Magnesium sulfate in DI water. 
TBS-Tween buffer (TTBS) 
20 x stock TTBS buffer (USB, OH, USA) was diluted with deionized 
water to 1 x prior usage. 
Western blot running buffer  
20 x stock NupageTM MES-SDS running buffer (Invitrogen, CA, USA) 
was diluted with deionized water to 1 x prior usage. 
Western blot blocking buffer 
Western blot blocking buffer is made of 2% BSA (w/v, Santa Cruz, CA, 
USA) in 1 x TTBS or 5% non-fat dry milk (Labscientific, NJ, USA) in 1 x 




Alsever’s solution  
100ml of Alsever’s solution is made of 55mg of citric acid, 800mg of 
sodium citrate, 420mg of sodium chloride and 2050mg of D-glucose in 
deionized water with pH adjusted to 6.1.  
2.2 Mice 
C57BL/6 and OT- transgenic mice were purchased from Charles River 
Laboratories (Wilmington, MA, USA). IFN--/- and perforin-/- mice were 
purchased from Jackson’s Laboratory (Maine, NE, USA). NKp46gfp/gfp 
mice, which GFP has been inserted into NKp46 loci to knockdown 
NKp46 expression, were a kind gift from Dr. K. Campbell (Fox Chase 
Cancer Center, PA, USA). SP-D-/- mice were a kind gift from Dr. F. 
Poulain (US Davis, CA, USA). 7-9 weeks old wildtype (WT) and 7-10 
weeks old genetically modified mice were used in all experiments. All 
mice were maintained under specific pathogen-free conditions within 
National University of Singapore and University of Pennsylvania’s animal 
holding unit and used according to institutional guidelines. All 
procedures were under the IACUC protocol number 137/08 (NUS), 
087/10 (NUS) and 804884 (Upenn). 
2.3 Mouse model of influenza A virus infection 
Influenza Virus Propagation in Hen’s Eggs 
Fertilized hen’s eggs (10 day-old, Bestar, Singapore) were candled to 
identify the injection sites into the allantoic cavity without picturing the 
major blood vessels. Eggshell was then punctured using a 21G needle 
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(Becton Dickinson, NJ, USA), disinfected with 70% ethanol and 200l of 
influenza virus A/PR8/34 (H1N1) stock (4 HAU, ATCC VR-95, ATCC, 
USA), diluted 100 x in sterile 1 x PBS, was then injected into the allantoic 
cavity using a 27G needle (Becton Dickinson, NJ, USA). The punctures 
were then sealed using melted wax. The eggs were incubated in a 37oC 
incubator in the absence of CO2. Three days later, the eggs were cooled 
at 4oC for 4 hours to kill the embryos and clot the blood. Afterwards, the 
eggs were broken around the air cell and the allantoic fluid was 
harvested. The allantoic fluid was then centrifuged at 3,000 g and stored 
in aliquots at -80oC until further processing.  
Influenza A virus concentration 
Harvested allantoic fluid was filtered with a 0.22m filter (Nalgene, USA) 
and then span through a Vivaspin 20 centrifugal concentrator with a 
membrane pore size of 100,000 molecular weight (Sartorius AG, 
Germany) at the max speed at 4ºC for one hour and the flow through 
was discarded. The column was spun repetitively at the max speed for 
one hour at 4ºC with flow through discarded at the end of each spinning. 
Once all the allantoic fluid has been spun through, sterile PBS was 
added to the top chamber and span down for another few rounds for one 
hour at 4ºC with flow through discarded at the end of each spinning. 
Once the virus containing supernatant has been concentrated to less 
than 5ml in volume, it was harvested from the top chamber and stored 
in aliquots at -80oC. 
Generation of DiD labeled virus  
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Influenza virus harvested from allantoic fluid was labeled with the 
lipophilic dye 1,1’-dioctadecyl-3,3,3’,3’,tetramethylindodicarbocyanine 
(DiD) (Molecular Probes, Invitrogen, CA, USA) as previously described 
(223) with modifications. Briefly, concentrated virus-containing allantoic 
fluid was filtered using a 0.22m filter. 20 l of the DiD stock solution 
(20mg/ml dissolved in DMSO) was added to 1ml of the allantoic fluid and 
incubated for one hour at room temperature with frequent mixing 
protected from light. Non-incorporated DiD was removed by 
concentrating at 13,000 g for 5 mins. The supernatant containing the 
virus was further purified by ultracentrifugation over a single 50-20% 
sucrose step gradient at 112,000 g for 90 mins. The layer containing the 
virus was harvested and run over NAP-5 columns (GE Healthcare, UK) 
or Zeba desalting columns (7,000 MW cut-off, Pierce, ID, USA) 
according to the manufacturer’s protocol to remove the sucrose. 
Hemagglutination Assay 
Fresh guinea pig RBCs were purchased and washed twice and stored 
in Alsever’s solution at 4oC up to 2 weeks. To performed the 
hemagglutination assay, RBCs were washed twice in 1 x PBS, diluted to 
1% (v/v) in 1 x PBS from the pellet. Influenza virus stock was serially 
diluted in a 96-well V bottom plate (25μl/well). 1% RBC solution 
(25μl/well) was then added and incubated for 2 hours. HAU was 






Intranasal infection of influenza A virus  
Influenza A/PR/8/34 was obtained from American Type Culture 
Collection (ATCC) (VA, USA) and recombinant influenza A/PR/8/34 
containing chicken OVA epitope SIINFEKL (OT- PR8) was a kind gift of 
Dr. P. Thomas (St. Jude children’s hospital, TN, USA). Mice were 
anesthetized by intraperitoneal (i.p.) injection of a cocktail containing 
ketamine (100mg/kg, Sigma-Aldrich, MO, USA) and medotomidine 
(15mg/kg, Orion Pharma, Finland) or xylazine (20mg/kg, Phoenix 
pharmaceutics, MO, USA). A total volume of 20l sterile saline 
containing 5-50 pfu influenza A virus was administered intranasally (i.n.). 
Atipamezole (5mg/kg, Orion Pharma, Finland) was administered i.p. as 
reversal to the medotomidine post infection. If xylazine is used, no 
reversal will be given. If mice do not recover from the procedure or 
display any signs of distress according to IACUC guidelines, euthanasia 
will be carried out.  
Lung homogenate 
Lungs were harvested and cut into smaller pieces with scissors in 7ml 
sterile bottle in 2ml of plain DMEM. To further disrupt the cells, 
homogenization was carried out using hand held homogenizer at max 
speed for 1-2 mins and cooling on ice at 30 sec intervals. The 
homogenate was then span down at max speed for 3 mins at 4°C and 
supernatant was collected and stored at -80°C until further processing.  
Plaque Forming Assay 
MDCK (Madin-Darby canine kidney) cells were obtained from American 
Type Culture Collection (ATCC) (VA, USA) and cultured (2.5 x 105 
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cells/well) in complete DMEM media until confluent in a 24-well plate. 
Cells were then washed with sterile PBS to remove serum, which 
interferes with virus attachment. Influenza virus stock or lung 
homogenate were diluted 10-fold serially in plain DMEM and incubated 
with MDCK cells in 250μl per well for 1 hour at 37oC to allow maximum 
virus attachment. 2% molten agarose solution was diluted 1:1 with 2 x 
DMEM pre-warmed to 37oC and supplemented with TPCK Trypsin 
(4μg/ml). After incubation, supernatant were removed from lowest 
dilution to highest dilution, and 1ml of agarose solution was carefully 
layered on top of MDCK cells. Once the agarose was solidified, the 
plates were placed in the incubator for 3 days at 37oC to allow formation 
of viral plaques. At the end of the culture, 1ml of sterile PBS was added 
and agarose layer was pulled out using a bent needle without scratching 
the cell layer in the bottom. Leftover PBS was removed and 0.5ml of 0.5% 
aqueous crystal violet was added to stain the cell layer for 5 mins. Plate 
was then washed gently with running tap water three times to remove 
excessive staining solution. The plate was left dried and plaques were 
visualized and counted afterwards. Virus titer (plaque forming unites, 
PFU) was calculated as the reciprocal of the last dilution that displayed 
the plaques.  
2.4 Natural Killer cell depletion  
The hybridoma cell line (HB 191) against NK 1.1 (Clone PK136) was 
purchased from ATCC (VA, USA). Cells were cultured in Hybridoma 
SFM (Gibco, NY, USA) and the supernatant was harvested. Antibody 
was purified using FPLC (GE healthcare, UK) and quantified using 
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Bradford assay (Thermo Scientific, VA, USA). Endotoxin was removed 
using endotoxin removal kit (Thermo Scientific, VA, USA) and the 
remaining level was around 20 EU/ml as tested with an endotoxin ELISA 
kit (Lonza, MD, USA). To deplete NK cells, mice were injected i.p. with 
rabbit anti-mouse Asialo GM-1 antibodies (1.5 mg/kg, Wako Chemicals, 
Japan) or anti-NK 1.1 antibodies (1 mg/kg, Clone PK136). NK cell 
depletion efficiency was determined by the percentage of NK1.1+CD3- 
population using FACS.  
2.5 Tissue harvesting, cell isolation and processing 
Pulmonary single cell suspension  
Mice were euthanized using either carbon dioxide or SomnaSolTM 
Euthanasia- solution containing pentobarbital (0.1l/mouse, Bulter 
Schein, OH, USA). The lungs were harvested, cut into small pieces, and 
digested with 1x Liberase solution (1-1.5ml per lung) for 45 mins at 37ºC 
water bath and then passed through a 61m or 70m cell strainer (BD 
Pharmignen, CA, USA). Red blood cells were removed using RBC lysis 
buffer (2-3ml/3 mins per lung). Pulmonary lymphocytes population was 
further enriched with Ficoll-Paque Plus (GE Healthcare, NJ, USA) 
through layering 6ml of Ficoll at the bottom and 3ml of cells in PBS on 
top in a sterile 15ml conical tube. Phase separation was carried out 
through spinning at 600 g for 20 mins at 20°C with no acceleration and 
deceleration. Cells in the interface were harvested, washed and re-
suspended. DCs and macrophages were enriched using OptiprepTM 
(Sigma, MO, USA) by layering 2ml of FBS on top of 3ml of Optiprep 
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containing cells in a sterile 15ml conical tube. Phase separation was 
carried out through spinning at 1,700 g for 10 mins at 4°C with no 
acceleration and deceleration. Cells in the interface were harvested, 
washed and re-suspended. 
Lymph node single cell suspension  
The MLNs were harvested and passed through a 61m or 70 m cell 
strainer (BD Pharmignen, CA, USA). To enhance the yield for DC and 
macrophage, MLNs were digested with 1x Liberase solution (100-200ml 
per sample) for 20-30 mins prior passing through a 61m or 70m cell 
strainer (BD Pharmignen, CA, USA).  
Bronchoalveolar lavage 
BAL was collected through aspiration of the lungs with 2.7ml of PBS 
supplemented with protease inhibitors (Roche Diagnostics, Germany) 
three times through an incision at the trachea. Red blood cells were 
removed from the BAL using RBC lysis buffer (1-2ml/2mins per sample). 
Supernatants were harvested and stored at -80°C for further analysis. 
Cells were used for Flow cytometry and/or differential cell count using 
cytocentrifuge preparations (Cytospin3; Thermo Shandon, Pittsburgh, 
PA) stained with Kwik™Diff (Thermo Shandon, Pittsburgh, PA). 
Natural Killer cell purification and adoptive transfer 
Naïve natural killer cells from spleen were isolated using EasySep® 
Mouse NK Cell Enrichment Kit (Stemcell Techonologies, BC, Canada) 
according to the manufacturer’s protocol. NK cells (CD3-NK1.1+) purity 
was ≥70% determined by FACS. NK cells were re-suspended in sterile 
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PBS and injected intravenously in 100l volume (1-1.5 x 106 NK 
cells/mouse). 
Lymphocyte activated killer (LAK) cell generation 
Splenic NK cells were first positively selected using anti-Dx5 antibody 
coated MACS beads (Miltenyi Biotec, CA, USA) and then negatively 
selected using anti-CD3 antibody coated MACS beads (Miltenyi Biotec, 
CA, USA) to further deplete the T cell population, according to the 
manufacturer’s instructions. NK cells (CD3-NK1.1+) purity was ≥80% 
determined by FACS. NK cells were then cultured with rIL-2 (1000U/ml, 
R&D, MN, USA) for 4 days to generate LAK cells. LAK cells were washed 
and re-suspended in sterile PBS and injected intravenously in 100l 
volume (2-3 x 106 LAK cells/mouse). 
Re-stimulation ex vivo with PMA and Ionomycin 
Pulmonary lymphocytes were cultured in 1 x 106 /ml in completed RPMI 
media supplemented with PMA and Ionomycin (Invitrogen, CA, USA) in 
96 well-plates for 4 hours. Cells were then washed and stained for 
surface and intracellular markers. 
Cr51 release assay  
Target cells –YAC-1 were obtained from ATCC (VA, USA) and cultured 
in completed DMEM media. YAC-1 cells were washed twice and plated 
and incubated with 1ml of cDMEM supplemented with 100Ci of Cr51 
(Perkin Elmer, MA, USA) for one hour at 37ºC. YAC-1 cells were then 
washed twice and plated at a density of 1 x 105 /well in 96-well round 
bottom plate. Effector cells –lung lymphocytes were isolated from 
infected lungs at various time points p.i.. Effector cells were then added 
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into the plate with E:T ratio of 30:1, 10:1, 3:1 and 1:1 in triplicate. 
Spontaneous release were measured from Cr51 pulsed YAC-1 cells 
cultured alone. Maximum release were measured using lysed Cr51 
pulsed YAC-1 cells. After 4 hours of incubation at 37ºC, cells were span 
down and supernatants were collected and transferred to a LumaPlateTM 
(Perkin Elmer, MA, USA). Cr51 release was determined by TopCountTM 
(Perkin Elmer, MA, USA) once the LumaPlateTM was completed air-
dried. % lysis was calculated as [(sample - spontaneous release) / 
(maximum - spontaneous release) x 100] and average of the triplicate 
was recorded. If the spontaneous release was more than 10% of 
maximum release, the results were discarded. 
OT- T cell isolation and CFSE labeling 
OT- T cells were purified from spleens and lymph nodes of OT- mice 
using Ficoll (GE Healthcare, UK) and anti-CD8 antibody coated MACS 
beads (Miltenyi Biotec, Germany). CD8 T cells were over 95% pure as 
determined by flow cytometry. Purified CD8 T cells were stained with 5 
M violet CFSE (Molecular Probes, Invitrogen, CA, USA) for 15 mins at 
37ºC. The reaction was quenched with addition of cRPMI or cDMEM. 
Cells were washed twice and re-suspended in sterile PBS. Mice were 
injected i.v. with 1 x 106 OT- T cells. 
CD11c antigen presentation cells (APCs) isolation 
Spleens and/or lungs were harvested and digested with 1xLiberase. 
DCs and macrophages were further enriched with OptiprepTM (Sigma, 
MO, USA). These enriched cells were then positively selected using 
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CD11c+ MACS beads (Miltenyi Biotec, CA, USA). Purity of CD11c+ 
population was ≥95% as determined by FACS.  
Pertussis toxin delivery 
Mice were anesthetized by intraperitoneal (i.p.) injection of a cocktail 
containing ketamine (100 mg/kg, Sigma-Aldrich, MO, USA) and 
medotomidine (15 mg/kg, Orion Pharma, Finland). 50l of Pertussis 
toxin (8 mM, Invitrogen, CA, USA) was administered intratracheally. 
Atipamezole (5 mg/kg, Orion Pharma, Finland) was administered i.p. as 
anesthetic reversal. 
Apoptotic cell delivery 
Secondary fibroblasts (passage 48 from isolated primary murine 
fibroblasts) were infected at 2 pfu/cell overnight and induced apoptosis 
with UV irradiation (60 mJ/cm2) using a UV-crosslinker (Spectroline, NY, 
USA). Apoptosis was determined using Annexin V and 7AAD staining by 
FACS. These virus-infected apoptotic cells were then labeled with 5M 
violet CFSE (Molecular Probes, Invitrogen, CA, USA) for 15 mins at 37ºC. 
The reaction was quenched with addition of cRPMI or cDMEM. CFSE 
labeling efficiency was determined using FACS and cells were >95% 
CFSE+. Cells were washed twice and re-suspended in sterile PBS and 
transferred intratracheally to WT, NK cell-depleted or perforin-/- mice (~2 
x 107 cells per mouse). Lungs were harvested 2 hours post cell transfer 






Pulmonary cell migration assay 
Mice were anesthetized by intraperitoneal (i.p.) injection of a cocktail 
containing ketamine (100 mg/kg, Sigma-Aldrich, MO, USA) and 
medotomidine (15 mg/kg, Orion Pharma, Finland). 50l of CFSE (8 mM, 
Invitrogen, CA, USA) was administered intratracheally. Atipamezole (5 
mg/kg, Orion Pharma, Finland) was administered i.p. as anesthetic 
reversal. Mice were then infected i.n. with 5 pfu of influenza A virus 
(H1N1) 6 hours post CFSE inoculation. pMLNs were collected for 
analysis at day 3 p.i.. 
2.6 Flow Cytometry and cell sorting 
Surface staining 
Single-cell suspensions were incubated with Fc blocking antibody 
(Clone 2.4G2) (Biolegend, CA, USA) for 5 mins at 4oC before staining. 
Samples were then incubated with various antibodies (1:200) in 60l 
volume for 20-30mins at 4oC protected from light. Samples were then 
washed three times with 2ml FACS buffer to remove non-binding 
antibodies and re-suspended in 500l FACS buffer prior acquisition 
using Cyan ADP (Beckman Coulter, CA, USA) or Fortessa (BD, NJ, 
USA). At least 10,000 cells were acquired per sample. Data were 
analyzed using FlowJo v9.3 software (Tree Star, CA, USA).  
Live dead staining 
Live dead staining was performed using LIVE/DEAD® Fixable Dead Cell 
Stains (Invitrogen, NY, USA) according to the manufacturer’s 
recommendation. Briefly, cells were washed twice with PBS and then re-
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suspended in PBS to a concentration of 1 million/ml. Cells were then 
stained with live/dead dye (1:1000) for 30mins at room temperature 
protected from light. When staining was done, cells were washed again 
in PBS and then surface staining was carried out.  
Annexin V and 7AAD staining 
Annexin V staining was carried out post surface staining and live/dead 
staining. Cells were washed with PBS then with Annexin V binding buffer 
and re-suspended to 1-2 millions/ml in binding buffer. PE conjugated 
Annexin V (5l per sample) was added to the cells and stained for 10-15 
mins at room temperature protected from light. Cells were then washed 
with binding buffer and re-suspended to 500l binding buffer. 7AAD was 
then added (5l per sample) and acquisition was carried out. 
IFN- and CD107- staining 
For IFN- and CD107- staining, cells were treated with monensin (5 
g/ml, Invitrogen, CA, USA) and brefeldin A (5 g/ml, BD Pharmingen, 
NJ, USA) in the presence of FITC anti-CD107 (eBioscience, CA, USA) 
for 4 hours in cRMPI. Cells were then stained for surface markers, fixed 
and permeabilized using fixation/permeabilization buffer (eBioscience, 
CA, USA). Intracellular staining with APC conjugated anti-mouse IFN- 
was then carried out for 45 mins at room temperature protected from 
light.  
HA staining  
For HA staining, cells were stained for surface markers, and then 
permeabilized using fixation/permeabilization buffer (eBioscience, CA, 
USA). Human anti-HA (H1N1) was used as primary antibody and then 
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followed with staining of Alexa Fluor® 488 goat anti-human IgG as 
secondary antibody (Invitrogen, CA, USA).  
Tetramer staining 
OVA specific CD8+ T cells were detected with house made H-
2Kb/SIINFEKL tetramer. Staining of virus-specific CD8 T cells with H-
2Db/ASNENMETM (Influenza A (PR8) NP) Pro5® MHC Pentamer 
(Proimmune, UK) was performed according to the manufacturer’s 
protocol. Briefly, 0.5–1 million cells were stained with 2l of 
tetramer/pentamer for 30 mins on ice. Cells were then washed twice with 
FACS buffer and then surface staining was carried out. After the staining 
was done, cells were fixed with 1% PFA to prevent endocytosis of 
tetramer/pentamer.  
Intracellular Cytokine Staining 
For intracellular staining of cytokines in cells, synthesis of cytokines was 
stimulated by addition of the appropriate stimulus. Cytokine secretion 
from the cell was blocked by the addition of Brefeldin A (BD Pharmingen, 
NJ, USA) and monensin (Sigma, MO, USA) into the culture medium. 
Both Brefeldin A and Golgi stop was added at 1l per 1ml of culture 
medium to a final concentration of 5g/ml. After 6 hours, cells were 
harvested, transferred into FACS tubes before proceeding for surface 
staining of markers. Once surface staining is done, cells were fixed using 
500l of fixation/permeabilization buffer (eBioscience, CA, USA) for 
overnight at 4ºC and then permeabilized using permeabilization buffer 
(eBioscience, CA, USA) for 45 mins at room temperature. Antibodies for 
intracellular markers (1:100) were then added and incubated for another 
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45 mins at room temperature. Cells were then washed and re-
suspended in 500l of permeabilization buffer prior to acquisition. 
Pulmonary dendritic cells sorting 
Lungs were pooled and pulmonary dendritic cells were enriched using 
Optiprep gradient post liberase digestion of the lungs under sterile 
conditions. Cells were then washed and re-suspended to a 
concentration around 50 million/ml in MACS buffer. Cells were then 
incubated with Fc block (0.2g/ml, clone 2.4G2) for 5mins at 4°C to block 
any non-specific binding. Surface staining was then carried out for 30 
mins at 4°C in the dark. Small amount of cells was used for single cell 
staining controls to compensate multi-color staining. After staining, cells 
were washed twice with 2-3ml MACS buffer and then re-suspended in 
2ml of MACS prior to passage through a 61m cell strainer to reduce 
clogging during sorting. After filtration, cells were washed and re-
suspended to a concentration around 20-50 million/ml in MACS buffer 
and sorting was carried out using the MOFLO (Beckman Coulter, USA). 
Desired populations were collected in 1ml of cRPMI in sterile tubes. 
Purity check was also performed using small amount of sorted 
populations. 
2.7 mRNA, Reverse transcription PCR and real-time PCR 
mRNA extraction with RNeasy Mini Kit 
Lungs and lymph node mRNA was extracted using RNeasy Mini kit 
(Qiagen, Singapore) according to manufacturer’s protocol. Briefly, 350l 
of RLT buffer was added to up 20mg of tissues and then the mixture was 
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homogenized using electric powered homogenizer. The lysate was spun 
at full speed for 3mins to pellet tissue debris. Supernatant was put into 
the QIA shredder column (Qiagen, Singapore) and spun at full speed for 
2mins. 350l of isopropanol was added to the flow through and mixed 
by pipetting. 700l of the mixture was applied to the RNeasy spin column 
and spin for 15 secs at full speed. 700l of RW1 buffer was then added 
to the column and spun for 15 secs at full speed to wash the bound 
mRNA. Addition two washes were carried out with 500l of RPE buffer 
spinning for 15 secs at full speed. To elute the mRNA, 30l of RNase-
free water was added to the column and spun for 1min at full speed. 
Flow through was collected and mRNA concentration was quantified 
immediately using Nanodrop 2000 (Thermo Scientific, MA, USA) and 
reverse transcription was carried out immediately.  
mRNA extraction with TRIzol® Reagent 
Pulmonary mRNA was extracted using TRIzol® Reagent (Ambion, CA, 
USA) according to manufacturer’s protocol. Briefly, 1ml of TRIzol® 
Reagent was added to 50-100mg lung tissue in a RNase free tube and 
homogenized using Tissuemiser (Fisher Scientific, MA, USA) at full 
speed until fully dissociated. Lysate was then spun at full speed for 10 
mins at 4ºC. Supernatant was transferred to a new RNase free tube and 
incubated for 5 mins at room temperature to allow dissociation of 
nucleoprotein. Then, 0.2ml of chloroform was added and mixed by 
vigorous shaking for 15 secs followed by 3 mins incubation at room 
temperature. After incubation, phase separation was carried out by 
spinning at full speed for 15 mins at 4ºC. The aqueous layer was 
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harvested and 1ml of 75% ethanol was added for RNA washing. RNA 
was then pelleted through spinning at full speed for 5 mins at 4ºC and 
left drying for 5-10 mins. Pelleted mRNA was then dissolved in 20l 
RNase-free water and heated at a heat block for 15 mins at 60ºC. mRNA 
was then quantified using Nanodrop 2000 (Thermo Scientific, MA, USA) 
and reverse transcription was carried out immediately. 
Reverse Transcription PCR 
cDNA was reverse transcribed from mRNA using the QuantiTect 
Reverse Transcription Kit (Qiaqen, Netherlands) according to the 
manufacturer’s instruction. Briefly, 6l of mRNA was incubated with 1l 
of gDNA wipeout buffer at 42ºC for 2 mins and immediately placed on 
ice afterwards. 3l of master mix made of Reverse-transcription master 
mix containing Quantiscript Reverse Transcriptase (0.5l per sample), 
Quantiscript RT buffer (2l per sample) and RT primer mix (0.5l per 
sample) was added to the mRNA mixture and incubated at 42ºC for 15 
mins. The mixture was then incubated at 95ºC for 3 mins. After the 
incubation, the mixture was cooled down on ice. cDNA concentration 
was determined using Nanodrop 2000 (Thermo Scientific, MA, USA) and 
stored at -20ºC until further processing. 
Real-time PCR 
Real-time PCR was performed using GoTaq® Real-Time PCR Systems 
with SYBR Green® Dye (Promega, WI, USA) on 7500 real-time PCR 
system (Applied Biosystems, CA, USA). IP-10, GAPDH and IFN- were 
amplified with following primers respectively – GGACGGTCCGCTGCAA 
(F), and GCTTCCCTATGGCCCTCATT (R); 
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AGGCCGGTGCTGAGTATGTCG (F), and 
GCAGAAGGGGCGGAGATGAT (R); ACTGGCAAAAGGATGGTGAC 
(F), and TGAGCTCATTGAATGCTTGG (R). 
2.8 Immunohistochemistry 
Cryopreserved lung section staining 
Lungs were removed, embedded into OCT compound (Tissue-Tek, 
Miles, USA) and immediately frozen on dry ice. Frozen lung sections of 
4m, were cut and mounted onto Shandon Polylysine Slides (Thermo 
Fisher Scientific, VA, USA) and dried overnight before staining. Slides 
were blocked with normal serum for 15 mins at room temperature. Slides 
were then stained with primary antibodies for two hours at room 
temperature protected from light, washed three times with 1% BSA in 
PBS for 5 mins each, followed with secondary antibodies for 45-60 mins 
protected from light and washed again three times with 1% BSA in PBS 
for 5 mins each, After washing, slides were mounted using Prolong Gold 
Anti-fade Reagent (Molecular Probes, Invitrogen, USA). Acquisition of 
images was performed on Carl Zeiss Axio imager.Z1 fluorescent 
microscope (Axiocam HRM camera; Carl Zeiss Micro Imaging, 
Germany). Images processing was carried out using Axiovision Rel 4.8 
software (Carl Zeiss Micro Imaging, Germany).  
TUNEL staining in lung sections 
TUNEL staining of the lung sections was carried out using in situ Cell 
Death Detection Kit, TMR red (Roche Applied Science, Germany) 
according to manufacturer’s protocol. Briefly, lung sections were fixed 
with 4% PFA for 20 mins at room temperature and then washed with 
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PBS for 30 mins. Sections were then permeabilized for 2 mins on ice 
using a solution of PBS supplemented 01% Triton X-100 and 0.1% 
sodium citrate. TUNEL reaction mix containing enzyme solutions and 
label solution (1:9) was applied to sections (50l per lung sections) and 
incubated for 1 hour at 37ºC in the incubator protected from light. 
Negative controls were only incubated with labeling solution. After 
incubation, slides were washed with 1% BSA in PBS for 5 mins repeated 
three times. Slides were then mounted prior acquisition of images. 
HA staining in lung sections 
Human anti-HA (H1N1) and isotype control antibodies were a kind gift 
from Dr. Brendon Hanson (DSO, Singapore). Slides were blocked with 
normal serum for 15 mins at room temperature. Primary antibody diluted 
100 times in 1% BSA in PBS was added to lung sections and incubated 
overnight at 4°C protected from light. After incubation, sections were 
washed three times with 1% BSA in PBS for 5 mins each. Alexa Fluor® 
488 Goat anti-human IgG (1:200; Invitrogen, CA, USA) in 1% BSA in 
PBS was used as the secondary antibody and stained for one hour at 
room temperature protected from light. After incubation, sections were 
washed three times with 1% BSA in PBS for 5 mins each. Slides were 
then mounted prior acquisition of images.  
NKp46 staining in lung sections 
NKp46 staining was carried out using a triple staining protocol. Slides 
were blocked with normal serum for 15 mins at room temperature. Lung 
sections were then blocked with Avidin biotin blocking kit (Vector lab, CA, 
USA) according to manufacturer’s instruction. Briefly, sections were 
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incubated with Avidin D solution for 15 mins, rinsed with 1% BSA in PBS 
and then incubated with biotin solution for another 15mins. After blocking, 
sections were washed with 1% BSA in PBS for 5 mins repeated three 
times. Sections were then incubated with primary antibody—rat anti-
mouse NKp46 (1:100; ebioscience, CA, USA) in 1% BSA in PBS 
overnight at 4°C protected from light. After incubation, sections were 
washed three times with 1% BSA in PBS for 5 mins each. Secondary 
antibody of biotin goat anti-Rat IgG (1:200; Biolegend, CA, USA) in 1% 
BSA in PBS was then applied to the slides and incubated for one hour 
at room temperature protected from light. Slides were again washed 
three times with 1% BSA in PBS for 5 mins each. Tertiary antibody of 
Dylight 594 Streptavidin (1:800; Jackson laboratories, PA, USA) were 
applied to the slides and incubated for another hour at room temperature 
protected from light. Slides were then washed three times with 1% BSA 
in PBS for 5 mins each and mounted prior acquisition of images.  
Lymph node staining  
Posterior mediastinal lymph nodes (pMLNs) were harvested and fixed 
overnight with 2% paraformaldehyde in 20% sucrose. After fixation, 
pMLNs were washed in 20% sucrose for at least one hour, embedded 
into OCT compound (Tissue-Tek, Miles, USA) and immediately frozen 
on dry ice. Frozen lymph node sections of 4 m were mounted onto 
Shandon Polysine Slides (Thermo Fisher Scientific, VA, USA) and dried 
overnight before staining. Goat anti-mouse CCL21 (R&D systems, MN, 
USA), and rat anti-mouse PNAd (BD Pharmingnen, NJ, USA) were 
incubated with sections overnight. Alexa Fluor® 647 Chicken Anti-Goat 
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IgG (Invitrogen, CA, USA), DyLight 546 goat-anti rat IgG+IgM (Jackson 
ImmunoResearch, PA, USA) and DAPI were then stained for one hour. 
Mounting of slides was carried out using Prolong Gold Anti-fade Reagent 
(Molecular Probes, Invitrogen, USA). Acquisition of images was 
performed on Carl Zeiss Axio imager.Z1 fluorescent microscope 
(Axiocam HRM camera; Carl Zeiss Micro Imaging, Germany). Images 
processing was carried out using Axiovision Rel 4.8 software (Carl Zeiss 
Micro Imaging, Germany). 
2.9 Hematoxylin and Eosin Staining 
Mice were sacrificed with carbon dioxide. Lungs were perfused with 10ml 
of sterile PBS and 1ml of 4% PFA through the right cardiac ventricle. The 
right lobes of the lungs were collected and fixed in 4% PFA for another 
48 hours. The fixed lobes were then embedded in paraffin using an 
automated tissue processor (Shandon, UK). Processed lungs were then 
embedded in wax and transverse sections (5mm) were cut and mounted 
to slides. Slides were then incubated with 100% xylene for 1min twice to 
remove paraffin and dehydrated through sequential incubation with 
100%, 95% and 70% ethanol for 1 min each. Slides were then stained 
with hematoxylin (Sigma, Singapore) for 3mins and washed in deionized 
water. Excessive staining was removed through incubated in acid 
alcohol solution (1% v/v HCl in 70% ethanol) for 30 sec to 1 min and 
washed again with deionized water. Slides were then incubated with 
Scott’s tap water substitute for 1 min and washed with deionized water. 
Afterwards, slides were incubated with 95% ethanol and stained with 
eosin (Sigma, Singapore) for 30 sec. Excessive staining was washed off 
53 
 
using 95% ethanol. Further dehydration was carried out with incubation 
with 100% ethanol for 1 min twice. Then, slides were incubated with a 
50% xylene, 50% ethanol solution for 1 min and then with 100% xylene 
for 1 minute twice prior mounting using histomount (Sigma, Singapore). 
2.10 IL-12p70 and IFN- ELISA 
Quantification of released IL-12p70 and IFN- was performed using 
mouse IL-12p70 DuoSet® ELISA kit and IFN- DuoSet® ELISA kit (R&D, 
MN, USA) according to the manufacturer’s instructions. Briefly, 50l of 
capture antibody (180 x dilution in PBS) was coated on a Nunc MaxiSorp 
96 well-plate (Thermo scientific, NY, USA) and incubated overnight at 
room temperature. After incubation, wells were washed with 300l of 
ELISA wash buffer three times and then blocked with ELISA reagent 
diluent for another hour at room temperature. After blocking, plates were 
washed three times with ELISA wash buffer and 50l of standards 
ranging from 0-2000 pg/ml or samples were added to the well. Dilution 
of standards and samples were done using ELISA reagent diluent. 
Samples were incubated for 2 hours at room temperature to allow 
specific binding. After incubation, plates were washed three times with 
ELISA wash buffer. 50l of detection antibody (180 x dilution in ELISA 
reagent diluent) was added to the plate and incubated for 2 hours at 
room temperature. Plates were then washed three times with ELISA 
wash buffer and 100l of Streptavidin-HRP (200 x dilution in ELISA 
reagent diluent) was added and incubated for another 20 mins at room 
temperature protected from light. Plates were then washed three times 
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with ELISA wash buffer and 100l of TMB substrate containing Reagent 
A and Reagent B (1:1; BD Biosciences, NJ, USA) was added and 
incubated with constant shaking for at least 20 mins. 50l of stop solution 
(2M H2SO4) was added and plates were read using a plate reader at 
wavelengths of 450nm and 570nm. Concentration of cytokines was 
calculated based on absorbance and standards. 
2.11 Mouse model of ozone exposure  
Mice were exposed to ozone (3ppm) or forced air for 2 hours in a 
restrained chamber. Ozone was generated from compressed air using 
an OzoneLabTM ozone generator (Yanco Industries, Canada). The signal 
and duty of ozone generation was controlled using OzoneLabTM software 
ver. 5.0 (Yanco Industries, Canada). Ozone level in the chamber was 
monitored using a photometric O3 analyzer (Model 400E; Teledyne, CA, 
USA). The fluctuation of ozone level was limited to ±20% of desired level. 





2.12 Western blotting 
BCA protein assay 
Protein concentration in the BAL was determined using PierceTM BCA 
protein assay kit (Thermo scientific, IL, USA) according to 
manufacturer’s instructions. Briefly, 25l of BSA standards ranging from 
0-2000 g/ml was added to a 96 well plate. Similarly, 25l of BAL 
samples were also added to a 96 well plate. 200l of working solution 
containing BCA reagent A and B (50:1) was added to all the wells 
containing standards or samples. After a brief mixing on a plate shaker, 
samples were incubated for 30 min at 37ºC. After incubation, plates were 
read on a plate reader at the wavelength of 562nm. Protein 
concentration was then calculated based on the absorbance of the BSA 
standards. 
Western blot 
BAL samples (3g per well) or rSP-D (1l per well; Sino Biological Inc., 
China) were mixed with 1 x NuPAGE® LDS sample buffer (4 x stock; 
Invitrogen, CA, USA), 10% NuPAGE® sample reducing agent (10 x stock; 
Invitrogen, CA, USA) and deionized water to a total volume of 25l. 
Denaturing of protein was carried out with heating on a heat block at 
70ºC for 10 mins. After heating, samples were loaded to a NuPAGE® 4-
12% Bis-Tris pre-cast gel (Invitrogen, CA, USA) and ran at 200V with 1 
x MES-SDS running buffer. PageRuleTM Plus prestained protein ladder 
(5l per well) was added to the gel as well. NuPAGE® antioxidant 
(0.5ml/200ml running buffer) was added to the upper buffer chamber to 
prevent oxidization of the samples during the electrophoresis. Once the 
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samples ran down in the gel (~30 mins), the cassette containing the gel 
was broke open and the gel was carefully layered on top of a 
nitrocellulose membrane (0.2 µm pore size) and iBlot® Transfer Stack 
(Invitrogen, CA, USA) was assembled. The transfer was carried out 
using iBlot® Gel Transfer Device (Invitrogen, CA, USA) using program 
P3 running for 7 mins. After transfer, the membrane was washed briefly 
with 1 x TTBS and then blocked with 2% BSA in 1 x TTBS for 20 mins 
with constant shaking at room temperature. Membrane was incubated 
with primary antibody – rabbit polyclonal anti-mouse SP-D (1:2000) in 1 
x TTBS overnight at 4ºC. After incubation, membrane was washed three 
times with 1 x TTBS for 15 mins each and then staining with secondary 
antibody – HRP conjugated goat anti-rabbit IgG (1:1000) in 5% non-fat 
dry milk in 1 x TTBS for 1 hour at room temperature with constant 
shaking. Afterwards, membrane was washed twice with 1 x TTBS and 
once with PBS for 15 mins each. After washing, membrane was blot dry 
and incubated with PierceTM ECL western blotting substrate for 2-3 mins 
and exposed in the dark room. Films were then scanned and total 
density of the bands was analyzed using Gel-Pro Analyzer ver. 6.0 






2.13 List of Antibodies Used 
Target  Host Clone Conjugation Source 
B220 Rat RA3-6B2 FITC BD Pharmingen 
CCR4 Hamster 2G12 BV421 Biolegend 
CCR7 Rat 4B12 Biotin eBioscience 
  Rat 4B12 APC eBioscience 
  Rat 4B12 PE-C7 eBioscience 
CCL17 
(TARC) Goat Polyclonal Biotin R&D 
CCL21 Goat Polyclonal None R&D 
CD3e Hamster 500A2 eFluor 450 eBioscience 
  Rat 17A2 APC eBioscience 
  Hamster 145-2C11 FTIC BD Pharmingen 
  Hamster 145-2C11 PE BD Pharmingen 
  Rat 17A2 
PerCP 
Cy5.5 Biolegend 
CD4 Rat RM4-5 PB BD Pharmingen 
  Rat RM4-5 PE BD Pharmingen 
  Rat RM4-5 APC eBioscience 





CD8a Rat 53-6.7 PB BD Pharmingen 
  Rat 53-6.7 PE BD Pharmingen 
  Rat 53-6.7 PE-C7 BD Pharmingen 
  Rat 53-6.7 FTIC eBioscience 
  Rat 53-6.7 PB Biolegend 
  Rat 53-6.7 APC eBioscience 
CD8b Rat H35-17.2 PE BD Pharmingen 
CD11b Rat M1/70 PE BD Pharmingen 
  Rat M1/70 PE-C7 eBioscience 
  Rat M1/70 APC BD Pharmingen 
  Rat M1/70 
PerCP 
Cy5.5 BD Pharmingen 
  Rat M1/70 BV605 Biolegend 
CD11c Hamster N418 FITC BD Pharmingen 
  Hamster HL3 PE BD Pharmingen 
  Hamster N418 
PerCP 
Cy5.5 eBioscience 
  Hamster N418 AF647 Biolegend 
  Hamster N418 
APC-
eFluor780 eBioscience 






CD16/32 Rat 2.4G2 None Biolegend 
CD19 Rat 1D3 PE BD Pharmingen 
CD25 Rat PC61 PE BD Pharmingen 
  Rat PC61 PE-C7 BD Pharmingen 
  Rat PC61 APC-
eFluor780 
eBioscience 
CD40 Rat 3/23 FITC BD Pharmingen 
CD45 Rat 30-F11 PE-C7 BD Pharmingen 
CD62L Rat MEL-14 FITC BD Pharmingen 
CD69 Hamster H1.2F3 PerCP 
Cy5.5 
Biolegend 
CD80 Rat 16-10A1 FITC BD Pharmingen 
CD86 Rat GL1 FITC BD Pharmingen 
CD103 Rat 2E7 PE eBioscience 
  Rat 2E7 APC eBioscience 
CD107a Rat eBio1D48 AF488 eBioscience 
  Rat 1D48 APC Biolegend 
CD335/NKp46 Rat 29A1.4 eFluor 660 eBioscience 
  Rat 29A1.4 AF700 BD Pharmingen 





F4/80 Rat BM5 PerCP 
Cy5.5 
Biolegend 
  Rat BM5 FITC Biolegend 
IA/IE Rat M5/114.15.2 eFluor 450 eBioscience 
  Rat M5/114.15.2 PE BD Pharmingen 
  Rat M5/114.15.2 PerCP 
Cy5.5 
eBioscience 
  Rat M5/114.15.2 PerCP 
Cy5.5 
eBioscience 
IFN- Rat XMG1.2 AF647 Biolegend 
  Rat XMG1.3 PE eBioscience 
IL-5 Rat TRFK5 PE eBioscience 
IL-17A Rat eBio17B7 AF647 eBioscience 
IL-22 Goat Poly5164 PE Biolegend 
Ly6C Rat HK1.4 PB Biolegend 
Ly6G Rat 1A8 PE BD Pharmingen 
NK1.1 Mouse PK136 PE eBioscience 
  Mouse PK136 PE-C7 eBioscience 
SIINFEKL-Kb Mouse 25-D1.16 PE  
Siglec F Rat E50-2440 PE BD Pharmingen 
SP-D Rabbit   None Santa Cruz 
IL-13 Rat eBio13A PE eBioscience 
Rabbit Goat Polyclonal FITC BD Pharmingen 




Chapter 3: Characterization of natural killer cells in a murine model 
of influenza A infection 
Influenza A virus is an airborne pathogen, which transmits through direct 
contact, cough and sneeze in humans (224). Influenza A virus directly 
infects the airway epithelial cells and leads to clinical symptoms including 
fever, chills, headache and sore throat, which resolves after around 14 
days. Acute influenza A infection can also lead to viral and bacterial 
pneumonia (224), leading to enhanced co-morbidity and mortality in 
humans. Influenza A virus is categorized by the surface expression of 
hemagglutinin (HA) and neuraminidase (NA). Influenza A/H1N1 has led 
to two major pandemics in the past—the Spanish flu in 1918 killed over 
100 million humans and the swine flu in 2009. H1N1 is also widely used 
in the animal models to study the immune responses to influenza A 
infection. An important arm of viral defense against influenza infection in 
humans is natural killer (NK) cells, demonstrated by the fact that NK cell 
deficiency was associated with higher susceptibility to viral infections 
(225). NK cells act to kill virus-infected cells via direct lysis, antibody and 
cell dependent pathways. Activation of NK cells is mediated through the 
balance of surface activating and inhibitory receptors (73), but is 
independent of specific antigen recognition. In addition, IFN- released 
by NK cells is important in controlling early stage virus infection (226), 
macrophage activation and CD4 T cell differentiation (143). Therefore, 
we established a murine model of sublethal infection with influenza 
A/H1N1/PR/8/34 and investigated the pathology, inflammation and NK 
cell activation in this model. 
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3.1 Murine model of sublethal infection with influenza A virus  
To establish the sublethal infection model of influenza A infection, 
C57BL/6 mice were infected with 5pfu of influenza A/PR/8/34 (H1N1) 
virus intranasally and observed for 14 days post infection (p.i.). No 
mortality was observed across the time points observed. Significant 
weight loss was observed from D7 to D10 p.i., which peaked around D8 
p.i. compared to the PBS treated group (Fig. 3.1A). By D14 p.i., infected 
mice have gained weight to a comparable level of mock infected (PBS) 
group (Fig. 3.1A). Then, we examined the pulmonary viral load to 
measure the extent of viral replication using standard plaque forming 
assay. Lung tissues were harvested and homogenized at various time 
points post infection. As early as D2 p.i., there was already detectable 
virus in the lung (Fig. 3.1B). The peak of viral burden in the lung was 
observed at D4 p.i., with 10 fold increase in the viral load (Fig. 3.1B). By 
D7 p.i., viral load was barely detectable indicating virus was cleared in 
the lung (Fig. 3.1B). To measure whether lung function was altered 
during our model of influenza A infection, lung permeability was 
measured using albumin leakage in bronchoalveolar lavage (BAL). 
During the first 5 days post infection, no significant increase in albumin 
level was observed in the BAL compared to naïve mice (Fig. 3.1C). At 
D7, p.i., albumin peaked with a 10-fold increase compared to naïve mice. 
The BAL albumin level remained elevated at D11 p.i. (Fig. 3.1C). The 
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Figure 3.1 Weight loss, viral load and BAL albumin level during a sublethal 
influenza A infection. Mice were infected with influenza A/PR/8/34 (5 pfu). Body 
weight was measured daily during the course of infection (A). Pulmonary viral 
load was determined at various days p.i. using plaque-forming assay (B). BAL 
albumin level was determined using ELISA at various time points p.i. (C). Data 
shown are mean ± SEM representing at least 2 independent experiments with at 
least 3 mice per group. *, p< 0.05; **, p< 0.01; and ***, p<0.001 compared to PBS-
treated, D2 p.i. and naive mice respectively, using two-way ANOVA and Mann-
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Next, we studied lung inflammation during the early phase of the 
influenza A infection model as this time frame would involve mainly 
innate immunity. As cell infiltration in BAL acts as a good indicator of 
pulmonary inflammation, we examined the BAL cells during the early 
course of infection. During the first 5 days post infection, the most 
pronounced increase was observed in neutrophils (Ly6G+CD11c-) 
population. The number of BAL neutrophils increased significantly on D2 
p.i., with a peak on D4 p.i. and remained elevated at D5 p.i. (Fig. 3.2A). 
There was also a moderate (but not statistically significant) increase in 
number of DCs (MHChighCD11c+) and T cells (CD3+) starting at D4 p.i., 
while macrophage (MHCintCD11c+) number stayed relatively 
unchanged (Fig. 3.2B). Similarly, in the lung, neutrophils had a 
significant increase as early as D2 p.i., and continued to increase across 
the time points measured (Fig. 3.3A). No changes were observed in 
macrophage number (Fig. 3.3B). T cells were significantly increased 
starting at D4 p.i., and further incremented at D5 p.i. (Fig. 3.3B). 
Pulmonary DCs number remained at the same level for the first 3 days 
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Figure 3.2 BAL cellular infiltrate during a sublethal influenza A 
infection. Mice were infected with influenza A/PR/8/34 (5 pfu). BAL was 
collected and total cell number enumerated at various time points post 
infection. BAL Neutrophil number was determined using FACS (A). BAL 
macrophages, DCs and T cells were also determined using FACS (B). 
Data shown are mean ± SEM representing at least 2 independent 
experiments. *, p< 0.05; **, p< 0.01; and ***, p<0.001 compared to PBS-
treated mice using two-way ANOVA and Dunnet multi-comparison.  
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Figure 3.3 Lung cellular infiltrate and lung during a sublethal 
influenza A infection. Mice were infected with influenza A/PR/8/34 
(5 pfu). Lungs were digested and total cell number enumerated at 
various time points post infection. Pulmonary neutrophil number 
was determined using FACS (A). Pulmonary macrophages, DCs 
and T cells were also determined using FACS (B). Data shown are 
mean ± SEM representing at least 2 independent experiments. *, 
p< 0.05; **, p< 0.01; and ***, p<0.001 compared to PBS-treated 




3.2 Recruitment of NK cells during influenza A virus infection 
Since NK cells are important for viral clearance during the early course 
of infection prior to T cell activation, we analyzed the kinetics of NK cell 
recruitment using our model of sublethal infection. NK cells, identified as 
NK1.1+CD3- population, were determined using FACS and numerated in 
the lung, BAL and pMLNs. We observed that NK cells numbers started 
increasing in the lung within 24 hours and almost tripled over the next 3 
days (Fig. 3.4 A). In the BAL, the number of NK cells increased 17-fold 
at day 2 p.i. and remained elevated during the first 4 days p.i. (Fig. 3.4 
B). In the lung draining lymph node, the number of NK cells increased 
13-fold 3 days after the infection (Fig. 3.4 C). These data confirm that 
NK cells are rapidly recruited to the site of infection and secondary 
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Figure 3.4 NK cells were recruited and activated during influenza A 
infection. Mice were infected with influenza A/PR/8/34 (5 pfu). Pulmonary 
lymphocytes, BALF and posterior MLN (pMLNs) were collected and analyzed 
at various time points post infection. NK cells were gated as CD3-NK1.1+ 
population and enumerated in lung (A), BAL (B) and posterior MLN (C). Data 
shown are mean ± SEM representing at least 6 mice from 2 independent 
experiments. *, p< 0.05; **, p< 0.01; and ***, p<0.001 compared to PBS-
treated mice using one-way ANOVA and Mann-Whitney test.  
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3.3 Localization of NK cells during the influenza A infection 
NK cells are localized in the parenchyma of the lung. To visualize the 
localization of NK cells in the lung during influenza A infection, we used 
immunofluorescence to visualize pulmonary NK cells. Lungs were 
harvested from various time points post infection and frozen immediately. 
Sections 7m thick were cut and stained to visualize NK cells using the 
fluorescent microscope.  
NK cells were identified by NKp46 expression shown in red, with virus 
(HA+) and CD11c expressed by pulmonary DCs and macrophages, 
shown in green and white respectively. To test the specificity of the 
staining, we utilized anti-asialo GM1 antibodies, which a classic 
depletion agent for NK cells in vivo follow i.p. injection (127). NKp46 stain 
was highly specific as NK cell-depleted mice barely showed any 
fluorescence in the lung section (Fig. 3.5). In the naïve lung, NK cells 
were found in parenchyma of the lung in close proximity to CD11c+ cells 
(Fig. 3.6). At 48 hrs post infection, NK cells were increased as visualized 
in the section but they were still located in the parenchyma and near to 
the CD11c+ cells (Fig. 3.7). By 72 hrs post infection, we observed some 
sections with a heavily infected region (Fig. 3.8). There was co-
localization of virus (HA+) and CD11c+ cells on the section; but no co-
localization was found with virus (HA+) and NK cells (NKp46). As a 
matter of fact, NK cells were found mainly surrounding the infected area, 
while CD11c+ cells were found both within and outside the heavily 
infected region (Fig. 3.8). At 72 hrs post infection, we also found a region 
of lung with no HA expression. In this region we observed that NK cells 
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Figure 3.5 Immunohistochemistry of NK cell depleted lung 
section. Mice were depleted with asialo-GM1for 48 hours. Lungs 
were harvested and frozen immediately at 48hr post treatment. 
NKp46, CD11c and HA were stained in the 7um cut section of the 
lung. Representative data (20x) was shown at least 3 mice from 2 








   
Figure 3.6 Immunohistochemistry of naive lung section. 
Naïve lungs were harvested and frozen immediately. NKp46, 
CD11c and HA were stained in the 7um cut section of the lung. 
Representative data (20x) was shown at least 3 mice from 2 






   
Figure 3.7 Immunohistochemistry of infected lung 
section at 48hr p.i.. Mice were infected with influenza 
A/PR/8/34 (5 pfu). Lungs were harvested at 48hr p.i. and 
frozen immediately. NKp46, CD11c and HA were stained in the 
7um cut section of the lung. Representative data (20x) was 










Figure 3.8 Immunohistochemistry of infected lung section at 
72hr p.i.. Mice were infected with influenza A/PR/8/34 (5 pfu). Lungs 
were harvested at 72hr p.i. and frozen immediately. NKp46, CD11c 
and HA were stained in the 7m cut section of the lung. Representative 







Figure 3.9 Immunohistochemistry of infected lung section at 
72hr p.i.. Mice were infected with influenza A/PR/8/34 (5 pfu). Lungs 
were harvested at 72hr p.i. and frozen immediately. NKp46, CD11c 
and HA were stained in the 7um cut section of the lung. 
Representative data (20x) was shown at least 3 mice from 2 






To trace NK cell migration, we utilized CFSE to label pulmonary NK cells. 
Mice were instilled intratracheally with CFSE (50l, 8M) and infected 
with 5 pfu of influenza A virus (H1N1) 6 hours post CFSE inoculation. 
Lung draining lymph nodes were harvested at D3 p.i. and analyzed by 
FACS. CFSE+NK cells were detected in the pMLN (Fig. 3.10). To confirm 
this observation, we administered pertussis toxin (PT) – a broad 
spectrum chemokine inhibitor, concurrent with virus. No CFSE+NK cells 
were detectable in the pMLN at D3 p.i in PT-treated mice. We also 
analyzed B cells (NK1.1-CD3-), which do not migrate to the pMLN during 
the early stage of influenza infection, were CFSE negative suggesting 
that CFSE is unlikely to leak to the pMLN (Fig. 3.10). These data 
suggested that pulmonary NK cells are able to migrate to the draining 
lymph node in a chemokine dependent pathway in response to influenza 
A infection. 
Figure 3.10 NK cell migration to the pMLN. Mice were inoculated 
with CFSE (8 m) i.t., and infected with influenza virus (5 pfu) with or 
without Pertussis Toxin (PT). At day 3 p.i., pMLN was harvested and 
stained. Representative figures of CFSE expression from 2 
independent experiments of 4 mice were shown. 
 






3.4 Activation status and IFN- expression of influenza A virus-
induced NK cells 
Besides the kinetics of NK cell recruitment to the site of inflammation, 
the effector functions of pulmonary NK cells are crucial in mediating anti-
viral inflammation. We utilized three different markers to access this– 
CD69, cytotoxicity and IFN- production. 
CD69 is an early activation marker for both T cells and NK cells. Hence, 
we assayed CD69 expression of freshly isolated lung cells. Within first 
48hrs, there was no difference in CD69 expression of NK cell population 
derived from influenza-infected mice compared to PBS-inoculated mice. 
By D3 p.i. however, CD69 expression was increased 2-fold compared to 
mock-infected mice and remained elevated at D4 p.i. (Fig. 3.11 A).  
NK cell mediated killing of infected cells is a hallmark of influenza A 
infection. We used both surface CD107- expression, a marker that has 
been shown to correlate with NK cytotoxicity (227) and classical Cr51 
release assay to access the kinetics of NK cell cytotoxicity in our model 
of influenza A infection. Single cell suspension from lungs was enriched 
with Ficoll and cultured with YAC-1 cells in an E: T ratio of 300:1 for 4hrs 
to determine the surface CD107- expression. Surface expression of 
CD107- on NK cells (Fig. 3.11B) was augmented 4-fold indicating that 
NK cells were activated to kill infected cells. To further confirm the 
cytotoxicity of NK cells was augmented during influenza A infection, we 
utilized Cr51 release assay to directly study the killing of YAC-1 cells by 
NK cells isolated from infected mice lungs. YAC-1 cells were labeled with 
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Cr51 and cultured with NK cells at various E: T ratio. LAK cells were used 
as a positive control (Fig 3.11C). Similarly, NK cells showed increased 
killing of target cell at D2 and D3 p.i., which correlates with surface 
CD107- expression (Fig. 3.1 B).  
IFN- represents another important arm of NK cell mediated anti-viral 
responses. IFN- can further augment NK cell function in an autocrine 
manner. It is also capable to stimulate DC function and promote Th1 and 
CTL response. Intracellular IFN- level of NK cells was measured after 
ex vivo re-stimulation with PMA/Ionomycin for 4hrs. Expression of IFN- 
in NK cells increased 5-fold at D3 p.i. while no significant augmentation 
of IFN- production was observed in the earlier time points studied (Fig. 
3.11D).  
Collectively, these data demonstrate that NK cells were activated early 
in response to influenza A virus infection. CD107- and IFN- expression 
both peaked at D3 p.i. upon re-stimulation, while CD69 expression 
peaked at D3 p.i. CD107- and IFN- expression returned to baseline 
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Figure 3.11 NK cell activation status post influenza A infection. 
CD69 expression was determined from freshly isolated pulmonary NK 
cells at various time point post infection (A). Surface CD107-α expression 
of NK cells was measured after in vitro co-culture with target cell – YAC-
1 at an effector to target (E:T) ratio of 300:1 for 4 hours (B). Pulmonary 
NK cells at various time points p.i.. Cr51 release was detected after 4hr 
co-culture of NK cells and Cr51 labeled YAC-1 cells with various E:T ratio 
(C). Intracellular IFN- expression of NK cells was measured after in vitro 
activation with PMA (10 ng/mL) and Ionomycin (400 ng/mL) for 4 hours 
(D). Data shown are mean ± SEM representing at least 2 independent 
experiments with at least 3 mice per group. *, p< 0.05; and ***, p<0.001 
compared to PBS-treated mice using one-way ANOVA and Mann-
Whitney test.  
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3.5 Effects of NK cell depletion on pulmonary viral load, 
histopathology & weight loss 
In order to evaluate the importance of NK cells during influenza A 
infection, we utilized antibodies to deplete NK cells 24 hours prior 
infection. Anti-asialo GM1 is a classic depletion agent for NK cells which 
is able to deplete both spleen and lung NK cells in vivo follow i.p. injection 
(127). Anti-NK1.1 (PK136) is also widely used to deplete NK cells 
through intraperitoneal administration. In order to examine the 
importance of NK cells in influenza A virus infection, mice were 
administrated anti-asialo GM, inoculated with influenza A virus, and 
changes in viral load, histopathology and weight loss were examined. 
Pulmonary single cell suspensions obtained from influenza infected mice 
treated with anti-asialo GM1 were only 0.55% NK1.1+CD3- at D2 p.i. in 
contrast to control in which 12.56% of pulmonary cells obtained were 
NK1.1+CD3- cells (Figure 3.12). Thus, anti-asialo GM1 reduced 
pulmonary NK cell numbers by approximately 95%. Similarly, mouse 
treated with anti-NK1.1 showed only 0.18% NK cells in the lung 








Figure 3.12 NK cell depletion efficiency. NK cell depleting 
antibodies were injected i.p.. Pulmonary NK cells were gated as 
NK1.1+CD3- population at D2 post treatment. Plots shown are 












We then utilized weight loss/mortality, pulmonary viral load, and lung 
permeability to study the severity of influenza A infection between non-
treated and NK cell depleted mice. Weight loss was found to correlate 
directly to pathology and viral titer (228). It is a relatively non-invasive 
method to apply across the whole infection course. At a 5pfu dose of 
influenza, NK-depleted mice showed similar weight loss compared to the 
un-depleted group. On day 8, both groups reached the lowest weight 
point with around 15% weight loss (Figure 3.13A). No mortality was 
observed in either group. All the mice recovered around D14 p.i.. 
However, with a 50pfu dose of influenza, a trend of higher mortality rate 
was observed in NK cell depleted group (Figure 3.13B). Hence, NK cell 
depletion did not impact severely on weight loss at a sublethal dose 
infection but it could impact the survival rate at a higher dose of infection.  
As weight loss is an indirect measurement of pathology, we studied 
further the pulmonary viral load, which represents the viral burden in the 
lung. Viral load was measured in the lung homogenate across several 
time points post infection, using a plaque forming assay. A significant 
2.4-fold increase in viral burden was evident at day 2 p.i. in NK cell-
depleted mice while no difference was observed at the peak of viral load 
(Fig. 3.13C) suggesting that, NK cell depletion did not greatly enhance 
viral replication at a sublethal infection.  
To study the effect of NK cell depletion on lung function, we measured 
BAL albumin leakage at various time points post infection. Lung 
permeability increased as indicated by increased albumin level in BAL 
at later time points with or without NK cell depletion (Fig 3.13D). At all 
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the time points examined, no significant differences in BAL albumin level 
were observed in NK cell-depleted or non-depleted mice. These data 
suggested that NK cell depletion did not significantly impair lung function 
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Figure 3.13 Weight loss, survival rate, pulmonary virus load and BAL 
albumin level during influenza A infection in NK cell depleted mice. Mice were 
infected with influenza A/PR/8/34 (5 pfu). NK cell depletion was performed 24hr 
prior to infection using asialo-GM1 or anti-NK1.1 antibodies. Body weight was 
measured daily during the course of 5pfu infection (A). Survival rate was tracked 
over 14 days point infection with 50pfu (B). Pulmonary viral load was determined at 
various days p.i. using plaque-forming assay with a 5pfu infection (C). BAL albumin 
level was determined using ELISA at various time points post a 5pfu infection (D). 
Data shown are mean ± SEM representing at least 2 independent experiments. *, 







To visualize the local inflammation in the airway during the infection, we 
performed histological examination of lung sections using H&E staining. 
When examining the histopathology of mice, the lumen of the 
bronchioles remains clear in naïve mice (Figure 3.14 A) while necrotic 
cellular debris is present in infected mice D4 p.i. with or without NK cell 
depletion as indicated by the black arrows in the histological session of 
the lung (Figure 3.14B, C). No apparent difference in inflammation was 
seen between non-depleted mice and NK cell depleted mice. 
Taken together, these data suggested that although NK cell depletion 
did not affect weight loss, lung permeability, or histopathology, but 
heightened viral burden (D2 p.i.) in the lung in our model of sublethal 











Figure 3.13 Representative histology sections infected and NK cell 
depleted mice. Histology section of lung from naïve mice (A), mice 
infected with 5pfu influenza A virus at D4 p.i. (B), and NK cell depleted-
mice infected with 5pfu influenza A virus at D4 p.i. (C) Black arrows 
indicate the necrotic debris accumulated within the bronchial lumens. 
Photomicrographs are representative of lungs from 4 sections per mice 









We investigated the kinetics of pulmonary NK cell infiltration and 
activation in a murine model of influenza A virus sublethal infection in 
this chapter. Stein-Streilein and co-workers (127) demonstrated that NK 
cell depletion potentiates pulmonary influenza A viral load in mice and 
hamsters, and is associated with increased mortality and morbidity. Neff-
La Ford and colleagues also observed a higher mortality rate in mice 
depleted of pulmonary NK cells with influenza infection (229). The two 
most important antiviral functions of NK cells are direct lysis of infected 
cells, and the initiation of adaptive immunity through secretion of 
cytokines such as IFN- (169, 230, 231). In the present study, we 
demonstrated that NK cells are recruited and activated early during the 
course of infection, as shown by elevated CD107- and IFN- 
expression. Furthermore, we studied the physiological relevance of NK 
cells through selective depletion experiments. At the low dose of 5pfu, 
NK cell depletion did not worsen virus-induced weight loss, while at the 
high dose of 50pfu, NK cell depletion did result in a trend to increased 
mortality compared to the control group (Fig 3.13B).  
The first part of our study aimed to establish NK cell recruitment kinetics 
during the natural course of influenza infection. In humans, NK cell 
numbers increased rapidly in the blood during the first 3 days of infection, 
reflecting the recruitment to the lung (132). Gazit and colleagues 
demonstrated that NK cell recruitment is initiated on D2 p.i. and 
continues to increase to D4 p.i. in mice (138). These findings are 
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consistent with the results of the present study, whereby pulmonary NK 
cells identified by NK1.1+CD3- increased rapidly following influenza A 
virus inoculation, with a near 2-fold increase over mock-inoculated mice 
within 24hr p.i. and NK cell number subsequently remained elevated 
across all time-points measured. These data clearly demonstrate that 
NK cells were recruited to the lung early in influenza A infection and as 
such were influential in viral clearance at D2 p.i.. NK cells were also 
found to increase sharply in the BAL and pMLNs after a slight delay 
compared to the lung, suggesting continued recruitment during influenza 
A infection.  
NK cell localization in the lung was further identified using 
immunohistochemistry in the frozen section. We found that NK cells 
were located exclusively at the parenchyma, which is in accordance with 
a previous study by Kanemi and colleagues (232). NK cells were also 
found in close proximity to CD11c+ cells implying that during infection, 
NK cells are able to interact with DCs and macrophages. However, we 
did not find co-localization of NK cells and virus, suggesting that NK cells 
might not be actively infected by influenza. Previous studies showed that 
influenza A virus could directly infect both primary human (166) and 
murine NK cells (165). Our data did not directly support that observation, 
which could be due to differences in infection dose, time course, and 
staining method. Another possibility is that the infected NK cells 
underwent apoptosis, which made them undetectable in our study. We 
also found that some of NK cells in the pMLN migrated from the lung. 
This is the first direct evidence that pulmonary NK cells migrate from lung 
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to the lymph nodes during influenza A infection. These data raise a 
possibility that migratory NK cells are able to directly activate LN cells 
through direct interaction or released mediators. This could be another 
mechanism besides DCs, to relay the inflammatory signal from the 
primary infection site to LNs. 
NK cell activation status was assessed by three markers – CD69, 
CD107- and IFN-. CD69 cross-linking induces cytotoxicity of activated 
NK cells and facilitates new recognition by activated NK cells (233-235), 
while surface CD107- correlates well with target cell lysis by NK cells 
upon stimulation with PMA/Ionomycin (227, 236). Surface CD107- is 
also indicative of cytokine secretion by NK cells (227). IFN- is a crucial 
cytokine against viral infection, which mediate Immunomodulatory and 
direct antiviral activity (148, 226).  
Initially, both CD69 and CD107- expression were examined ex vivo 
without exogenous stimulation. This approach resulted in extremely low 
CD107- positive staining, a possible result of transient expression of 
CD107- and difficulty in direct staining of CD107- on the cell surface 
(237). We therefore adopted a culture assay with Golgi block and 
monensin to increase staining for surface CD107-, although the level 
was still low for unstimulated cells. A possible explanation for the low 
level of CD107- expression is adverse culture conditions, as 
approximately half of NK cells died after 5 hours in culture. Since 
stimulation with PMA/Ionomycin was used in the study by Alter and 
colleagues (227), to establish the essential correlation between CD107-
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 and NK cell activation, readouts with stimulated cells were used to 
demonstrate the killing potential of NK cells. Similarly, intracellular IFN-
 level was also examined within a stimulated population.  
In the present study, all three markers examined were upregulated early. 
CD69, CD107- and IFN- expression peaked at D3 p.i., while CD69 
and IFN- expression remained elevated across all time-points 
examined, CD107- expression returned to basal level by D3 p.i. These 
results suggest that NK cell-mediated killing only happened on D3 p.i., 
although IFN- secretion fluctuated after elevation throughout all time-
points examined. The fluctuation of IFN- level may be a result of 
activated adaptive immunity on D4 p.i., whereby secretion of mediators 
such as IL-2 from adaptive immune cells may stimulate IFN- production 
by NK cells (238-240). The exact role of CD69 on activated NK cells is 
still uncertain (241), but it is implicated in the modulation of activated NK 
cells and may be involved in NK cell retention (86, 242-245). In our study, 
CD69 expression peaked later than CD107- and IFN-γ, suggesting that 
CD69 is involved in the maintenance and enhancement of NK cell 
activation but is not directly involved in the initial activation, consistent 
with previous reports which suggested CD69 expression is triggered 
after activation of NK cells (233, 246-249). When comparing the kinetics 
of NK cell activity and NK cell recruitment, it is clear that NK cell 
activation lags behind recruitment. Hence, it appears likely that freshly 
recruited NK cells require activation by other cells (e.g. DCs) or soluble 
mediators (e.g. Type I interferon) in the lung. This is supported by the 
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findings of Draghi and colleagues (241), who noted that without DCs, NK 
cell CD69 and IFN- expression was unaffected by influenza A virus 
alone. The data on NK cell recruitment activity and virus titer obtained in 
this study, suggests that NK cells recruited within 24hrs were the major 
effectors that killed infected cells on D2 p.i. and they are also largely 
responsible for IFN- expression level. 
In order to further understand the role of NK cells in protective innate 
immunity against influenza A virus, we conducted a series of NK cell 
depletion experiments. While previous studies have demonstrated that 
NK cell depletion leads to potentiated infection outcomes (127, 236), Bot 
et al. showed that NK cell depleted scid mice do not show a difference 
in survival compared to non-depleted littermates (130). At the low dose 
of 5pfu, mice depleted of NK cells demonstrated significantly higher viral 
loads during D2 p.i. although there was no difference between groups 
by D4 p.i. This is consistent with other studies that show NK cells are 
important to restrict viral replication in the early course of infection (144, 
156, 250), while once adaptive immunity is initiated T cells are 
responsible for viral clearance (229, 251). Surprisingly, NK cell-depleted 
mice did not demonstrate more weight loss compared to control, 
although at a dose of 50pfu, mortality showed a trend of increment in NK 
cell depleted mice. There was also no observed difference in lung 
permeability or histopathology between NK cell depleted and non-
depleted mice with sublethal infection, although these negative findings 
may reflect the insensitivity of the techniques used as opposed to lack 
of physiological activity by NK cells. Another possible explanation is that 
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NK cells mediate pulmonary immunopathology during influenza A 
infection as demonstrated by Zhou and colleagues (252). IFN- and 
TNF- produced by CD8+ T cells have been shown to mediate influenza 
virus-associated immunopathology (253, 254). As activated NK cells 
also produce both cytokines, NK cell depletion may not lead increased 
weight loss or pathology. Moreover, higher viral loads did not essentially 
link to less protection, and the exact opposite conclusion is drawn from 
the study of TLR3-/- mice, which have a survival advantage despite 
higher pulmonary viral load during influenza infection (255).  
In summary, results obtained from this chapter support the view that NK 
cells are activated to kill infected cells and produce cytokines during the 




Chapter 4: Natural killer cells promote DC function during primary 
influenza A infection 
In the previous chapter, we showed that NK cells were located in close 
proximity to dendritic cells (DCs) in the lung. Therefore, we speculate 
that NK cells could influence DC function during influenza A infection.  
Previous studies have shown that there is a reciprocal interaction 
between NK cells and DCs. DCs promote NK cell mediated cytotoxicity 
and IFN- production through cytokine and contact dependent pathways 
in vitro and in vivo (256). On the other hand, NK cells induce maturation 
and cytokine secretion from DCs through released mediators such as 
TNF- and IFN-, as well as cell-to-cell contact (257). However, NK cells 
also kill immature DCs to prevent inappropriate immune activation (258) 
by NKp30 (259) and TNF- apoptosis-inducing ligand (TRAIL) (260) 
dependent mechanisms. NK-DC interactions take place both in the 
peripheral tissues and regional lymph nodes, suggesting that they could 
actively contribute to local and systemic inflammation (256). This cross 
talk between NK cells and DCs also initiate CTL responses against 
tumor (261), control MCMV infection (262), and mediate immunity 
against HIV infection (263).  
Hence, in this chapter, we aim to investigate the interaction between NK 
cells and DCs in vitro and in vivo in the sublethal infection model of 
influenza A virus.  
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4.1 NK cells promote DC maturation and IL-12p70 production in 
vitro 
DCs potentiate the effector functions of NK cells through secretion of IL-
12 (146), IL-18 (264) and IL-15 (265). NK cells, in response to this 
stimulation, increase IFN- production. IFN- will in return, induce DC 
maturation and further amplify IL-12 secretion from DCs (266). Therefore, 
in this section, we studied the role of NK cells on regulating DC 
maturation and IL-12p70 production.  
We first utilized a NK-DC co-culture system to probe the possible 
regulation of DC functions by NK cells. CD11c+ pulmonary antigen 
presenting cells (APCs) were isolated by MACS and co-cultured with 
pre-activated splenic NK cells (activated with PMA/Ion ex vivo) for 18 
hours. Maturation of DCs was assessed by surface expression of CD86. 
When cultured with naïve NK cells, pulmonary DC population 
(MHChighCD11c+ population) did not show any increase in CD86 
expression (Fig 4.1A). However, a substantial increase of CD86 was 
observed after co-culture with activated NK cells. This increase in CD86 
was only found in the DCs, but not in the macrophage population 
(MHCintCD11c+ population) (Fig 4.1B) indicating specific NK cell 




Figure 4.1 Expression of CD86 on pulmonary APCs co-cultured 
with NK cells. Splenic NK cells were isolated using anti DX-5 
microbeads. Activated NK cells were incubated with PMA/Ionomycin for 
2hr. NK cells were then washed and co-cultured with CD11c+ lung APCs 
enriched using CD11c microbeads for 18hrs. CD86 expression on DCs 
(A) and macrophages (B) were analyzed by FACS. Representative data 
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To understand whether this NK cell-mediated DC maturation is contact 
dependent; we repeated this co-culture using a transwell cell culture 
plate. Pulmonary CD11c+ APCs were seeded on the top and activated 
NK cells were plated together on the top, or in the bottom to prevent 
contact with APCs for 18 hours. When NK cells were plated in the bottom 
without any contact with APCs, expression of CD86 on DCs (gated as 
MHChighCD11c+ population) showed a slight decrease compared to the 
co-cultured DCs (Fig 4.2). These data altogether suggested that 
activated but not naïve NK cells could selectively promote CD86 
expression on pulmonary DC in a partially contact-dependent and 






Figure 4.2 Expression of CD86 on pulmonary DCs co-cultured with 
NK cells in a transwell. Spleen NK cells were isolated and activated 
for 2hr in the presence PMA/Ionomycin. NK cells were then washed and 
co-cultured or separated by the transwell with CD11c+ lung APCs 
enriched for 18hrs in a 4:1 ratio. CD86 expression on DCs was analyzed 




Top: Activated NK cells + DC Bottom: Media 
Top: DC Bottom: Activated NK cells 
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Besides maturation status, another important aspect of DC function is 
IL-12 production. IL-12p70 has been showed to promote Th1 
differentiation and IFN- production from NK cells (267). In order to 
determine whether NK cells regulate IL-12p70 production by DCs, we 
co-cultured isolated splenic DCs and LAK cells (primed NK cells 
generated by culturing with rIL-2 for 4 days) in the presence of TLR9 
agonist—CpG and measured the released IL-12p70 in the culture 
supernatant using ELISA. IL-12p70 was detected when DCs were 
cultured with CpG (Fig 4.3), but not detected in the supernatants with 
DCs alone or co-cultured of DCs and LAK cells. However, the amount of 
IL-12p70 in the supernatant increased 5-fold, when LAK cells were 
added in the presence of CpG (Fig 4.3). These data suggested that NK 
cells could synergize with CpG to enhance DC dependent IL-12p70 
production, but that NK cells alone could not induce IL-12p70 production 
from DCs.  
Since IFN- produced by NK cells is known to stimulate IL-12p70 
production from DCs (268), we repeated these experiments using IFN--
/- LAK cells. As expected, co-culture with IFN--/- LAKs induced less than 
half of the amount of IL-12p70 production compared to WT LAKs at the 
presence of CpG (Fig 4.3), suggesting that DC dependent IL-12p70 is 
partially mediated by IFN- production by NK cells.  
Our data from the previous section already showed that contact 
dependent pathways played a role in NK cell mediated DC maturation. 
Hence, we set out to test whether IL-12p70 production required contact 
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with NK cells. NKp46 is a NK cell surface activation receptor and was 
shown to enhance NK cell dependent IFN- production (269) and 
influenza induced mortality in mice (138). In order to investigate the role 
of NKp46, we performed co-culture experiment with LAKs and DCs in 
the presence of various doses of NKp46 blocking antibodies. IL-12p70 
production showed a dose-dependent reduction upon NKp46 blockade 
(Fig 4.3), suggesting that NKp46 is likely to be involved in mediating DC-











Figure 4.3 IL12p70 production from splenic DCs co-cultured with 
LAK cells. WT and IFN--/- splenic NK cells were enriched using Dx5 
microbeads and cultured with IL-2 for 5 days to generate LAK cells. 
Sorted splenic DCs (0.2M per well) were cultured with or without TLR 
agonists and LAK cells overnight. Culture supernatant was assayed 





To further confirm the role of NKp46, we cultured DCs with plate-bound 
NKp46 Fc (fusion protein of mouse NKp46 and human IgG1, which 
retain the binding function of NKp46) in the presence of CpG and IFN-. 
A significant increase in IL-12p70 production was observed using 2µg of 
NKp46 Fc (Fig 4.4A). This enhanced IL-12p70 production was observed 
as early as 4 hours post culture and also showed a time-dependent 
increase in both control and NKp46 Fc treated plate (Fig 4.4B). However, 
we did not observe a significant up-regulation of IL-12p35 and IL-12p40 
mRNA expression at all the time points measured (data not shown). 
These data confirmed that NKp46 is likely to be involved in promoting 
DC-dependent IL-12p70 production.  
Besides IL-12p70 production, we also examined expression of 
maturation markers on DCs – CD80, CD86 and CD40 in the presence 
of NKp46 blockade or plate-bound NKp46 Fc (data not shown). No 
difference was observed in the expression of maturation markers on DCs 
in either situation. Thus, NKp46 is only involved in promoting IL-12p70 
production but not affecting DC maturation.  
Taken together, these in vitro studies showed that NK cells could 
potentiate DC activation and IL-12p70 production through both contact-
dependent and IFN- dependent pathways. The NK surface activation 
marker, NKp46 was found to be important in enhancing IL-12p70 









































0.1% BSA NKp46 Fc 2ug
IL-12p70
Figure 4.4 IL12p70 production from splenic DCs culture with pre-
coated NKp46 Fc. Recombinant mouse NKp46 Fc (2ug) (R&D) was 
coated on a 96 well plate in 20µl of 0.1% BSA overnight. Sorted splenic 
DCs (0.2M per well) were isolated and added in to the plate with IFN-
 (10ng/ml), GM-CSF (10ng/ml) and CpG (0.2µM). Supernatant was 
assayed for IL-12p70 after overnight culture (A) or every 2 hours (B). 











4.2 NK-DC cross talk during influenza A infection  
Since the in vitro data demonstrated an important role of NK cells in 
mediating DC functions, we aimed to assess the effect of NK cells on 
DC function during influenza A infection in vivo and ex vivo.  
We first examined the activation status of pulmonary DC subsets in WT 
and NK-cell depleted mice using FACS. Mice received -Asialo GM-1 
antibodies to deplete NK cells 24 hour prior infection with influenza A 
virus (5pfu). A pulmonary single cell suspension was obtained and 
enriched for DCs with Optiprep. Two major subsets of DCs – 
CD11b+CD103-, CD11b-CD103+ were analyzed for the expression of 
CD80 and CD86 at D3 p.i. Compared to isotype control, CD80 and CD86 
expression increased in both subsets at D2 (Fig 4.5) and D3 (Fig 4.6) 
p.i., suggesting that DCs were activated during the early course of 
infection. In NK cell-depleted mice, expression of CD80 or CD86 was not 
significantly altered on these DCs subsets on either D2 (Fig 4.5) nor D3 
(Fig 4.6) p.i., indicating that NK cell depletion did not affect the 
maturation status of DCs during influenza A infection.  
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Figure 4.5 CD80 and CD86 expression on pulmonary DCs 
from WT and NK cell-depleted mice at D2 p.i.. Mice were 
infected with influenza A/PR/8/34 (5 pfu). NK cell depletion was 
performed 24hr prior to infection using asialo-GM1 or anti-NK1.1 
antibodies. Single cells were isolated from lungs on D2 p.i. from 
WT and NK cell-depleted mice. DCs were further enriched using 
Optiprep. CD80 and CD86 expressions were assessed using 
FACS. Representative data were shown from two independent 
experiments.  
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Figure 4.6 CD80 and CD86 expression on pulmonary DCs 
from WT and NK cell-depleted mice on D3 p.i.. Mice were 
infected with influenza A/PR/8/34 (5 pfu). NK cell depletion was 
performed 24hr prior to infection using asialo-GM1 or anti-NK1.1 
antibodies. Single cells were isolated from lungs on D3 p.i. from 
WT and NK cell-depleted mice. DCs were further enriched using 
Optiprep. CD80 and CD86 expressions were assessed using 
FACS. Representative data were shown from two independent 
experiments.  
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To investigate the effect of NK cells on DC dependent IL-12p70 
production ex vivo, we sorted pulmonary DC subsets—CD11b+CD103- 
and CD11b-CD103- from infected mice at D2 and D3 p.i. as well as mock 
infected mice. These DCs were then incubated with CpG (0.2M) and 
IFN-10ng/ml) overnight. Released IL-12p70 level was determined 
using ELISA. IL-12p70 production was measured with the CD11b-
CD103+ population (Fig 4.7) but was barely detectable in the 
CD11b+CD103- population (data not shown). IL-12p70 also showed a 
trend to increase following the course of infection (Fig 4.7). Compared 
to WT mice, pulmonary DCs from NK cell-depleted mice showed a 
reduction in IL-12p70 production especially on D3 p.i., suggesting that 
NK cells were important in enhancing IL-12p70 production by pulmonary 
































Figure 4.7 Production of IL-12p70 from sorted pulmonary 
CD103+CD11b- DCs at various time points post infection. 
Mice were infected with influenza A/PR/8/34 (5 pfu). NK cell 
depletion was performed 24hr prior to infection using asialo-
GM1 or anti-NK1.1 antibodies. Single cells were isolated from 
lungs at D3 p.i. from WT and NK cell-depleted mice. 
CD103+CD11b- DCs were sorted out using cell sorter. 0.1-0.2 
million of DCs were plated in the presence of CpG (0.2M) and 
IFN-10ng/ml) overnight, IL-12p70 production was analyzed 
using ELISA.  
 
D3 p.i. D2 p.i. 
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We also examined the effect of DCs on promoting NK cell-dependent 
IFN- production during influenza A infection. We isolated naïve splenic 
NK cells using Dx5+ microbeads and pulmonary APCs including DCs 
and macrophages, using CD11c microbeads from infected lungs at D4 
p.i. APCs and NK cells were then co-cultured at various ratios for 5.5 
hours in the presence of monensin and brefeldin A. IFN- production was 
quantified using intracellular staining. Compared to isotype control, NK 
cells showed an enhanced IFN- expression upon co-culture with APCs 
isolated from infected mice (Fig 4.8). These data suggested that 
pulmonary CD11c+ APCs population from the infected lung could 
stimulate IFN- production from naïve NK cells.  
Taken together, these data showed that NK cells did not affect DC 
maturation during influenza A infection, but that they might be involved 
in potentiating DC production of IL-12p70. On the other hand, pulmonary 
APCs from infected lungs could also induce IFN- production from naïve 
NK cells.  
109 
 
Figure 4.8 IFN- production by splenic NK cells after co-culture 
with CD11c+APCs isolated from infected lungs on D4 p.i.. 
Splenic NK cells were isolated with DX-5 microbeads and cultured 
with 1x105 CD11c+ APCs magnetically isolated from lungs of 
influenza infected mice (4 days p.i.) Cells were co-cultured for 5.5 
hrs in the presence of Monensin and Brefeldin A. IFN- was 
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4.3 NK cells promote DC recruitment to the pMLN during the 
influenza A infection 
Besides maturation and mediator release, migration of antigen carrying 
DCs to the lung draining lymph nodes is pivotal in priming the adaptive 
immune responses against viral infection. Hence, we next determined 
whether DC migration to the lung draining lymph nodes was also 
impaired in NK cell-depleted mice in response to influenza A infection. 
Compared to non-depleted mice, the total cell number (Fig 4.9A) and 
two major subtypes (CD11b+CD103- and CD11b-CD103+) of the 
migratory pulmonary DCs were significantly reduced at 3 days p.i. (Fig. 
4.9B) in the posterior mediastinal lymph node (pMLN) in NK cell-
depleted mice. However, no difference was observed in the anterior 
mediastinal lymph nodes (aMLNs) (Fig 4.9A). These data suggest: (a) 
that initiation of inflammation is exclusive to one of the lung draining 
lymph nodes – the pMLN and (b) that NK cell depletion abrogates DC 
migration to the pMLN. We speculate therefore that NK cells regulate 





Figure 4.9 Total cells and DCs recruitment to MLNs on D3 p.i. 
with influenza A virus. Mice were treated with anti-Asialo GM-1 
antibody (i.p.) 24 hours before infection with influenza A/PR/8/34 (5 
pfu) or PBS. 3 days p.i. both posterior (pMLN) and anterior (aMLNs) 
mediastinal lymph nodes were harvested and the total cell numbers 
were enumerated (A). pMLN DCs were gated as NHCII+CD11c+. 
CD11b+CD103- and CD11b-CD103+ DC subsets were enumerated 
(B). Data shown are mean ± SEM representing at least 9 mice from 3 
independent experiments. *, p< 0.05; **, p<0.01; and **8, p< 0.001 






Next, we tested the role of two important effector functions of NK cells: 
IFN- and perforin mediated cytotoxicity in DC migration to the pMLN 
using respective knockout mice. The numbers of CD11b+CD103- and 
CD11b-CD103+ DCs were significantly decreased in IFN--/- mice 
suggesting that migration of pulmonary DCs critically depend on IFN- 
(Fig 4.10A). In contrast to IFN--/- mice, migration of pulmonary DC to the 
draining lymph node was not altered in perforin-/- mice compared to WT 
mice (Fig 4.10B). However, we did not observe significant difference in 
survival or virus titer in the both strains of knockout mice with 5pfu of 
PR8 (data not shown). In summary, these data indicated that IFN-, likely 
produced by NK cells during early phase of influenza infection is 
important for DC migration to the draining lymph node and the initiation 




Figure 4.10 DC recruitment to MLNs on D3 p.i. in WT and 
knockout mice. WT and knockout mice were infected with 
influenza A/PR/8/34 (5 pfu) or PBS. At D3 p.i., pMLN were 
collected and analyzed using FACS. Recruitment of both 
subsets of DCs to the pMLN was analyzed in IFN--/- (A) and 
perforin-/- mice (B) using FACS. Data shown are mean ± SEM 
representing at least 9 mice from 3 independent experiments. 







The previous data only show that NK cells affect total DC migration. The 
role of NK cells on the migration of the antigen-carrying DCs remains 
unknown. To further test if NK cells are involved in efficient uptake and 
transport of influenza antigen by DCs, we stained DCs for viral antigen - 
HA and compared HA+DC between WT and NK cell-depleted mice. 
Pulmonary DCs could take up virus and infected cells through 
endocytosis and thus the viral surface protein—HA will be present in the 
DCs. This enables us to track viral antigen uptake through intracellular 
staining of HA. A significant reduction in number of HA+DCs in the pMLN 
was found in NK cell-depleted mice at day 3 p.i. (Fig 4.11A), which 
suggested a deficiency in virus-carrying DCs migration to the pMLN in 
NK cell-depleted mice. However, there were no differences in HA levels 





Figure 4.11 Number of HA+ DCs in the lung and pMLN at D3 p.i. with 
influenza A virus. HA expression levels of pulmonary DCs from control 
and NK cell-depleted mice. Mice were infected with 5pfu of influenza A 
virus. At D3 p.i, the pMLN (A) and pulmonary (B) DCs were collected and 
analyzed for HA expression using intracellular staining. Data shown are 
mean ± SEM representing at least 8 mice from 3 independent 
experiments. *, p< 0.05; **, p< 0.01; and ***, p<0.001 using one-way 






Besides HA staining, we utilized labeled influenza with the lipophilic dye, 
DiD, which is attached to the lipid layer of the virus and has previously 
been used to follow influenza virus infections in vivo (223, 270). DiD is 
not incorporated into progenitor virus released from infected cells and 
therefore allowed us to track antigen uptake by DCs from primary 
infected cells. After infection with DiD-labeled influenza A virus (200 
pfu—this is the dose which enable the sufficient readout of DiD), we 
observed a significant increase of DiD+ CD103+ DCs in the pMLN two 
days p.i. (Fig 4.12A). In contrast, a significant decrease in DiD+ DCs was 
observed in NK cell-depleted mice compared to WT mice (Fig 4.12A). 
To better understand the requirement of the NK cell effector functions in 
antigen uptake, we also infected IFN--/- and perforin-/- mice with DiD-
labeled influenza virus. The number of DiD+ DCs in the pMLN of IFN--/- 
and perforin-/- mice were similar to those in NK cell depleted-mice 
suggesting that both IFN- and perforin contribute to the virus transport 
by DCs to the pMLN. (Fig 4.12B&C). Since IFN- affects the migration of 
DCs it was possible that the virus uptake by lung DCs was not deficient 
in IFN--/- mice. Consistent with this possibility, we observed that IFN--/- 
mice had similar numbers of DiD+ DCs in the lung two days p.i. compared 
to WT mice (Fig 4.13B). In contrast, the number of pulmonary DiD+ DCs 
was significantly reduced in NK cell-depleted and perforin-/- mice (Fig 
4.13A&C). These data suggested that perforin-dependent cytotoxicity 
was required for efficient virus uptake by pulmonary DCs while IFN- 
mediated the antigen transport to the pMLN.  
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Figure 4.12 Number of DiD+ DCs in pMLN at D3 p.i. in WT and 
knockout mice. WT, NK cell-depleted, IFN--/- and perforin-/- mice were 
infected with DiD-labeled influenza (200 pfu). Day 2 p.i., DCs from the 
pMLN were harvested and analyzed for DiD expression (A). DiD+ DCs in 
the pMLN were also enumerated in IFN--/- (B) and perforin-/- mice (C). 
Data shown are mean ± SEM representing at least 8 mice from 3 
independent experiments. *, p< 0.05; **, p< 0.01; and ***, p<0.001 using 








Figure 4.13 Number of DiD+ DCs in the lung at D3 p.i. in WT and 
knockout mice. WT, NK cell-depleted, IFN--/- and perforin-/- mice were 
infected with DiD-labeled influenza (200 pfu). Day 2 p.i., Pulmonary DCs 
were harvested and analyzed for DiD expression (A). DiD+ DCs in the lung 
were also enumerated in IFN--/- (B) and perforin-/- mice (C). Data shown 
are mean ± SEM representing at least 8 mice from 3 independent 
experiments. *, p< 0.05; **, p< 0.01; and ***, p<0.001 using one-way 








Lastly, we performed a pulse-chase experiment to confirm the role of NK 
cells in mediating the antigen uptake by pulmonary DCs in an on-going 
infection. WT, NK cell-depleted and perforin-/- mice were infected with 5 
pfu of influenza, and then at D3 p.i., inoculated with DiD-labeled 
influenza A virus (3.5 × 104 pfu—this dose provides sufficient DiD signal 
to be read within a short period of time). Pulmonary DCs were harvested 
for analysis 4 hours post DiD virus inoculation. Due to the limited time, 
virus replication is unlikely and hence allows us to study the virus uptake 
in pulmonary DCs in an on-going infection. A significant reduction in DiD+ 
DCs were observed in NK cell-depleted and perforin-/- mice in the lung 
(Fig 4.14) suggesting that efficient antigen uptake by pulmonary DCs is 
partially dependent on NK cells through perforin-mediated pathways in 
an on-going infection.  
Taken together, our data strongly suggest that NK cells are important for 




Figure 4.14 Number of pulmonary DiD+ DCs in the pulse-chase 
experiment. Mice were infected with 5 pfu of influenza A virus for 3 days 
and then infected again with DiD-labeled virus (3.5 × 103 pfu). Lungs were 
harvested and analyzed for DiD uptake by DCs at 4 hours post DiD virus 
inoculation. Reduction in numbers of DiD+ DCs was observed in NK cell 
depleted and perforin-/- mice. Data shown are mean ± SEM representing 
at least 8 mice from 3 independent experiments. *, p< 0.05; **, p< 0.01; 




4.4 NK cells promote antigen uptake by DCs through perforin 
dependent apoptosis induction  
The previous results suggested an important role for NK cells in 
mediating antigen-uptake and transport by pulmonary DCs during 
influenza A infection. Next, we set out to understand the role of perforin 
in mediating viral uptake in the lung. It is generally believed that viral 
antigens are acquired through infection of DCs or by endocytosis of 
infected cells by DCs (271-275). One possibility is that the absence of 
perforin might lead to defective endocytosis by DCs using some novel 
mechanisms. To address this, we utilized the uptake of FITC-dextran as 
an indication of endocytosis. No difference in the in vitro uptake of FITC-
dextran was found between WT and perforin-/- mice (Fig 4.15). Therefore, 

















Figure 4.15 Endocytosis of pulmonary DCs using FITC-dextran 
in vitro. Pulmonary DCs were isolated and enriched using Optiprep 
from naïve WT and perforin-/- mice. DCs were then cultured with FITC-
dextran beads at 37°C for 1hr. Uptake of dextran was analyzed using 




Recently, Desch and colleagues showed that CD11b-CD103+DCs 
preferentially took up antigens from apoptotic bodies (276). We then 
hypothesized that NK cell-mediated killing of infected cells through 
perforin-dependent pathway would lead to generation of apoptotic 
bodies containing viral antigen, which would then facilitate viral antigen 
uptake. To address this, we determined the level of apoptosis in the lung 
from WT, NK cell-depleted and perforin-/- mice at day 2 p.i. using in situ 
TUNEL staining. In agreement with our hypothesis, WT mice showed a 
higher intensity of TUNEL positive cells in the section while NK cell-
depleted and perforin-/- mice displayed a reduced level of TUNEL 
staining intensity (Fig 4.16). We then went on to determine whether 
perforin could also affect the phagocytosis of apoptotic cells by DCs. We 
transferred CFSE-labeled virus-infected apoptotic mouse fibroblasts to 
WT, NK cell-depleted and perforin-/- mice (~2 × 107 cells/mouse) and 
harvested lungs 2 hours later to determine the uptake of CFSE+ cells. 
No difference in uptake of CFSE+ cells was observed in CD11b-CD103+ 
DCs or CD11b+CD103- DCs among three groups indicating perforin did 
not affect phagocytosis of apoptotic cells (Fig 4.17). Hence perforin is 
likely to affect the apoptosis of infected cells, which then facilitate the 
viral uptake by pulmonary DCs.  
Taken together, these data suggested that NK cells regulate the T cell 
response to influenza by promoting uptake and transport of influenza 
virus by DCs to the pMLN, which is required for efficient priming of T cell 






Figure 4.16 Apoptosis induction in the lung post infection in WT, NK cell-
depleted and perforin-/- mice. Lungs were harvested, sectioned and stained 
for TUNEL expression at day 2 p.i. with 5 pfu of influenza A infection from WT, 
NK cell-depleted and perforin-/- mice. Representative staining of 2 independent 















Figure 4.17 Percentage of CFSE+DCs in the lung post apoptotic cell 
transfer. A mouse secondary fibroblast cell line was infected at 2 pfu/cell 
overnight. Apoptosis was induced by exposing cells to UV (60 mJ/cm2). 
More than 58% cells were Annexin V+ post treatment and less than 1% 
cells were 7AAD+. Subsequently, these cells were labeled with CFSE and 
inoculated into WT, NK cell-depleted and perforin-/- mice i.t. (~2 × 107 
/mouse). The percentage of CFSE+DCs was assayed in the lung 2 hours 
post transfer. No difference of CFSE level was observed in pulmonary DC 
subsets among all groups. Data shown are mean ± SEM representing 
with 6 mice from 2 independent experiments. Statistics was done using 





In this chapter, we have shown that NK cells can promote DC functions 
including maturation, migration, antigen uptake and IL-12p70 production 
in vitro and in vivo. These NK cell mediated effects are likely to be both 
IFN- and contact dependent. Pulmonary DCs from infected lung can 
also promote IFN- production from NK cells. These data confirm the 
previous studies on NK-DC crosstalk and highlight the important 
regulatory roles of NK cells on DCs.  
In the in vitro experiments, we first studied NK cell mediated DC 
maturation marked by CD86 expression. We demonstrated that only 
activated NK cells, but not naïve NK cells, were able to enhance DC 
maturation, partially through a contact dependent mechanism. These 
results agree with previous studies that NK cell mediated DC maturation 
requires two stimulatory signals (277). In the ex vivo and in vivo 
experiment, we measured the activation markers such as CD80, CD86, 
MHC and CD70 (data not shown) on both CD11b+ and CD103+ DC 
subsets in NK cell-depleted and WT mice. Contrary to the in vitro 
experiments, no significant differences were observed in the expression 
of activation markers between NK cell-depleted and WT mice. These 
findings suggested that during the influenza infection, NK cells might not 
be involved in the initial maturation of DCs. One of the possible reasons 
is that NK cell activation was dampened by the virus as showed in other 
studies (164), (166).  
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We then specifically studied the role of NK cells in potentiating DC 
dependent IL-12p70 release. IL-12p70 plays a critical role in initiation, 
polarization and maintenance of Th1 immune responses (278, 279). DC 
mediated IL-12 release is potently stimulated by TLR agonists (280), 
especially by TLR9 agonist—CpG in the mouse (281, 282). Our data 
agree with the previous studies that CpG was a potent inducer for IL-
12p70 production, but also suggested that activated NK cells strongly 
synergized with CpG for DC dependent IL-12p70 production. Our ex vivo 
data also supported this observation by the fact that pulmonary DCs from 
NK cell depleted mice showed much reduced IL-12p70 production 
following re-stimulation ex vivo. Interestingly, we observed that CD103+, 
but not CD11b+ DCs produced a significant amount of IL-12p70 during 
the early course of infection. In our previous and current study, we have 
found that CD103+ DCs migrated to the lung draining lymph nodes and 
activated a T cell response during the early course of influenza A 
infection, while CD11b+ DCs remained in the lung and maintained 
pulmonary inflammation during the early course of infection (270). Our 
data supported this differential functionality of pulmonary DC subsets, 
and demonstrated that only migratory DCs (CD11b-CD103+) is capable 
of producing Th-1 polarizing cytokines while lung resident DCs 
(CD11b+CD103-) are not. These data imply that during influenza A 
infection, the presence of TLR agonists and activated NK cells promote 
optimal IL-12p70 production and leading to Th1 polarization, which is 
important in viral defense and memory induction.  
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DC dependent IL-12p70 production was also strongly enhanced by 
CD40-CD40L interaction (281), as well as released mediators such as 
IFN- and TNF- (283) in the presence of TLR agonists. We performed 
co-culture of DCs and NK cells from CD40L (data not shown) and IFN- 
deficient mice and observed a reduced level of released IL-12p70, 
confirming that both CD40-CD40L and IFN- play a role in mediating DC 
dependent IL-12p70 production. Moreover, one of the mechanisms 
underlying this NK cell mediated IL-12p70 production by DCs is found to 
be NKp46 specific. Our data suggested that NKp46 blockade induced 
an inhibition of IL-12p70; while plate bound NKp46 Fc could enhance IL-
12p70 production from DCs. These data implied that possible binding of 
DC and NK cells through NKp46 might be one of the pathways that 
mediate IL-12p70 production in the presence of TLR agonists and IFN-
. Previous studies have shown that NKp46 could bind to DCs and 
dampen DC mediated NK cell activation (269). NKp46 expression was 
also increased in patients after two rounds of DC vaccination treatment 
(284). Our data supports these studies while emphasizing that 
interaction of NKp46 and its ligand(s) on DCs not only promotes NK cell 
function but also plays an important role in DC dependent IL-12 
production. When we examined the CD80/86 expression on DCs co-
cultured with LAK cells and CpG in the presence of NKp46 blockage, no 
difference was observed, indicating the NKp46 does not serve as a 
second signal for DC maturation.  
In the in vivo model, we studied the migration of DCs as successful 
generation of a CTL response depends on migration of mature DC to the 
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draining lymph nodes (285, 286). Activated NK cells are required to 
promote optimal recruitment of DCs as depletion of pulmonary NK 
impaired DC migration to the pMLN suggesting that pulmonary NK-DC 
interaction could promote DC migration and ensuing CTL responses. To 
further study this effect, the migration of virus-carrying DCs was tracked 
using intracellular HA staining, DiD labeled virus and a pulse-chase 
experiment. There were less HA+DCs and DiD+ CD103+DCs in the pMLN 
in NK cell-depleted, compared to WT mice. A similar defect was 
observed in perforin-/- mice infected with DiD virus. Furthermore, we 
observed reduced DiD+ DCs in the lung in NK cell-depleted and perforin-
/- mice compared to WT mice using DiD labeled virus or pulse-chase 
method indicating a defect in viral uptake in the lung. Many studies have 
suggested that DCs could acquire antigen either through direct infection 
by influenza A virus, or through phagocytosis of either dead or dying 
epithelial cells (271-275). Through in situ staining using TUNEL assay, 
our data suggest that optimal viral antigen uptake requires active killing 
of infected cells through perforin-mediated cytotoxicity This strongly 
supports the view proposed in earlier studies that perforin did not only 
have an effector function but also a regulatory role in immunity (287, 288). 
Perforin was found to be important in regulating CTL response to LCMV 
(289), Theiler’s virus (290) and HSV infection (291). In an MCMV 
infection model, a perforin-dependent mechanism was found to limit 
antigen presentation that led to a contraction of the CTL response (288, 
292). Other reports have demonstrated the opposite effect, namely that 
NK cell mediated killing of target cells enhances cross-presentation and 
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the attendant T cell response (293). Another study demonstrated 
enhanced endocytosis by CD8+ DCs after effective killing of allogeneic 
cells by NK cells (294). Our data support the latter view by showing that 
NK cell-mediated killing of infected cells enhanced uptake of influenza 
viral antigens by pulmonary DCs – especially the CD103+ DC subset 
which was shown to be important in priming CTL response during 
influenza infection (270). This effect of perforin-mediated cytotoxicity 
probably enhanced the pool of apoptotic cell-associated antigens, which 
are preferentially taken up by pulmonary CD103+ DCs for CD8 T cell 
priming (276). In summary, NK cells are required for optimal pulmonary 





Chapter 5: Natural killer cells promote T cell responses during 
influenza A infection 
Besides activation of innate immunity, influenza A virus also leads to 
activation of adaptive immunity including virus specific T cells and 
antibody producing B cells. There are three main functions of virus 
specific T cells ensuing the infection – 1) lysis of infected cells mainly by 
CD8 T cells through granzyme and perforin dependent mechanisms; 2) 
induction of apoptosis of infected cells through FAS-FAS ligand or TNF-
related apoptosis inducing ligand (TRAIL) pathways; 3) release pro-
inflammatory mediators, such as TNF- and IFN-(295). Initiation of 
virus specific T cell responses critically depends on migratory antigen-
presenting DCs (296, 297). Pulmonary antigen carrying DCs migrated to 
the lung draining lymph nodes, encounter rare antigen recognizing naïve 
T cells and support their activation and proliferation in the lymph nodes 
(298). Activated T cells then migrate to the lung to exert their effector 
functions. Besides DCs, NK cells also act to influence the generation of 
virus-specific cytotoxic T cells (CTLs). In 1984, Burlington et al 
demonstrated that Large Granular Lymphocytes (i.e. NK cells) were 
necessary to induce CTL responses against Influenza in vitro (88). 
Depletion of NK cells were also found to abrogate virus-specific CD8 T 
cell generation in human PBMC in vitro and in vivo (169). NK cells were 
also found to support Th1 differentiation in the lymph nodes through 
secreting IFN- in response to OVA-pulsed DCs (86), Leishmania major 
infection (299), Bordetella pertussis infection (300) and similar findings 
were observed in human secondary lymphoid tissue (87). Therefore, we 
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investigated the possible regulatory effects of NK cells on virus specific 
T cell activation and its underlying mechanisms in this chapter.  
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5.1 NK cells promote virus specific T cells generation during 
influenza A infection  
First, we studied the virus specific CD8 T cell response in WT and NK 
cell-depleted mice using our sublethal infection model of influenza A 
virus. Pulmonary virus-specific CD8 T cells were detected using 
pentamers that recognize nuclear peptide (NP366-374) of H1N1 virus, 
which is shown to be the major epitope recognized by CD8 T cells post 
infection. Consistent with previous studies, a significant reduction in Db-
NP366-374+ CD8 T cells was observed at day 7 and day 9 p.i. in the pMLN 
(Fig. 5.1A) and a two-fold reduction in the Db-NP366-374+ CD8 T cell 
number was found in the lung on day 11 p.i. in NK cell-depleted mice 
(Fig 5.1B). These data confirm that NK cells play a role in CTL generation 
during a sublethal influenza A infection model.  
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Figure 5.1 Virus specific T cell induction during the 
influenza A infection in WT and NK cell depleted mice. Anti-
NK 1.1 antibodies were injected i.p. on day -1 and day 4 p.i. 
during a sublethal influenza A infection. At various time points 
p.i., cells from the lung (A) and pMLN (B) were isolated and 
stained for expression of Db-NP366-374 pentamers in CD3+CD8+ T 
cell population. Data shown are mean ± SEM representing at 
least 9 mice from 3 independent experiments. *, p<0.05; **, 





As NP366-374 only represents one of the epitopes recognized by CD8 T 
cells, we utilized an in vivo T cell proliferation assay to further study the 
impact of NK cells on virus specific CD8 T cell generation during 
influenza A infection. CFSE-labeled OT- CD8 T cells were adoptively 
transferred to mice 24 hours prior infection with OT- PR8 (50 pfu). Four 
days p.i., the number of proliferating OT- specific CD8 T cells was 
quantified using FACS. Significant reduction in CFSElow OT- specific 
CD8 T cells was found in NK cell-depleted compared to WT mice, 
suggesting that NK cell depletion dampened the virus specific T cell 





Figure 5.2 CFSElow OT- specific CD8 T cells OT- in the 
pMLN in both WT and NK cell depleted- mice post 
infection. CD8 T cells were isolated from spleens and 
lymph nodes from OT- transgenic mice. These cells were 
then labeled with CFSE and adoptively transferred into NK 
cell-depleted and WT mice (1 × 106 cells/mice) 24 hours 
before infection with OT- PR8 virus (50 pfu). Day 4 p.i., the 
pMLN were harvested and the percentage of 
CFSElowSIINFEKL+CD3+CD8+ T cells was measured. Data 
shown are mean ± SEM representing at least 8 mice from 
3 independent experiments. ***, p<0.001 using one-way 
ANOVA and Mann-Whitney test. 
137 
 
5.2 NK cells promote T cell recruitment to the pMLN during 
influenza A infection  
Successful generation of virus specific T cells also depends on the 
available pool of migrating T cells in the pMLN. Hence, we expanded our 
study to investigate whether NK cells impact on the recruitment of T cells 
in the pMLN. To understand this aspect, we again depleted NK cells 24 
hours prior to influenza A infection and quantified the infiltrating T cells 
to the pMLN. In NK cell depleted mice, both CD4 and CD8 T cell 
infiltration to the pMLN was reduced 2-fold compared to WT mice at day 
3 p.i. (Fig 5.3A). We also measured T cell recruitment to the lung at D3 
p.i. in both WT and NK cell depleted mice. No significant differences in 
pulmonary CD4 or CD8 T cell number was observed between the two 
groups (Fig 5.3B). These data suggest that NK cells promoted T cell 
recruitment to the pMLN during the early course of influenza A infection, 





Figure 5.3 T cells migration to the pMLN and lung at D3 p.i. 
in WT and NK cells depleted mice. Mice were treated with 
anti-Asialo GM-1 antibody (i.p.) 24 hours before infection with 
influenza A/PR/8/34 (5 pfu) or PBS. At day 3 p.i., recruitment of 
CD3+CD4+ and CD3+CD8+ T cells to the pMLN (A) and lung (B) 
were measured. Data shown are mean ± SEM representing at 
least 9 mice from 3 independent experiments. *, p< 0.05; and 
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To further dissect whether migration of pulmonary cells or lymph node 
resident cells contribute to T cell recruitment to the pMLN, we 
administered pertussis toxin (PT) concurrently with virus. PT inhibits 
chemokine functions including CCR7-dependent efflux from the lung 
(301, 302), while T cell mobility is not directly affected (301). PT 
administration abrogated CD8 and CD4 T cell recruitment to the pMLN 
significantly at day 3 p.i. (Fig 5.4), indicating an important role of 
migration of pulmonary cells in mediating T cell recruitment to the pMLN. 
Therefore, our results highlight the possibility that impairment of 
pulmonary DCs and/or NK cells migration, could lead to defective T cell 






Figure 5.4 T cells infiltration to the pMLN at D3 p.i. in WT 
and PT treated mice. Mice were treated with anti-Asialo GM-1 
antibody (i.p.) 24 hours before infection with influenza A/PR/8/34 
(5 pfu) or PBS. Pertussis toxin (PT) was given i.n. concurrently 
with influenza virus. Day 3 p.i., T cell recruitment to the pMLN 
was measured. Data shown are mean ± SEM representing at 
least 9 mice from 3 independent experiments. *, p< 0.05; and **, 
p< 0.01 using one-way ANOVA and Mann-Whitney test. 
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We have also demonstrated in Chapter 4, that NK cells promoted both 
DC migration and antigen uptake. Therefore, one of the possible 
mechanisms underlying NK cell mediated LN T cell recruitment could be 
mediated through modulating antigen carrying DCs. In order to study this, 
CFSE labeled OT- CD8 T cells, specific for SIINFKEL peptide, were 
adoptively transferred into mice 24 hours prior to infection with influenza 
A H1N1/PR/8/34 virus (Fig 5.25A). Since these OT- CD8 T cells would 
not recognize any of the influenza A virus epitope, the recruitment of 
these T cells would not be influenced by pulmonary DCs carrying 
influenza viral peptides. At D3 p.i., cells from pMLN were harvested and 
quantified by flow. The recruitment of CFSE labeled OT- CD8 T cells to 
the pMLN was significantly reduced in NK cell depleted mice compared 
to WT mice (Fig 5.5B). Similar reduction was observed in total CD8 T 
cells number as well as total cell number in the pMLN (Fig 5.5B). These 
data suggest that the recruitment of T cells to the pMLN was unlikely to 
be dependent on antigen carrying DCs or other antigen mediated 
pathways during the early course of influenza A infection. However, we 
were not able to exclude the possibility that DCs play a role in T cell 
migration by modulating chemokine release. Taken together, our data 
suggest that NK cells promote T cell recruitment to the pMLN in an 
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Figure 5.5 CFSE+ OT- CD8 T cells infiltration to the pMLN at D3 
p.i. in PR8 infected mice. CD8 T cells were isolated from spleens 
and lymph nodes from OT- transgenic mice. These cells were then 
labeled with CFSE and adoptively transferred into NK cell-depleted 
and WT mice (1.5~2 × 106 cells/mice) 24 hours before infection with 
PR8 virus (5 pfu) (A). At day 3 p.i., total cell, CD3+CD8+ T cells and 
CFSE+ OT- to the pMLN were measured (B). Data shown are mean 
± SEM from 2 independent experiments. *, p< 0.05 using one-way 





5.3 NK cell depletion dampens T cell activation status during 
influenza A infection  
The previous data have shown that total T cell recruitment was affected 
by NK cell depletion in influenza A infected mice. Whether NK cells 
promote the activation status of T cells in the pMLN would also be 
important to study. To assess this, we chose three activation markers—
CD62L, CD25 and CD69 to examine the T cell activation status in the 
pMLN post influenza A infection. Activated T cells express a low level of 
CD62L, but high levels of CD25 and CD69. In infected WT mice, 
CD62Llow CD4 T cell population showed a 2.5-fold increase compared 
to mock infected mice (Fig 5.6A). There was also a slight increase 
observed in CD25+ and CD69+ CD4 T cell population in the pMLN (Fig 
5.6A). In NK cell depleted mice, we observed a significant reduction in 
CD62Llow CD4 T cell population compared to WT mice, which had no 
difference compared to mock infected mice (Fig 5.6A). Similarly, in PT 
treated mice, no increase of CD62Llow CD4 T cell population was 
observed post infection (Fig 5.6A). Consistent with CD4 T cell data, CD8 
T cells showed a 3-fold increase in both CD62Llow and CD69+ 
populations in infected mice (Fig 5.6B). NK cell depletion or PT 
administration abolished this increase in both CD62Llow and CD69+ 
populations (Fig 5.6B). On the other hand, the CD25+ population was not 
greatly affected by NK cell depletion or PT administration. These data 
suggested that influenza A infection effectively activated both CD4 and 
CD8 T cell in the pMLN, especially down regulating CD62L and 
upregulating CD69 expression the latter restricted to CD8 T cells. NK 
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cell depletion effectively abolished this virus-induced activation implying 
that, NK cells played an important role in mediating the early activation 
of both CD4 and CD8 T cells in the pMLN. Greatly dampened T cell 
activation was also observed in PT treated mice suggesting again that, 
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Figure 5.6 CD62Llow, CD25+ and CD69+ T cell population in the 
pMLN in influenza A infected mice. Mice were treated with anti-
Asialo GM-1 antibody (i.p.) 24 hours before infection with influenza 
A/PR/8/34 (5 pfu) or PBS. PT was administrated concurrently with 
influenza A virus. At day 3 p.i., number of CD62Llow, CD25+ and CD69+ 
CD3+CD4+ (A) and CD3+CD8+ T cells (B) in the pMLN was determined 
using FACS. CD25+ and CD69+ CD8 T cells were plotted on right y-
axis (B). Data shown are mean ± SEM representing at least 6 mice 
from 2 independent experiments. *, p< 0.05; and ***, p<0.001 
compared to PBS; #, p< 0.05; and ###, p<0.001 compared to 5pfu using 






Since NK cell depletion had a significant impact on pMLN T cell 
activation, we also examined the effect of NK cell depletion on 
pulmonary T cell activation. We quantified CD69+ T cells in the lung at 
D3 p.i. in WT and NK cell depleted mice. There was a trend toward an 
increase in both CD69+ CD4 and CD8 T cells post influenza A infection, 
but this was not statistically significant (Fig 5.7). However, NK cell 
depletion did not significantly affect the activated T cell population (Fig 
5.7). Hence, these data suggest that NK cells do not affect pulmonary T 
cell activation during the early course of infection. 
In summary, our data suggest that NK cells play an important role in 
enhancing T cell activation in the pMLN during the early course of 
influenza A infection. This effect was at least partially dependent on 
migratory cells from the lung as PT administration abolished activation 
of T cells in the pMLN post influenza A infection. However, NK cells did 
not affect the population of activated T cells in the lung during the early 
course of infection. These data do not exclude the possibility the 
activation status of pulmonary T cells would be affected at the later time 
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Figure 5.7 CD69+ T cell population in the lung in influenza A 
infected mice. Mice were treated with anti-Asialo GM-1 antibody 
(i.p.) 24 hours before infection with influenza A/PR/8/34 (5 pfu) or 
PBS. At day 3 p.i., number of CD69+ CD3+CD4+ and CD3+CD8+ 
T cells in the lung was determined using FACS. Data shown are 




5.4 NK cell-derived IFN- mediates T cell recruitment partially 
through promoting chemokine release  
Since NK cells exert their antiviral effect mainly through direct 
cytotoxicity and secreted IFN-, we infected IFN--/- and perforin-/- mice 
to determine whether NK cell-dependent T cell recruitment to the pMLN 
post influenza infection depends on these effector functions. Infection of 
IFN--/- and perforin-/- mice with 5 pfu of influenza A virus did not result in 
an increased viral load at the peak of viral replication (Fig 5.8). However, 
recruitment of both CD8 and CD4 T cell to the pMLN was reduced 3-fold 
in IFN--/- mice (Fig 5.9A), while no difference was observed in perforin-
/- mice at day 3 p.i. (Fig 5.9B). Thus, our data suggest that T cell 
infiltration into the pMLN critically depends on IFN- but not perforin.  
We also examined the pulmonary T cell recruitment in the IFN--/- since 
these mice displayed a significant reduction in both T cell subsets in the 
pMLN. There was a trend of reduction in both CD4 and CD8 T cell 
population at D3 p.i. (Fig 5.10), but this reduction is not statistically 





Figure 5.8 Virus titer in knockout and WT 
mice. Mice were infected with 5pfu of 
influenza A. Lungs were collected and 
homogenized. Viral titer was determined 
using plaque forming assay. Data shown are 
mean ± SEM representing 2 experiments with 




Figure 5.9 CD4 and CD8 T cell recruitment to the pMLN in WT, IFN-
-/- and perforin-/- mice post infected with influenza virus (5 pfu) or 
PBS. Day 3 p.i., the pMLN were harvested from WT, IFN--/- and 
perforin-/- mice. Both CD4 and CD8 T cell infiltration were measured in 
IFN--/- (A) and perforin-/- (B) mice. Data shown are mean ± SEM 
representing of at least 8 mice from 3 independent experiments. *, p< 
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Figure 5.10 Pulmonary CD4 and CD8 T cell recruitment 
to WT, and IFN--/- mice post infection with influenza 
virus (5 pfu). Day 3 p.i., pulmonary lymphocytes were 
harvested from WT, and IFN--/- mice. Both CD4 and CD8 
T cell infiltration were measured. Data shown are mean ± 





Besides gross recruitment of T cells to the lung and pMLN, we also 
determined activated T cell recruitment to the pMLN in both IFN--/- and 
perforin-/- mice. In the IFN--/- mice, we found a significant reduction in 
CD62Llow CD4 T cells, while this reduction was absent in perforin-/- 
compared to WT mice (Fig 5.11A). However, IFN- deficiency or perforin 
deficiency did not greatly alter the number of the CD25+ or CD69+ CD4 
T cells in the pMLN (Fig 5.11A). Similar to the CD4 T cell, IFN--/- mice 
showed an almost 3-fold reduction in CD62Llow CD8 T cells in the pMLN, 
while no difference was observed in perforin-/- compared to WT mice (Fig 
5.11B). There was a trend toward reduction in CD69+ CD8 T cell 
population in both IFN--/- and perforin-/- mice compared to WT mice (Fig 
5.11B). CD25+ CD8 T cells did not show any difference among the WT 
and two strains of knockout mice (Fig 5.11B). In summary, both total and 
activated T cell recruitment to the pMLN was reduced in IFN--/- mice, 
while little difference was observed in perforin-/- mice. These data 
suggest that IFN-was likely to be involved in NK cell mediated T cell 
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Figure 5.11 CD62Llow, CD25+ and CD69+ T cell recruitment to 
the pMLN in WT, IFN--/- and perforin-/- mice post infection. 
Day 3 p.i., the pMLN were harvested from WT, IFN--/- and 
perforin-/- mice. CD62Llow, CD25+ and CD69+ CD4 (A) and CD8 
(B) T cell infiltration were measured in IFN--/- and perforin-/- mice. 
Data shown are mean ± SEM representing of at least 6 mice from 
2 independent experiments. *, p< 0.05; and ***, p<0.001 using 






Since both T cells and NK cells could secrete IFN- following influenza 
A infection, it was still possible that the observed recruitment defect in 
IFN--/- was due to a lack of T cell IFN- production. To confirm that IFN-
 produced by NK cells affected T cell recruitment to the pMLN, we 
performed a rescue experiment using in vitro primed NK cells (LAK cells). 
LAK cells were generated from purified WT splenic NK cells cultured with 
rIL-2 (1000U/ml) for 4 days. At the end of culture, LAK cells were shown 
to produce significant amounts of IFN- in response to in vitro re-
stimulation with PMA/Ionomycin (data not shown). LAK cells were 
adoptively transferred to IFN--/- mice one day prior to infection (3 x 106 
cells per mouse) and T cell recruitment was determined at D3 p.i.. Upon 
LAK cell transfer, recruitment of both subsets of T cells to the pMLN was 
restored (Fig 5.12B). We also examined the effect of LAK cell transfer 
on pulmonary T cell recruitment. No difference was observed between 
groups that received LAK cell or not (Fig 5.12B). These data suggested 
that, IFN- produced by LAK cells could mediate T cell infiltration to the 






Figure 5.12 CD4 and CD8 T cell recruitment in IFN--/- 
mice post infection with LAK cell transfer. Splenic NK 
cells were purified and cultured with rIL-2 for 4 days to 
generate LAK cells. LAC cells were then transferred i.v. into 
IFN--/- mice 24 hours prior to infection (3 × 106 
cells/mouse). T cell recruitment to the pMLN (A) and lung 
(B) were measured at day 3 p.i.. Data shown are mean ± 
SEM representing of at least 6 mice from 2 independent 
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Because LAK cells effectively restored T cell recruitment to the pMLN in 
IFN--/- mice, we also tested whether LAK cell transfer also restored the 
population of activated T cells in the pMLN post infection. As expected, 
all the activated CD4 T cell populations marked by CD62Llow, CD25 and 
CD69 showed a significant increase in the group that received LAK cell 
transfer (Fig 5.13A). CD62Llow and CD69+ CD8 T cells were increased 
3-fold upon LAK cell transfer (Fig 5.13B). We then tested the pulmonary 
T cell activation status post LAK cell transfer. Consistent with the total 
pulmonary T cell numbers, no differences were observed in either CD25+ 
or CD69+ population from CD4 T cells (Fig 5.14A) and CD8 T cells (Fig 
5.14B) between the groups that received LAK cell transfer or not. These 
data again confirm that IFN- produced by LAK cells effectively restored 
both total and activated T cell populations in the pMLN post influenza A 
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Figure 5.13 CD62Llow, CD25+ and CD69+ T cell recruitment to the 
pMLN in IFN--/- mice post infection with LAK cell transfer. Splenic NK 
cells were purified and cultured with rIL-2 for 4 days to generate LAK cells. 
LAC cells were then transferred i.v. into IFN--/- mice 24 hours prior to 
infection (3 × 106 cells/mouse). At day 3 p.i., number of CD62Llow, CD25+ 
and CD69+ CD3+CD4+ (A) and CD3+CD8+ T cells (B) in the pMLN was 
determined using FACS. CD25+ and CD69+ CD8 T cells were plotted on 
right y-axis (B). Data shown are mean ± SEM representing at least 6 mice 
from 2 independent experiments. *, p< 0.05; and ***, p<0.001 using one-
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Figure 5.14 CD62Llow, CD25+ and CD69+ T cell recruitment to the lung 
in IFN--/- mice post infection with LAK cell transfer. Splenic NK cells 
were purified and cultured with rIL-2 for 4 days to generate LAK cells. LAC 
cells were then transferred i.v. into IFN--/- mice 24 hours prior to infection 
(3 × 106 cells/mouse). At day 3 p.i., number of CD62Llow, CD25+ and 
CD69+ CD3+CD4+ (A) and CD3+CD8+ T cells (B) in the lung was 
determined using FACS. Data shown are mean ± SEM representing at 






Since LAK cells were primed in vitro prior to the transfer, we moved on 
to investigate unstimulated NK cells purified by negative selection from 
the spleens of WT and IFN--/- mice. We adoptively transferred purified 
IFN--/- or WT NK cells to IFN--/- mice one day prior to infection (1~1.5 x 
106 cell per mice). The group that received WT NK cells demonstrated a 
complete restoration of both CD4 and CD8 T cell recruitment to the 
pMLN (Fig 5.15). However, the group that received IFN--/- NK cells had 
no difference in either CD4 or CD8 T cell recruitment to the pMLN (Fig 
5.15). These data clearly show that IFN- produced by NK cells could 
mediate T cell infiltration to the pMLN during the early course of infection. 
Taken together these rescue experiments show that NK cell dependent 
IFN- production could effectively restore both total and activated T cell 
populations in the pMLN during the early course of influenza A infection. 
However, pulmonary T cells were not affected by this pathway at the 





Figure 5.15 CD4 and CD8 T cell recruitment in IFN--/- mice post infection 
with WT and IFN--/- NK cell transfer. Naïve NK cells were purified from 
spleens and transferred i.v. into IFN--/- mice 24 hours prior to infection (1-1.5 
× 106 cells/mouse). CD4 and CD8 T cell recruitment to the pMLN were 
measured at day 3 p.i.. Data shown are mean ± SEM representing of at least 
8 mice from 3 independent experiments. ***, p<0.001 using one-way ANOVA 




To gain further insight into the molecular pathways underlining the NK 
cell-mediated T cell recruitment to the pMLN, we investigated the 
expression of chemokines especially IFN-inducible protein 10 (IP-10) 
and CCL-21 in the pMLN. IP-10 has been shown to promote NK cells, T 
cell and possibly DC recruitment (303). CCL-21, constitutively expressed 
in lymphoid tissue, is a ligand for the CXCR7 receptor that is expressed 
on both T cells and DCs (304), which promotes their homing to the lymph 
nodes. We harvested pMLN at day 1 and day 2 p.i. and assayed IP-10 
mRNA expression in WT, NK cell depleted and IFN-/- mice. The level of 
IP-10 mRNA increased 6-fold at day 1 p.i. in WT mice while NK cell-
depleted and IFN-/- mice had no increase (Fig 5.16). However, at day 2 
p.i., IP-10 expression returned to the baseline and no differences were 
observed among groups (Fig 5.16).  
To address the role of CCL-21, we stained pMLN sections for CCL-21 
and high endothelial venule (HEV) marker—peripheral lymph node 
addressin (PNAd, clone MECA-79) at day 3 p.i. in WT, NK cell-depleted 
and IFN--/- mice. A marked reduction in CCL-21 expression was evident 
in NK cell depleted and IFN--/- mice compared to WT mice (Fig 5.17). 
Hence, our data suggested that regulation of IP-10 and CCL-21 
secretion in the pMLN through IFN- dependent pathways was one likely 







Figure 5.16 IP-10 expression in the pMLN at D1 and D2 
p.i. in WT, NK cell depleted and IFN--/- mice. Mice were 
infected with 5 pfu of influenza A infection. pMLNs were 
harvested and mRNA extracted at day 1 and day 2 p.i.. 
cDNAs were transcribed and expression level of IP-10 was 
assayed in triplicate for each time point by real-time PCR. 
Data shown are mean ± SEM representing at least 6 mice 
from 2 independent experiments. **, p< 0.01 using one-way 






Figure 5.17 CCL-21 expression in pMLN at D3 p.i. in WT, NK cell 
depleted and IFN--/- mice. Mice were infected with 5 pfu of influenza 
A infection. At day 3 p.i., pMLNs were collected and stained for CCL-
21. Representative CCL-21 staining in the pMLN was shown from 3 




Our data revealed that NK cells played an important role in CTL 
generation post influenza A infection. There was a significant reduction 
in virus specific T cell generation in the absence of NK cells. NK cells 
are known to augment tumor specific T cell generation in the secondary 
lymphoid organs (305), virus specific CD8 T cell response against 
MCMV infection (306) and promotion of allogenic Th1 response in vitro 
(307). However, Wang and colleagues reported that NK cell depletion 
did not affect Th1 polarization in the OVA model (308). Our data provide 
another line of evidence that NK cells play an important role in shaping 
anti-viral T cell responses, particularly CD8 T cell responses following 
virus infection. The data suggested that NK cells promote antigen uptake 
and transport by pulmonary DCs and naïve CD4 and CD8 T recruitment 
to the pMLN to ensure the optimal activation of virus specific T cell 
response. Previous reports also demonstrate that NK cells enhance both 
regulatory T cell infiltration through CCL-22 secretion (309), and effector 
CD8 T cell recruitment through DC dependent pathways (357). Our data 
support these findings and further reveal the effects of NK cell mediated 
T cell recruitment to sites of pulmonary viral infection. In common with 
Wong and colleagues (310), our data also show that this NK cell 
mediated T cell recruitment is partially dependent on regulation of DC 
function. However, we found this effect is unlikely to be antigen 
dependent, suggesting that helper NK cell function is likely to be 
bystander activation. Besides T cell recruitment, we also observed 
differences in T cell activation status, especially in the expression of 
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CD62L and CD69 in WT and NK cell depleted mice. These data are in 
agreement with previous reports which suggest that NK cells stimulate 
T cell proliferation (311) and antigen independent T cell activation (312). 
Our data confirmed that NK cells can also influence the activation status 
of T cells during a sublethal infection with influenza A. 
IFN- was also found to be one of the key factors that contribute to NK 
cell-mediated T cell infiltration. IFN- mediates T cell recruitment, 
partially through induction of IP-10 and CCL21 in the pMLN. IFN- has 
been shown to influence the induction and expansion of CTL response 
in vitro and in vivo (313, 314). During influenza A infection, IFN- 
deficient mice did not show higher mortality (161) but reduced migration 
of CD8 T cell into the lung (315). Our data provided clear evidence that 
IFN- deficient mice also have impaired T cell recruitment to the pMLN. 
It also demonstrated that naïve NK cell transfer restored T cell 
recruitment. These data accord with the previous study of IFN-deficient 
mice using an allograft model (316). Migration of blood naïve T cell to 
the draining lymph nodes via high endothelial venules (HEVs) is critically 
dependent on the chemokines CCL-19 and CCL-21 (317). Our results 
demonstrated that CCL-21 expression was found to co-localize to PNAd, 
which defines the HEV, as well as in the region of stromal cells in the T 
cell cortex of the pMLN post influenza A infection. These data agree with 
a previous study (318), confirming that CCL-21 plays an important role 
in recruiting blood lymphocytes to the lung draining lymph nodes. Our 
data also demonstrated that expression of IP-10 and CCL-21 in the 
pMLN was markedly reduced by NK cell depletion and IFN- deficiency. 
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This suggests that IP-10 and CCL-21 may mediate NK cell dependent 
IFN- release. IP-10 is an IFN- regulated chemokine and its receptor 
CXCR3 is highly expressed on polarized Th1 cells (319, 320), MCMV 
specific CD8 T cells (321) and cerebral infiltrating T cells post malaria 
infection (322). Inhibition of IP-10 impaired Th1 migration to the blood 
vessels (323), IFN-+ CD8 T cell to the liver (321), effector T cell 
trafficking to the kidney (324) and pulmonary T cell recruitment (325). 
Enhanced IP-10 levels increased recruitment of activated T cells to the 
airway in vitro and in vivo (326) and human blood T cell in vitro (327). 
Our data agreed with these studies and implied a possible role of IP-10 
in mediating both activated and naïve T cell recruitment to the pMLN in 
a NK cell-dependent pathway. In contrast, CCL-21 was not previously 
reported to be regulated directly by NK cell dependent IFN-production. 
There are ways that NK cells could potentially mediate CCL-21 
expression. CCL-21 and CCL-19 expression was strongly augmented 
post influenza A infection (328) and CCL-21 was also found to be rapidly 
transported to the HEV post external injection (317, 329). Hence, it is 
possible that NK cells enhance pulmonary CCL-21 expression in the 
lung through IFN- dependent pathways, which was subsequently 
transported to the HEV. Another possible mechanism is that migratory 
NK cells enhanced local CCL-21 expression in the pMLN through IFN- 
production as we have shown that pulmonary NK cells can migrate to 
the pMLN in Chapter 3. Moreover, NK cells may exert this effect through 
interaction with other cells such as monocytes, macrophages, and DCs 
to enhance the inflammation and hence CCL-21 upregulation. As we 
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found that naïve T cell recruitment to the pMLN is sensitive to pertussis 
toxin inhalation, it is likely that migration of pulmonary NK cells or DCs is 
critical in mediating T cell infiltration to the pMLN. However, we still do 
not have enough evidence to confirm the regulatory pathways of IFN- 
on CCL-21 expression. Additionally, all the hypothesized pathways may 
act synergistically to mediate CCL-21 expression on the HEVs and 
stromal cells in the pMLN.  
Taken together, our data demonstrate that NK cells play an important 
role in virus specific T cell generation. This effect is found to be mediated 
by two mechanisms—1) enhanced antigen uptake and transport by DCs; 
2) enhanced naïve T cell infiltration to the pMLN and T cell activation 
status in an antigen independent manner. Our data also reveal that NK 
cell dependent IFN- release may mediate CCL-21 expression in the 









Chapter 6: The involvement of NKp46 in mediating natural killer cell 
function during various inflammatory processes 
Ground level ozone (O3) is a highly toxic and oxidizing air pollutant 
formed by nitrous oxide and volatile organic compounds under heat and 
sunlight. Exposure to O3 can lead to lung damage (196, 330), increased 
susceptibility to airway infection (331), allergic sensitization (332, 333), 
and asthma exacerbation (334). O3 induced pulmonary inflammation 
manifests mainly in neutrophil infiltration, both in humans (335, 336) and 
mice (337). O3 also damages the lung epithelial layer. Lung epithelial 
damage leads to compromised barrier function (195, 196), impaired 
macrophage function (338, 339), and release of pro-inflammatory 
cytokines such as IL-1, TNF-α, IL-6, IL-8 and GM-CSF (336, 340, 341). 
O3 exposure was also found to dampen T cell dependent immune 
responses in delayed hypersensitivity (342) and Listeria monocytogenes 
infection (343). Human response to O3 induced airway inflammation 
causes reduced induction of immune cell trafficking pathways (344), 
suggesting that ozone induced pulmonary inflammation may be 
associated with impaired cell migration. 
In the preceding chapters, we have demonstrated that NK cells are 
important in mediating immune cell trafficking during influenza A 
infection. This chapter focuses on DC migration during ozone induced 
pulmonary inflammation and the possible regulatory role of NK cells in 
this model.  
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6.1 Murine model of ozone-induced pulmonary inflammation 
Ozone exposure is known to induce pulmonary inflammation. In our 
model, using a single acute O3 exposure protocol (3ppm for 2hrs), we 
observed a significant increase of neutrophil infiltration into the BAL 12 
hours post ozone exposure, when compared to forced air control (Fig. 
6.1). This time point was selected because previous time course studies 
showed that the height of the proinflammatory changes occur 12 hr after 
O3 inhalation in mice. 
Figure 6.1 BAL cellular infiltration post ozone 
inhalation. BAL samples were collected 12hr post ozone 
or forced air inhalation. Differential counting was used to 
determine the percentage of macrophages (MP), 
eosinophils (EP), neutrophils (NP) and lymphocytes (LC) 
(A). Data shown are mean ± SEM representing at least 6 
mice from 2 independent experiments. *, p< 0.05; **, p< 






6.2 Ozone suppresses pulmonary innate immunity 
Migration of DCs to lung draining lymph nodes is important in 
maintaining immune homeostasis during steady-state and promoting 
resolution under inflammatory conditions (345). We hypothesized that 
O3-induced airway inflammation is associated with altered DC migration. 
We examined the two major subsets of conventional DCs, 
CD11b+CD103- and CD11b-CD103+ in the pMLN 12hr post forced air or 
O3 exposure. The total percentage of DCs gated as MHChighCD11c+ 
demonstrated a reduction in the O3-treated group compared to controls 
(Fig 6.2A). When broken down to the two main subsets of pulmonary 
DCs, we observed a significant reduction in the CD11b-CD103+ 
population post ozone exposure, while no overt difference was observed 
in CD11b+CD103- population (Fig 6.2B). These data suggested that O3-




Figure 6.2 DCs migration to the pMLN post ozone inhalation. 
pMLNs were collected at 12hr post ozone or filter air inhalation. 
Percentage (A) and number (B) of DC in forced air and ozone 
treated mice were determined by FACS. Data shown are mean ± 
SEM representing at least 6 mice from 2 independent 






To confirm this observation, we utilized CFSE to trace pulmonary DC 
migration. CFSE was inoculated intratracheally 6 hour prior to ozone 
exposure. 12hr post treatment, the percentage of CFSE+ DC in the 
pMLN was reduced in ozone group compared to forced air control (Fig 
6.3) supporting the view that ozone exposure inhibited DC lymph node 
homing.  
Figure 6.3 CFSE+DC migration to pMLN post ozone 
inhalation. CFSE was administrated intratracheally 6 hours 
prior to ozone inhalation. pMLNs were collected at 12hr post 
ozone or forced air inhalation. DC migration was traced using 
CFSE expression. Data shown are mean ± SEM representing at 






DC homing to the draining lymph node is mediated by chemokine 
receptor CCR7 and its ligands CCL-19/21 during lung inflammation (345, 
346). We have shown previously that lymph node homing of DCs 
through a CCL-21 dependent pathway was impaired in IFN--/- mice 
(347). We therefore examined pulmonary CCL-21 and IFN- expression 
in O3 treated mice. Expression of both CCL-21 (Fig 6.4A) and IFN- (Fig 
6.4B) mRNA gradually decreased post O3 exposure compared to forced 
air treated mice, indicating that O3 exposure suppressed both pulmonary 
CCL-21 and IFN-production. 
174 
 
Figure 6.4 pulmonary CCL-21 and IFN- expression post 
ozone inhalation. Lungs mRNA was harvested from filter air 
or ozone treated mice at various time points. Expression of 
CCL-21 (A) and IFN- (B) was quantified using microarray. 
Data shown are mean ± SEM representing at least 6 mice 
from 2 independent experiments. *, p< 0.05 using one-way 







To identify whether ozone specifically suppresses NK cell dependent 
IFN-production, we performed intracellular staining. IFN- expression 
by pulmonary NK cells was reduced in the ozone exposed group 
compared to the forced air group (Fig 6.5 A). A significant reduction in 
the total number of IFN- producing NK cells was also found in O3 treated 
mice while the overall CD107-+ NK cells showed no difference between 
groups (Fig 6.5B). Collectively, these data suggested that ozone 
exposure suppressed DC migration, diminished pulmonary CCL-21 and 
NK cell dependent IFN- production. 
Figure 6.5 Pulmonary NK cell dependent IFN- production post ozone 
inhalation. Pulmonary lymphocytes were collected and enriched. 
Intracellular IFN- expression of NK cells was measured after in vitro 
activation with PMA (100 ng/mL) and Ionomycin (1000ng/mL) for 4 hours. 
Representative FACS plot (A) and number of IFN- production NK cells (B) 
are shown. Data shown are mean ± SEM representing at least 6 mice from 



















6.3 NKp46 is involved in ozone induced immune suppression 
One of the possible mechanisms of ozone induced suppression of NK 
cell IFN-production is through blocking the NK cell activation receptor. 
NKp46 is a highly conserved activation receptor on NK cells. To evaluate 
whether O3 suppresses pulmonary NK cell dependent IFN-production 
through inhibiting NKp46 dependent pathways, we exposed NKp46-/- 
mice to O3 or forced air. As observed in WT mice, in NKp46-/- mice there 
was significant neutrophilia in the BAL suggesting that O3 induced 
inflammation is also observed in the NKp46 deficient mice (Fig 6.6).  
Figure 6.6 BAL cellular infiltrations in NKp46-/- mice post 
ozone inhalation. BAL samples were collected at 12hr post 
ozone or forced air inhalation from NKp46-/- mice. Differential 
counting was used to determine the percentage of macrophages 
(MP), eosinophils (EP), neutrophils (NP) and lymphocytes (LC). 
Data shown are mean ± SEM representing at least 6 mice from 2 
independent experiments. ***, p<0.001 using one-way ANOVA 





We then examined IFN- production by pulmonary NK cells 12hrs post 
ozone exposure in NKp46-/- mice with ex vivo re-stimulation. In contrast 
to WT mice, NKp46-/- mice did not demonstrate a reduction in total 
number of IFN- producing NK cells in the lung between ozone and 
forced air treated groups (Fig 6.7). Similarly, no difference was observed 
in CD107-+ NK cell population (Fig 6.7). These data suggest that in the 
absence of NKp46, ozone induced suppression of IFN- production by 
pulmonary NK cells is abrogated.  
Figure 6.7 Pulmonary IFN- production NK cells in NKp46-/- mice 
post ozone inhalation. Intracellular IFN- expression of NK cells 
was measured after in vitro activation with PMA (100 ng/mL) and 
Ionomycin (1000 ng/mL) for 4 hours. Number of total IFN- producing 
NK cells is shown. Data shown are mean ± SEM representing at least 




As the suppression of IFN- production was alleviated in NKp46-/- mice, 
we postulated that DC migration would not be inhibited either. Indeed, 
the total number of DCs in pMLN showed no difference in ozone and 
forced air treated mice (Fig 6.8A). No reduction was observed in CD11b-
CD103+ DCs subset in pMLN post ozone exposure compared to forced 
air group (Fig 6.8B). To further confirm the abolition of DC migration in 
NKp46-/- mice, we also performed CFSE tracing of pulmonary DCs. 
Again, no difference was observed in the percentage of CFSE+ DCs in 
ozone treated mice compared to forced air control (Fig 6.8C). Therefore, 
these data suggested that DC migration and IFN- production were not 
impaired in NKp46-/- mice compared to WT mice, which supported the 
view that ozone inhibited DC migration through suppression of NKp46 






Figure 6.8 DC migration post ozone exposure in NKp46-/- mice. pMLNs 
were harvested at 12hr post ozone or forced air exposure. Percentage of 
pMLN DCs in filtered air and ozone treated mice were determined by FACS 
(A). Total numbers of DC subsets were calculated (B). DC migration was 
traced using CFSE (i.t.) post ozone or filtered air treatment (C). Data shown 









6.4 Surfactant protein D (SP-D) promotes DC migration and NKp46 
dependent NK cell functions  
Our laboratory demonstrated that DC migration to lung draining lymph 
nodes was impaired in SP-D-/- mice in response to allergic inflammation 
(348). Therefore, we went on to test whether SP-D influences DC 
migration during ozone-induced pulmonary inflammation. We inoculated 
CFSE intratracheally to both WT and SP-D-/- mice 6 hr prior exposure to 
ozone or filtered air. At 12 hours post exposure, we collected the pMLN 
from both strains and traced the migration of DC (MHChighCD11c+) by 
their expression of CFSE. Again, we found an inhibition of DC migration 
in the WT mice post ozone exposure (Fig 6.9A). Similarly, an inhibition 
of DC migration was observed in SP-D-/- mice post ozone exposure (Fig 
6.9A). Compared to the WT mice, there was a 2-fold reduction in CFSE+ 
DC expression in SP-D-/- mice. We then assessed the pulmonary 
expression of CCL-21 and IFN-, as both of them were found to mediate 
pulmonary DC migration. Unsurprisingly, there was a 2-fold reduction in 
both CCL-21 and IFN-expression at baseline in SP-D-/- mice compared 
to WT mice (Fig 6.9B). These data clearly suggested that SP-D played 












Figure 6.9 DC migration and pulmonary CCL-21 and IFN- 
expression in SP-D-/- and WT mice. DC migration was traced using 
CFSE (i.t.) in WT and SP-D-/- mice. pMLNs were harvested at 12 hour 
post exposure and CFSE+ DCs were analyzed using FACS. 
Representative FACS plots showing CFSE+ DCs were shown (A). Lungs 
mRNA was harvested from naïve WT and SP-D-/- mice. Expression of 
CCL-21 and IFN- was quantified using microarray (B). Data shown are 
mean ± SEM representing at least 6 mice from 2 independent 






Since SP-D is found to mediate DC migration to the pMLN post ozone 
exposure, the difference in DC migration found in WT and NKp46-/- mice 
could be due to differential expression of SP-D post ozone exposure. In 
order to eliminate this possibility, we measured the SP-D levels in BAL 
using western blot. Similar to WT mice, NKp46-/- mice had an increased 
SP-D level post ozone exposure in BAL (Fig 6.10). However, no 
difference was observed in SP-D production between WT and NKp46-/- 
mice. Hence, the observed differences in DC migration was not likely 
due to differential SP-D production between NKp46-/- and WT mice. 
Figure 6.10 Released SP-D level in the BAL in WT and 
NKp46-/- mice post ozone exposure. BAL SP-D level was 
determined using western blot and quantified as fold change 
compared to filter air treated groups. Data shown are mean ± 
SEM representing at least 6 mice from 2 independent 
experiments. *, p< 0.05; and **, p<0.01 using one-way 




SP-D has also been shown to promote pulmonary IFN- production in 
the murine model of invasive pulmonary aspergillosis (349) and dust 
mite induced allergic airway inflammation (350). Therefore, we 
hypothesized that SP-D could promote pulmonary IFN- production by 
NK cells. We cultured naïve splenocytes in the presence of rSP-D for 
48hrs and measured the IFN- release in cultured supernatant by ELISA. 
There was a marked enhancement in the level of IFN- with addition of 
rSP-D in naïve splenocytes (Fig 6.11A), indicating that SP-D did promote 
IFN- release in vitro. As naïve T cells are not capable of producing IFN-
, NK cells were likely to be the major contributors of IFN- production 
detected in the supernatant. To test whether the effect of SP-D in 
enhancing IFN- production was also present in pulmonary NK cells, we 
harvested pulmonary NK cells from both WT and SP-D-/- mice and tested 
for IFN- expression post in vitro stimulation with PMA/Ionomycin. There 
was a reduction in IFN- expression in SP-D-/- NK cells compared to WT 
NK cells despite an increase in surface expression of CD107- (Fig 
6.11B), CD25 and CD69 (Data not shown). These data suggested that 
although NK cells were activated in SP-D-/- mice, IFN- production was 
impaired in the absence of SP-D, supporting the notion that SP-D is 














Figure 6.11 IFN- production post SP-D supplement and 
deficiency. Splenocytes were isolated from naïve WT mice and 
culture with or without rSP-D (1mg/ml) for 48hrs. Released IFN- 
was assayed using ELISA (A). Pulmonary lymphocytes were 
collected and enriched from naïve WT and SP-D-/- mice. Surface 
CD107- and Intracellular IFN- expression of NK cells was 
measured after in vitro activation with PMA (40 ng/mL) and 
Ionomycin (100 ng/mL) for 4 hours (B). Data shown are mean ± 











One of the possible mechanisms of SP-D enhanced IFN- production by 
NK cells is through direct binding. SP-D was previously found to bind 
surface glycoconjugates expressed on the surface of macrophages, 
neutrophils and lymphocytes (351). NKp46 is a highly glycosylated 
activating receptor on NK cells (352). Activation of NKp46 could lead to 
activation of PI3K and IP3, which could eventually lead to transcriptional 
activation of IFN-. Hence, it is likely that SP-D binds to NKp46 to induce 
IFN- production by NK cells. To test this hypothesis, we incubated 
pulmonary lymphocytes from SP-D-/- with recombinant SP-D at 4°C for 2 
hours and tested surface binding of SP-D on NK cells using FACS. We 
observed a significant increase in surface SP-D expression gated on 
pulmonary NK cells (NK1.1+CD3-), with addition of SP-D (Fig 6.12A). To 
confirm that this binding is specific to NKp46, we utilized NKp46-/- mice, 
which have no NKp46 expression on pulmonary NK cells (Fig 6.12B). 
We incubated pulmonary lymphocytes from SP-D-/- and NKp46-/- mice 
with various doses of rSP-D and examined the surface expression of SP-
D. In SP-D-/- mice, we observed a dose dependent increment of surface 
SP-D expression on NK cells, whereas, in NKp46-/- mice, no dose 
dependent increase in SP-D binding was observed (Fig 6.12C). These 




















FMO 2M rSP-D 20M rSP-D 
Figure 6.12 Binding of rSP-D on pulmonary NK cells. Pulmonary 
lymphocytes were isolated from naïve SP-D mice and culture with 
rSP-D (20g/ml) for 2hrs at 4°C. Surface biding of SP-D on NK cells 
(NK1.1+CD3-) were assessed using flow (A). Pulmonary 
lymphocytes were collected and enriched from naïve WT and NKp46-
/- mice. NKp46 expression was determined using FACS gated on NK 
cells (NK1.1+CD3-) (B). Pulmonary lymphocytes were collected and 
enriched from naïve WT and NKp46-/- mice and culture with rSP-D (2 
or 20g/ml) for 2hrs at 4°C. Surface biding of SP-D on NK cells 
(NK1.1+CD3-) were assessed using flow (C). Representative 



















In this chapter we have shown that pulmonary CD103+ DC migration was 
suppressed during ozone induced pulmonary inflammation. As DCs 
were actively recruited to the lung through chemokines released by 
injured epithelial cells, this blockage of DC migration, in fact, retained 
more inflammatory DCs in the lung. This retention could contribute to 
observed lung function impairment and inflammation post ozone 
exposure. A previous study by Brand and colleagues indicated that there 
was an accumulation of DCs, especially the CD103+ population in the 
MLNs post ozone exposure (353). The discrepant results are likely due 
to the different ozone models used in these studies. We have employed 
an acute single exposure protocol while the other study utilized chronic, 
low dose exposure. Moreover, we have specifically examined the 
posterior MLN, which has been showed to be the major site of T cell 
activation in influenza infection (354), while all MLNs were studied in the 
previous study. Nonetheless, both studies concluded that O3 can 
modulate DC migration in addition to alter their antigen presentation 
capacity (332, 355, 356).  
DC migration critically depends on CCR7 and CCL-21/19 interaction. Not 
surprisingly, our data has shown that ozone exposure led to a reduction 
in pulmonary CCL-21 expression. We also demonstrated that ozone 
inhalation suppresses IFN-, especially NK-cell derived IFN- in the lung. 
IFN- was shown to induce pulmonary chemokine expression including 
CCL-21 (347). In agreement with our data, chemokine expression 
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involved in immune cell trafficking was suppressed in responders to 
ozone inhalation (344). Previous studies have also demonstrated that 
ozone suppressed IFN- production in isolated peripheral blood 
mononuclear cells (357) as well as in the lung at early time points post 
exposure (222). In a study by Muller and colleagues, IFN- expression 
by NK cells was dampened upon co-culture with ozone exposed 
epithelial cells (358). Another study by Van Loveren and colleagues 
showed that pulmonary NK cells were suppressed post chronic ozone 
exposure at 1.6mg/m3 (359). Our study supports all these observations 
and added that ozone is able to suppress pulmonary NK cell dependent 
IFN- production with an acute single exposure in a murine model. 
NKp46 is an activating receptor, which is thought to play an important 
role in mediating NK-DC cross talk (360) and influenza A infection (138). 
NKp46 expression on NK cells was also found to be decreased upon co-
culture with ozone exposed epithelial cells (358). Our data in this chapter 
extended previous studies and identified an important role for NKp46 in 
ozone-mediated inflammation for the first time. Ozone induced inhibition 
of DC migration was not seen in NKp46-/- mice suggesting that NKp46 is 
a possible target in ozone induced immune suppression. In NKp46-/- 
mice, the total number of IFN- producing NK cells showed no reduction 
post ozone exposure, implying that under normal conditions in wild type 
mice, the NKp46 mediated IFN- production pathway was blocked by O3. 
In NKp46-/- NK cells, this blockade was rendered ineffective while other, 
possibly redundant pathways became activated that compensated for 
IFN- production and restored DC migration. These data suggested that 
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the NKp46 mediated IFN- production by NK cells may be responsible 
to promote pulmonary DC migration to the pMLN and that this pathway 
is sensitive to inhibition by ozone exposure.  
We also identified a reduction in DC migration in SP-D-/- mice post ozone 
exposure together with a reduction in basal expression of CCL-21 and 
IFN- production, suggesting that SP-D is an important regulator of DC 
migration. Indeed, similar observations were made (i.e. a blockade in DC 
migration in SP-D-/- mice in allergic inflammation (348). SP-D plays an 
important role in regulating innate immune responses. SP-D was found 
to bind directly to DCs in a dose dependent manner and to alter bacterial 
antigen presentation (361, 362). SP-D was also found to suppress TNF-
 production from DCs and macrophages (363, 364). SP-D 
administration induced splenic IFN- production in allergic mice (365), 
while reduction of pulmonary IFN- production was found in SP-D-/- mice 
(366). Data from our studies confirmed these previous findings and 
suggested that SP-D is mediating NK cell dependent IFN- production 
and DC migration through modulation of chemokine expression.  
One of the possible regulatory mechanisms of SP-D on NK cell 
dependent IFN- production was a direct binding of SP-D to NKp46. This 
pathway was suppressed during ozone-induced inflammation. While the 
mechanism for this is unclear, O3-induced post translational 
modifications of the native SP-D molecule can lead to a loss of function 
(367, 368). Thus O3 could modify the native structure and function of SP-
190 
 
D, which would eventually lead to decreased IFN- production by NK 
cells.  
Taken together, our study has revealed that ozone suppresses the SP-
D/NKp46/IFN- mediated DC egress from the inflamed lung. This 
suppression is likely linked to altered SP-D function and NKp46 binding, 
leading to reduced IFN- and subsequent decrease in chemokine 
release in the lung. This eventually could halt DC migration and sustain 
pulmonary inflammation. This antigen independent interaction of SP-D 
with NKp46 could play an important role in regulating lung homeostasis 




Chapter 7: Final discussion 
7.1 Summary of findings 
In this study, we investigated the effector functions and regulatory roles 
of NK cells on DCs and T cells using two pulmonary inflammatory 
models–-sublethal influenza A virus infection and ozone induced acute 
sterile inflammation.  
In the influenza A model, NK cells were rapidly recruited to the lung, BAL 
and pMLN, and, showed enhanced cytotoxicity and IFN- production in 
the lung during the early course of infection. NK cells were also shown 
to mediate both T cell and DC migration to the pMLN through IFN- 
regulated IP-10 and CCL-21 expression. Moreover, NK cells potentiated 
antigen uptake by pulmonary DCs through killing of infected cells by 
perforin mediated pathways. Lastly, NK cells, partly through NKp46 
receptor binding and IFN- release, promoted DC dependent IL-12p70 
production in vitro and ex vivo. Therefore, NK cells promoted optimal 
virus specific CD8 T cell response during influenza A infection. 
In the ozone induced sterile inflammation model, NK cell dependent IFN-
 production and DC migration were dampened. DC migration and IFN-
 production were also impaired in SP-D-/- mice suggesting a functional 
linkage of SP-D and NK cell mediated DC migration. We found that SP-
D could bind to NK cells to enhance IFN- production, at least in part 
through NKp46, in a dose dependent manner in vitro. These 
observations suggested that SP-D promotes NK cell mediated IFN- 
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release and hence pulmonary DC migration through possibly, NKp46 
dependent pathways. In agreement with this hypothesis, we found that 
NK cell dependent IFN- production and DC migration in NKp46-/- mice 
were restored post ozone exposure.  
In summary, we have identified novel NK cell dependent regulation of 
both DC and T cell function through perforin, IFN-, and NKp46 mediated 
pathways. Additionally, we observed that pulmonary surfactant protein 
D binds to NK cells to mediate their function in resting and various 
pulmonary inflammatory conditions. These findings reveal novel targets 
for the treatment and prevention of influenza A infection and pulmonary 
inflammation. 
7.2 Limitations of current study 
The first limitation is the low dose (5pfu) of influenza A virus used for this 
study. We did not observe a significant increase in pulmonary viral load 
and mortality in NK cell depleted mice. This is not in agreement with 
previous studies suggesting that NK cell depletion leads to enhanced 
morbidity and mortality during lethal influenza infection. However, we 
observed that NK cell depletion caused a decreased CTL response. This 
is consistent with previous studies using higher doses of influenza virus. 
Therefore, the nature of the immune response depends on the infection 
dose. Some of our observations may be unique to sublethal infection and 
not applicable to lethal infection. Moreover, anti-asialo GM 1 and anti-
NK1.1 antibodies, not only deplete NK cells, but also some of other cells 
such as NK T cells. This raises the possibility that these cell populations 
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may also contribute to the observed effects. To rule out this possibility, 
we also used knockout mice and rescue experiments to confirm that NK 
cells are sufficient to lead to the observed phenomena. However, we 
were unable to rule out the possibility that other depleted cell populations 
contribute to our observations. Another limitation is the use of DiD-
labelled virus to track viral antigen uptake and transport. DiD can only 
label the lipid layer of the virus. This means that DiD in the initial 
inoculated virus will not be expressed in the progenitor virus. Hence, DiD 
expression can only reveal the amount of the initial viral antigen uptake 
and transport by DCs, but not all the DCs that carried influenza A viral 
antigens. Moreover, DiD labeling could impair the infectivity of the virus 
although our laboratory observed similar HAU and pfu comparing DiD 
and unlabeled virus. For efficient readout, we also need to use a much 
higher dose of DiD labelled virus. However, current methods to track 
total viral antigen uptake remain limited. GFP-influenza A virus, which 
has the GFP-encoding gene in the virus, does provide a means of 
tracking both initial and progenitor viral uptake, but the infectivity of this 
modified virus could be attenuated. Hence, it still does not offer the best 
way to trace viral antigen uptake. To circumvent this problem, we 
performed HA staining and pulse-chase experiments to confirm our 
observation of NK cell mediated viral antigen uptake by pulmonary DCs.  
Finally, our ozone model also has limitations. There are various different 
methods of ozone exposure in the literature including chronic and acute 
exposure with various level of ozone. In humans, ozone exposure occurs 
chronically and at a lower level. In our model, we adopted an acute single 
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exposure of ozone. The immune response can be different between 
acute and chronic ozone exposure. In our model, we observe similar 
neutrophilia in BAL compared to human exposure. However, our 
observations may not extend to the human populations chronically 
exposed to ozone. We used high concentrations of rSP-D to observe in 
vitro binding of rSP-D to NK cells. Therefore, the SP-D binding studies 
will require further confirmation and in vivo verification.  
7.3 NK cells as therapeutic targets 
In our study, we have demonstrated multiple facets of NK cell function, 
especially the ability to interact with and influence various immune and 
non-immune cells in the lung. With these observations and other 
advances in NK cell biology, NK cell targeted therapy has many potential 
benefits. Since NK cells are important in clearing infected and 
transformed cells, it is not surprising that NK cells have been explored in 
cancer immunotherapies.  
Several approaches have been developed to enhance NK cell mediated 
antibody dependent cellular cytotoxicity (ADCC) through modulating NK 
cell co-stimulatory and inhibitory signals (369). CD137 has been found 
to be up-regulated in target cells and serves as a co-stimulatory 
molecule for NK cells; hence, anti-CD137 antibodies have been 
combined with anti-CD20 to promote NK cell mediated ADCC (370). On 
the other hand, programmed cell death 1 (PD-1) and MHC- are 
inhibitory to NK cell mediated ADCC. Therefore, PD-1 blocking antibody 
(371) and anti-KIR antibody blocking MHC- interaction (372) have been 
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used to potentiate NK cell anti-tumor function in pre-clinical and clinical 
studies (373-375). Inhibition of KIR-MHC- interaction has also been 
showed to improve hematopoietic stem cell (HSC) transplantation and 
reduce graft-versus-host disease (GVHD) in treating acute myeloid 
leukemia (AML) (376-378). Patients with mismatched KIR and MHC- 
ligand genotypes, show a significantly lower chance of relapse post HSC 
transplantation (379, 380). Similar observations have been made in 
acute leukemia patients that received mismatched NK cells during 
umbilical cord blood transplantation (381), suggesting a valuable and 
novel therapeutic intervention with KIR/MHC- match/mismatch. 
Another straightforward therapy is to transfer ex vivo activated NK cells 
to cancer patients. Pre-activated KIR mismatched NK cells are shown to 
expand normally post transfer and increases the success of graft 
tolerance with almost no incidence of GVHD in patients with AML across 
different ages (382-384). This approach has also been tested on brain 
tumors. Direct injection of IL-2 activated NK cells to tumor regions 
effectively enhances vaccine efficacy in the rat model (385). In patients 
with recurrent brain tumors, transfer of pre-activated NK cells is safe and 
partially effective (386). However, this therapeutic option requires 
relatively more sophisticated processing, storage, and hence, presents 
more difficulties in practice in remote areas. Recent studies have shown 
the possibility of utilizing this therapy at small remote clinics, supporting 
the wide application of this method (387).  
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Besides these interventions, genetic modification of NK cells to express 
chimeric antigen receptors (CARs) targeted towards specific malignant 
cells is also an encouraging option for cancer therapy. NK cells are ideal 
to express CARs due to their shorter lifespan compared to T cells, which 
prevents the chronic depletion of normal cells. This approach has been 
applied in both primary NK cells as well as human NK cell lines such as 
NK-92. Primary NK cells expressing CARs are found to be effective in 
eliminating cancerous B cells in vitro (388, 389). However, primary NK 
cells are difficult to modify and expand in vitro, which limits the use of 
primary cells to pre-clinical studies. On the other hand, NK-92 cell line is 
uniform, easy to manipulate and culture, and most importantly, well 
tolerated in cancer patients (390). These data point to the feasibility and 
of engineering CARs-NK cells as a novel therapeutic approach for 
cancer patients.  
Lastly, some of the drugs aim to directly potentiate NK cell effector 
function—cytotoxicity and cytokine release. Lenalidomine is shown to 
promote NK cell dependent cytotoxicity through IL-2 mediated pathways 
(391, 392) along with NK cell mediated ADCC effects against tumors 
(393). Bortezomib has been shown to up-regulate NK cell activation 
through increased expression of TRAIL receptor, NKG2D and reduced 
MHC- expression on malignant cells (394, 395). Combinational 
treatment of bortezomib with ex vivo activated NK cells is more effective 
in treating tumors in mice compared to single treatment (396), as well as 
in patients with advanced cancer (397).  
197 
 
In summary, NK cell targeted immunotherapy has provided valuable and 
exciting options for treat cancer and potentially other diseases. Currently, 
there are various clinical trials in process to harness the benefit of NK 
cells (398).  
7.4 Influenza vaccine and treatment 
Control of influenza infection still relies primarily on vaccination (399). 
There are two forms of seasonal flu vaccines available in the clinic—the 
trivalent inactivated vaccine administrated via the intramuscular or 
intradermal routes, and the live attenuated vaccine administrated 
intranasally (400). Seasonal vaccines contain recommended strains 
prevalent in the previous flu seasons and require annual administration. 
However, the challenge of pandemic influenza A virus lies in the quick 
re-arrangement and re-assortment of viral surface proteins, allowing the 
virus to evade the immune system. Hence, the seasonal vaccine may 
not be effective towards novel mismatched pandemic strains of influenza 
A virus. Even when matched with new seasonal strains, the efficacy of 
vaccination in high risk groups such as elderly and children, is generally 
lower than in adults (401). Moreover, current flu vaccines mainly induce 
B cell responses and antibody production, without virus specific CD8 T 
cell response. As CD8 T cells recognize both surface and nuclear 
epitopes of the virus while antibodies only recognize surface epitopes, 
current vaccines offer less protection against infection of novel strains. 
Therefore, there is an urgent need for new vaccine and therapeutic 
intervention for influenza virus. 
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Vaccines that target CD8 T cell responses against influenza A virus is 
an active field of research. CD8 T cells have the potential to recognize 
highly conserved epitopes, which provide cross-reactivity towards novel 
strains (402, 403). Current approaches include DNA vaccines and DC 
based vaccines to elicit anti-viral CD8 T cell responses.  
7.5 Future work 
In our study, we have observed the important role of NKp46 in DC 
activation and migration in vitro and during ozone induced pulmonary 
inflammation. To support the significance of this pathway we will 
continue study the role of NKp46 during primary influenza A infection 
using NKp46 deficient and sufficient mice. Pulmonary DC migration, 
naïve T cell recruitment and CTL response induction will be measured 
during a primary infection of influenza A virus. We will also determine the 
IFN- and IL-12p70 production from pulmonary NK cells and DCs. Once 
we confirm the role of NKp46, we will try to activate NKp46 dependent 
pathways by administrating NKp46 Fc i.p. or i.n. before and after 
infection and determine the immune cell activation and overall survival 
and pathology of infected mice. We will also study the importance of 
other NK cell receptors such as NKG2D using the relevant knockout 
mice. Once the roles of NK cell receptors are established, we will further 
our study to manipulate the pathways using drugs or known 
agonists/antagonists to improve infection outcome. We will continue to 
study the stimuli for NK cell activation, including both epithelial derived 
factors, other surfactant proteins, and TLR agonists such as poly I:C and 
CpG. We will pre-treat the mice with these agents or transfer pre-
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activated NK cells inducing by these agents to naïve mice and observe 
the pathology, mortality, DC migration, and T cell responses during the 
influenza A infection. Since NK cells are required for optimal CD8 T cell 
responses during influenza A infection, the reagents that modulate NK 
cell activation will provide a valuable avenue for vaccination and 
treatment of influenza A infection in the future. Moreover, we will also 
utilize the approaches of NK cells in cancer immunotherapy for the 
prevention and treatment of influenza A infection. Activation of NK cells 
using Lenalidomine, transfer of ex vivo activated NK cells or using 
activated NK-92 cells will be an interesting area to study for influenza A 
infection treatment.  
Another area for our future work is the study of NK cells during the re-
call response. We will study the role of NKp46 and other NK cell 
receptors on the immune responses during the re-call response. 
Moreover, NK cell memory has been established in many models, it will 
be important to identify the memory populations of NK cells. We will 
study both pulmonary and liver NK cell populations and look for the 
responding population of NK cells during the re-call responses. Once we 
identify the population, we will characterize their surface receptor 
expression and functional profiles. We will then try to isolate this 
population and study the cross-protection of memory NK cells during 
influenza A infection. We will also look into the pathways that lead to 
memory NK cell formation and try to manipulate the system to generate 




Lastly, we also observed an important regulatory role of SP-D on DCs 
and NK cells. Further probing of the underlying signaling pathways could 
reveal drug targets for improving DCs and /or NK cell function. These 
novel insights will also be useful to improve current DCs/NK cell targeted 
therapy as well as provide new designs for vaccine and therapies against 
various inflammatory pulmonary diseases. This information is also 
helpful to understand SP-D polymorphisms and the differential immune 
responses towards pulmonary pathogens and allergens. With the 
understanding of various genotypes and their association with disease, 
personalized medicine would be further developed to achieve best 
treatment outcomes. Also, prediction of disease incidence would be 
more accurate and early prevention/treatment could be carried out to 
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